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General Introduction 
1. GENERAL INTRODUCTION  
 
Sleep and mood disorders often occur simultaneously. The connection between sleep 
disorders and specifically major depressive disorder is a relation that has been called “the 
chicken and egg situation” because there is such a close connection between disrupted 
sleep and mental disorders. It is difficult to determine which came first: “the chicken or the 
egg” (Van Moffaert, 1994). This metaphor has mostly been used to describe patients with 
insomnia and to a lesser extent, patients with hypersomnia. Indeed, insomnia is 
recognized as a core symptom across mood disorders but less is known about the 
relationship between hypersomnia and mood disorders (Kaplan & Harvey, 2009).  
Depression is frequently reported in narcolepsy and idiopathic hypersomnia, although an 
overrepresentation of the symptoms is argued by some authors. In fact, several authors 
reported depressive symptoms in 6% to 56% of the narcolepsy patients (Dauvilliers et al., 
2009; Rovere, Rossini & Reimao, 2008; Vignatelli et al., 2004; Vandeputte & de Weerd, 
2003; Billiard & Dauvilliers, 2001; Daniels, King, Smith & Shneerson, 2001; Broughton et 
al., 1981). In idiopathic hypersomnia, patients’ depressive symptoms are reported in a 
range from 14 to 26% (Roth & Nevsimalova, 1975).  
The difference in the prevalence of depression reported by authors, which in some cases 
was huge, was something worthy of consideration. The variation in these studies could 
reflect varying measurements, the use of different research instruments and varying cut-off 
scores. Even so, it could be influenced by specific questions in the psychometric tests 
related to sleep and the overlap between symptoms of depression and the clinical 
spectrum of narcolepsy. Furthermore, the prevalence of depression after the division of 
narcolepsy with cataplexy and without cataplexy in the ICSD-2 is almost unexplored. 
Another point of interest was idiopathic hypersomnia because it is in the spectrum of 
narcolepsy. In idiopathic hypersomnia depressive symptoms are often present, although 
the diagnosis of idiopathic hypersomnia excludes patients with major depressive disorder 
(American Academy of Sleep Medicine, 2005). This is because mood disorders can be 
one of the causes of hypersomnia. However, hypersomnia may have initiated prior to 
mood changes (Montplaisir and Fantini, 2001).  
CLINICAL IMPRESSION 
Patients with narcolepsy during an appointment in the sleep laboratory frequently do not 
seem to be depressed. However, when they are asked about his/her feelings and 
thoughts, usually underlying depressive symptoms are revealed. Moreover, the same 
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patients participate in a patients support group and actively organize social meetings even 
under the presence of depressive symptoms. Thus, this paradoxical behavior- active 
participation and depressive symptoms- was also an incentive to carry out this work.  
The possibility that the depressive symptoms reported by narcoleptics are essentially 
different from those reported by depressed patients was an opportunity to investigate. This 
problem was taken into account when comparing narcoleptics and depressives having a 
similar level of depressive symptoms.  
ORGANIZATION OF THE DISSERTATION 
The central research topic of this dissertation is embedded within two major fields of 
research, i.e. sleep and depression. In order to achieve the aim of this dissertation, it is 
useful to revise the recent findings in narcolepsy and idiopathic hypersomnia as well as to 
review the core symptoms of depression. This background information will be presented in 
the theoretical part of the dissertation. In the theoretical part, the concept of daytime 
sleepiness is initially developed, because it is the most important feature of narcolepsy and 
idiopathic hypersomnia. Secondly, the characteristics of narcolepsy and idiopathic 
hypersomnia are described, examining the history, the forms, symptoms and differential 
diagnoses according to the International Classification of Sleep Disorders (American 
Academy of Sleep Medicine, 2005). Thirdly, the association of hypersomnia with 
depression disorder is illustrated, analyzing the criteria in the diagnostic manuals DSM-IV 
and ICD-10, and later on, giving a general sense of the most important theories about 
depression and sleep abnormalities. To conclude the theoretical part, the dissertation 
focuses on the depressive symptoms and other psychological characteristics of patients 
with narcolepsy and idiopathic hypersomnia. In this section, relevant studies on the topic 
thus far are reviewed and discussed.  
In the empirical part, three studies are developed addressing the association between 
narcolepsy and depression. In the first study of this dissertation, patients with narcolepsy 
(with and without cataplexy) and with idiopathic hypersomnia are compared. In particular, 
differences in the depressive symptoms in comparison with a control group are 
investigated. As a continuation, another study compares those narcoleptic patients with 
depressive symptoms, with primary depressed patients who are not said to have 
narcolepsy or a sleep disorder different from insomnia due to depression. The final study is 
further developed to investigate the relevant items of Beck Depression Inventory 
contributing to the scores of depression in patients with narcolepsy.  
Theoretical part 
2. THEORETICAL PART 
2.1. Definition of excessive daytime sleepiness 
During the day, one is expected to be capable of staying awake in spite of being in 
monotonous situations. Considering that nearly 5% of the population suffers from daytime 
sleepiness, this symptom is a significant social problem. Excessive daytime sleepiness is 
not a disease or disorder per se but a symptom of a sleep disorder that cannot easily 
improve with more hours of sleep (Ohayon, 2008; Aldrich, 1992). An official definition, 
according to ICSD-2, of daytime sleepiness is “the inability to stay awake and alert during 
the major waking episodes of the day resulting in unintended lapses into drowsiness or 
sleep” (American Academy of Sleep Medicine, 2005).  
2.1.1. Evaluation of sleepiness 
The measurement of sleepiness is not an effortless matter. Sleepiness can be assessed 
considering the ability to stay awake or the facility to fall asleep. For the assessment of the 
facility to fall asleep the multiple sleep latency test is the most important method. Among 
the currently available tests to assess the ability to stay awake here will be discussed the 
maintenance of wakefulness test and introspective measurements of sleepiness.  
MULTIPLE SLEEP LATENCY TEST (MSLT) 
Mary Carskadon designed a standard test in 1976, which has been used up to now. She 
called it multiple sleep latency test (MSLT) based on the observation that the time to fall 
asleep was a reliable indicator of the somnolence level. This test consists of short nap 
opportunities -four to six times- during the day in 2-hour intervals. The patient lies down in 
bed in a dark and quiet room for 20-minute sessions and is instructed not to resist falling 
asleep (Carskadon, Harvey & Dement, 1981).   
MAINTENANCE OF WAKEFULNESS TEST (MWT) 
Regarding the evaluation of the ability to stay awake, the maintenance of wakefulness test 
(MWT) was designed. The main difference from MSLT is the instruction given to the 
patient: that they should avoid falling asleep. The patient sits comfortably in a bed with low 
lighting during two or four daytime 20 or 40 min sessions. The end of the test either occurs 
after 15 seconds of micro sleep or at the end of the session if no sleep occurs (Dauvilliers, 
2005). Currently, MWT is not a standard method for the diagnosis of narcolepsy, although 
it is commonly used in some sleep centers. 
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INTROSPECTIVE MEASUREMENT OF SLEEPINESS (LONG AND SHORT-TERM OBSERVATION)  
The Epworth sleepiness scale (ESS) represents a subjective long-term observation of 
sleepiness (Details of ESS in subdivision 2.1.2 Methods). The Stanford Sleepiness Scale 
(SSS) (Hoddes, Dement & Zarcone, 1972) together with Karolinska Sleepiness Scale 
(KSS) (Akerstedt & Gillberg, 1990) corresponds to the short-term (or actual) observation of 
sleepiness. SSS and KSS were designed to detect sleepiness over the course of the day. 
Both scales can be administered repeatedly and are used in experimental environments. 
Normative data do not exist and are usually not used to make clinical judgments. 
2.1.2. Causes of excessive daytime sleepiness 
The typical causes of sleepiness comprise sleep deprivation, fragmented sleep and 
medication side effects (Arand et al., 2005). Specifically, among the causes of EDS is 
insufficient quality or quantity of night time sleep. Another cause of sleepiness is 
misalignments of the circadian rhythm (e.g. jet lag, shift work or other circadian rhythm 
sleep disorders). Some medical illnesses and traumata such as tumors, head trauma, 
anemia, testosterone disturbances, kidney failure, hypothyroidism and Lyme disease can 
also cause EDS (Greenberg, Ney, Scharf, Ravdin & Hilton, 1995). 
Other triggers that can increase EDS are alcohol, exercise, heavy meals, warm 
environments (Bassetti & Aldrich, 1997), side effect of medication, abuse of substances, 
bruxism and gastro-esophageal reflux (Sateia, Doghramji, Hauri & Morin, 2000). 
Sleepiness can also be caused by psychiatric disorders such as major depressive disorder 
and is a characteristic symptom of atypical depression (American Psychiatric Association, 
2000). In addition, the cause of EDS can be the presence of an underlying sleep disorder, 
such as narcolepsy, sleep apnea, idiopathic hypersomnia or restless legs syndrome. It is 
worth mentioning that EDS in sleep apnea and restless legs syndrome is induced by night 
sleep fragmentation, whereas EDS in idiopathic hypersomnia and narcolepsy is caused by 
a disorder in the regulation of sleep and wakefulness (American Academy of Sleep 
Medicine, 2005).   
2.1.3. Hypersomnias of central origin  
The International Classification of Sleep Disorders second version (ICSD-2) is a manual 
which classifies 85 sleep disorders into eight major categories (Figure 1).  
This dissertation has its focus on “hypersomnia of central origin not due to a circadian 
rhythm sleep disorder, sleep related breathing disorder or other cause of disturbed 
nocturnal sleep” (Figure 2). In this category of hypersomnia of central origin, this 
Theoretical part-11 
dissertation will be centered on narcolepsy and idiopathic hypersomnia (American 
Academy of Sleep Medicine, 2005). The reason is both disorders share wide similarities in 
the symptoms and the faintest line of division with narcolepsy without cataplexy.  
The explanation for the exclusion of the other hypersomnias of central origin from this 
dissertation is that they are extremely rare and the symptoms are not constant. In addition, 
the subcategory behaviorally induced insufficient sleep syndrome seems to be mainly 
caused by a sleep hygiene problem. Therefore, the inclusion in the category of 
hypersomnia of central origin is discussible. 
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Figure 1.  Categories of sleep disorders according to the International classification of 
sleep disorders 2nd edition (ICSD-2). In dark blue, the selected category of sleep 
disorders studied in this dissertation. 
Insomnias
Sleep related breathing disorders
Hypersomnias of central origin not due to circadian rhythm 
sleep disorder, sleep related breathing disorder or other 
cause of disturbed nocturnal sleep
Circadian rhythm sleep disorder
Parasomnias
Sleep related movements disorders
Isolated symptoms, apparently normal variants and 
unresolved issues 
Other sleep disorders
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Hypersomnias of 
central origin not 
due to a circadian 
rhythm sleep 
disorder, 
sleep-related 
breathing disorder 
or other cause of 
disturbed nocturnal 
sleep
Narcolepsy
Narcolepsy with 
cataplexy
Narcolepsy without 
cataplexy
Narcolepsy due to 
medical condition
Narcolepsy 
unspecified
Recurrent 
hypersomnia
Kleine-Levin 
syndrome
Menstrual related 
hypersomnia
Idiopathic 
hypersomnia
Idiopathic 
hypersomnia with 
long sleep time
Idiopathic 
hypersomnia 
without long sleep 
timeBehaviorally 
induced insufficient 
sleep syndrome
Hypersomnia due to
Medical condition
Drug or substance 
use (abuse)Hypersomnia not 
due to substance or 
known physiological 
condition
Physiological (organic) 
hypersomnia, unspecified 
(organic hypersomnia, not 
otherwise specified)  
Figure 2. Hypersomnias of central origin due to narcolepsy and idiopathic hypersomnia: In 
dark blue, the selected sleep disorders studied in this dissertation (adapted from ICSD-2). 
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2.2. Narcolepsy 
2.2.1. The history of the diagnosis of narcolepsy 
The German physician, Carl Friederich Otto Westphal from Berlin first described two cases 
of narcolepsy with cataplexy in 1877 (Westphal, 1877). One year later so did Franz Fisher 
in Baden-Württemberg (Fischer, 1878). In 1880, Jean-Baptiste-Édouard Gélineau named 
the disease narcolepsy (Gelineau, 1880). In 1926, Adie reported the younger case of 
narcolepsy with an onset at the age of 12 years (Adie, 1926). In 1928, Wilson mentioned 
several causes of narcolepsy such as traumatic, psychopathological, endocrine, epileptic, 
toxic-infective, circulatory tumor related (a tumor situated in the third ventricle) or with no 
“Grundkrankheit” (underlying illness) (Wilson, 1928). In 1931 Hoff and Stengel postulated 
a familiar form (Hoff & Stengel, 1931) although already Westphal in 1877 reported the 
familiar occurrence of narcolepsy with cataplexy (Westphal, 1877). In 1934, Luman 
Daniels published a complete description of the symptoms (Daniels, 1934). Afterwards, 
narcolepsy was considered a type of response to emotional conflicts that patients cannot 
resolve (Langworthy & Betz, 1944; Spiegel & Oberndorf, 1946).  
In the fifties, Aserinsky and Kleitman published the first description of REM sleep 
considered the beginning of the modern sleep research (Aserinsky & Kleitman, 2003). 
Only seven years later, Vogel observed that narcoleptic patients have a short REM latency 
at the sleep onset (Vogel, 1960). Vogel’s discovery was central because it was the first 
objective parameter for narcolepsy. In 1960, Yoss and Daly of the Mayo Clinic described 
the narcolepsy tetrad which consists of excessive and persistent sleepiness, cataplexy, 
sleep paralysis and hypnagogic hallucinations (Yoss & Daly, 1960).  
In the First International Symposium on Narcolepsy held in La Grande Motte (France) in 
1975, participants drew up a definition of narcolepsy. This definition included excessive 
daytime sleepiness (EDS), disturbed night sleep and pathological manifestations of REM 
sleep as characteristics of narcolepsy. EDS and cataplexy were deemed to be the main 
symptoms of narcolepsy (Guilleminault, 1976). Richardson proposed the MSLT as an 
assessment method to attest pathological sleepiness in narcolepsy in 1978 (Richardson et 
al., 1978).  
In the seventies, narcolepsy was reported in dogs in 1973 by Knecht and Mitler (Mignot, 
2001). Later, Dement and Mitler contacted several veterinarians in the USA and collected 
a sample of narcoleptic dogs (Mignot, 2001). The canine model is a resource for the 
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pharmacological and physiological study of EDS and cataplexy (Nishino, Ripley, Overeem, 
Lammers & Mignot, 2000).  
Later, Bedrich Roth suggested a classification of narcolepsy according to three criteria: 
etiology, clinical features and pathophysiology (Roth, 1980). Roth described idiopathic and 
symptomatic forms. The idiopathic form was diagnosed when it was not possible to find 
causal factors and the symptomatic form when the disease was believed to be a 
consequence of organic brain lesions such as cranial injuries or encephalitis.   
The proportion of Roth’s patients with idiopathic and symptomatic forms of narcolepsy was 
4:1, respectively. The clinical features were the classic tetrad described by Yoss and Daly. 
When only one of the four symptoms was present, Roth diagnosed monosymptomatic 
narcolepsy. Hence, he differentiated monosymptomatic narcolepsy (sleep attacks), 
monosymptomatic cataplexy and monosymptomatic sleep paralysis (Roth, 1980). Roth did 
not describe monosymptomatic hypnagogic hallucinations. Using a sample of more than 
600 narcoleptics, Roth reported three patients with cataplexy without sleepiness (Roth, 
1980).  
Other researchers have also described some single cases of cataplexy without sleepiness 
(van Dijk, Lammers & Blansjaar, 1991; Guilleminault, 1975), but these single cases have 
not turned into a diagnosis until now. Isolated cataplexy is observed at the onset of the 
disease, although it is rare (Passouant & Billiard, 1976). 
Honda in 1983 described an association of narcolepsy with a certain histocompatibility 
antigen (Honda, Asaka, Masako & Furusho, 1983). In 1986, when the findings on the HLA-
association of narcolepsy were well established, Honda defined very strict criteria for the 
diagnosis of narcolepsy. These criteria included the presence of sleep attacks, cataplexy, 
at least one instance of sleep onset REM and the presence of HLA DR2 / DQw1 in 
immunogenetic typing (Honda et al., 1986).  
In the first edition of the International Classification of Sleep Disorders (American Sleep 
Disorders Association, 1991), the diagnosis of narcolepsy was a single diagnosis (without 
division of types), always strongly related to cataplexy but including narcoleptics patients 
without cataplexy when the MSLT demonstrated the presence of two or more sleep onset 
REM periods (SOREMP) (Table 1).  
Theoretical part 
Table 1. Diagnostic criteria of narcolepsy according to the International Criteria of 
Sleep Disorders first version (ICSD-1) (American Sleep Disorders Association, 
1991). 
ICSD-1 diagnostic criteria of narcolepsy 
A. A complaint of excessive sleepiness or sudden muscle weakness 
B. Recurrent daytime naps or lapses into sleep that occur almost daily for at least three 
months 
C. Sudden bilateral loss of postural muscle tone in association with intense emotion 
(cataplexy)  
D. Associated features include: 
1. Sleep paralysis 
2. Hypnagogic hallucinations 
3. Automatic behaviours 
4. Disrupted major sleep episodes 
E.  Polysomnography demonstrates one or more of the following : 
1. Sleep latency less than 10 min. 
2. REM sleep latency less than 20 min. 
3. An MSLT that demonstrates a mean sleep latency of less than 5 min. 
4. Two or more sleep-onset REM periods 
F. HLA typing demonstrates DR2 positivity 
G. Absence of any medical or psychiatric disorder that could account for the symptoms 
H. Other sleep disorders may be present, but are not the primary cause of the 
symptoms, e.g. periodic limb movement disorder or central sleep apnoea  
 
Later, Silber proposed alternative criteria for diagnosing narcolepsy based in the HLA 
typing that incorporated the following: definite narcolepsy, probable narcolepsy with a 
laboratory confirmation and probable narcolepsy with clinical confirmation (Silber, Krahn & 
Olson, 2002). As early as 1998, two research groups reported a deficiency of hypocretin 
(or orexin) to be a cause of narcolepsy (see details in section 2.2.4 etiology), opening a 
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new era for the narcolepsy research (Peyron et al., 1998; De Lecea et al., 1998). One 
consequence of this discovery was that the diagnosis could include a measure of 
cerebrospinal fluid (CSF) levels of hypocretin-1 although a negative test (values over 
110pg/ml) is not a reason to exclude a diagnosis of narcolepsy with cataplexy and there is 
no special recommendation for this test as diagnostic criterion (American Academy of 
Sleep Medicine, 2005). Regarding narcolepsy without cataplexy, hypocretin levels are 
abnormally low only in rare cases (Mignot et al., 2002).  
2.2.2. Classification: narcolepsy with and without cataplexy 
A new definition of narcolepsy was proposed in the second edition of the ICSD published 
in 2005 (ICSD-2). Owing to the latest insights into the pathophysiology of narcolepsy 
related to the role of a hypocretin deficit, two forms of narcolepsy, with (NC+) or without 
cataplexy (NC-), are distinguished. NC- is diagnosed when EDS and two or more 
SOREMP, together with a mean sleep latency shorter than 8 minutes in the MSLT, are 
found (Table 2). The recommendation for a valid MSLT also includes: (a) Adequate sleep 
documented by sleep log or actigraphy for two weeks prior to testing; (b) At least 6 hours 
of polysomnographically defined sleep recorded prior to MSLT; and (c) Keeping patients 
awake before and between MSLT naps (American Academy of Sleep Medicine, 2005). 
Theoretical part 
Table 2. Diagnostic criteria of narcolepsy with and without according to the 
International Criteria of Sleep Disorders second version (ICSD-2) (American Sleep 
Disorders Association, 1991). 
ICSD-2 diagnostic criteria for narcolepsy 
I. Criteria for narcolepsy with cataplexy 
A. The patient complains of excessive daytime sleepiness occurring almost daily for at 
least three months. 
B. A definite history of cataplexy, where cataplexy is defined as sudden and transient 
episodes of loss of motor tone triggered by emotions is present. 
C. The diagnosis of narcolepsy with cataplexy should whenever possible, be confirmed 
by nocturnal polysomnography followed by an MSLT; the mean sleep latency on 
MSLT is less than or equal to 8 min and two or more SOREMP are observed 
following sufficient nocturnal sleep (minimum 6h) during the night prior to the test. 
Alternatively, hypocretin-1 levels in the cerebrospinal fluid are less than or equal to 
110pg/ml or one third of mean normal values. 
D. The hypersomnia is not better explained by another sleep disorder or neurological 
disorder, mental disorder, medication use or substance use disorder. 
II. Criteria for narcolepsy without cataplexy: 
A. The patient complains of excessive daytime sleepiness occurring almost daily for at 
least three months. 
B. Typical cataplexy is not present, although doubtful or atypical cataplexy-like 
episodes may be reported. 
C. The diagnosis of narcolepsy without cataplexy must be confirmed by nocturnal 
polysomnography followed by an MSLT. In narcolepsy without cataplexy, the mean 
sleep latency on MSLT is less than or equal to 8 min and two or more SOREMP are 
observed following sufficient nocturnal sleep (minimum 6h) during the night prior to 
the test. 
D. The hypersomnia is not explained better by another sleep disorder, medical or 
neurological disorder, mental disorder and medication use or substance use 
disorder. 
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2.2.3. Clinical symptoms 
The main symptom of narcolepsy is EDS and the most specific one is cataplexy.  
Associated symptoms of narcolepsy are hypnagogic hallucinations (HH), sleep paralysis 
(SP), and nocturnal sleep disruption.  
EXCESSIVE DAYTIME SLEEPINESS (EDS) 
EDS is the core symptom of narcolepsy and occurs in episodes of urgent need to sleep 
several times per day (Billiard et al., 2006). These episodes take place in monotonous 
situations and also in situations where the patient should stay awake, for example, during 
talking, eating, driving a car or being in a business meeting. The episode has a duration 
which varies from minutes to hours. After a sleep episode, a narcoleptic patient will wake 
up refreshed and the next episode will occur 2 or more hours later. In consequence, 
narcolepsy is characterized by a marked disorganization of sleep/wake behavior 
(Scammell, 2003). Patients can experience extreme drowsiness causing memory lapses 
and automatisms also called automatic behavior. This means that the patient will continue 
with the activity despite the sleepiness automatically without consciousness of the task. 
For example, patients will write a note or scribble words that do not make any sense. 
CATAPLEXY 
Cataplexy is the second most common symptom of narcolepsy after EDS (Billiard et al., 
2006). The word cataplexy comes from the Greek word kataplēxis which means the 
fixation (of the eyes) and from kataplēssein, to astound or terrify. In addition, it comes from 
the Latin word cataplēxis, which means “hoc est stupor, mens attonita, admiratio” 
(Forcellini, 1965), the English translation of which is astonishment, amazement, 
admiration.   
In the etymological analysis, the origin of the word cata in English was borrowed from 
other languages. “Most English words with cata were borrowed, often through Latin, after 
the 1500´s as part of Greek words (…) Cata was known in Latin (as in catacomb), it is a 
borrowing from Greek kata-, from katá down, against, over, and is cognate with Old Welsh 
cant with, Old Irish cēt, Hittite katta down, under, with and possibly with Latin com” 
(Barnhart, 1988, p.149). The origin of the word lepsy is also originated from Greek and 
Latin words, it comes from “combining form meaning ´a violent attack´ as in catalepsy, 
epilepsy (medicine) from Greeκ ληψια, literally a seizing, from ληψ the future stem of 
λαμβανειν (lambanein) to take grasp, seize” (Klein, 1967, p.880). The word cataplexy was 
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coined by Henneberg (Henneberg, 1916) and adopted ten years later by Adie (Adie, 
1926).  
Cataplexy is characterized by sudden bilateral loss of muscle tone triggered by strong 
emotions. All striated muscles except the diaphragm may be affected (American Academy 
of Sleep Medicine, 2005) causing the collapse of the patient. Yoss and Daly described that 
narcoleptic patients report “that pleasure or a sense of exaltation on completion of a 
difficult task also may provoke attacks” (Yoss & Daly, 1960). 
Indeed, current studies show that the emotions triggering cataplexy are mainly positives, 
such as laughter, pride, elation or surprise, although negative emotions can also provoke 
cataplexy (Anic-Labat et al., 1999; Krahn, Lymp, Moore, Slocumb & Silber, 2005). 
However, the emotional trigger must be spontaneous because during experiments, even in 
patients with frequent cataplexy, it is not easy to trigger an episode of cataplexy 
(Dauvilliers et al., 2010). The attacks can also be triggered by a sensation of elation while 
watching a movie or listening to music, remembering a funny situation, telling a joke or 
when a patient anticipates saying something amusing (American Academy of Sleep 
Medicine, 2005).  
Cataplexy can affect all skeletal muscle groups simultaneously or can be localized in parts 
of the body that can be regionally affected such as limbs (lower or upper), neck, mouth or 
eyelids (American Academy of Sleep Medicine, 2005). The episode of cataplexy can be 
short and partial, and for that reason it can go undetected during a medical examination 
(Guilleminault, Huang & Lin, 2006). Regarding the reflexes, deep tendon reflexes are 
temporarily suppressed during cataplexy and the H-reflex is normally absent. In healthy 
subjects, the H-reflex can be diminished during laughter but a long-lasting complete lack of 
this reflex is characteristically seen in an episode of cataplexy (Guilleminault, Lee & Arias, 
2006). Checking deep tendon reflexes is reported as a simple and definitive test that 
confirms transient areflexia and atonia of voluntary muscles. During cataplexy, increased 
phasic muscle activity (twitches) may be present. 
Consciousness and awareness of the environment are maintained throughout the episode. 
It has been described that patients have slurred speech but are able to hear (Krahn et al., 
2005). This description is useful for clinicians when the episodes are not typical. The 
electroencephalogram (EEG) during a cataplexy episode shows a pattern of wakefulness 
in humans and animals. When the cataplectic attack is longer, the subjects report 
dreaming and EEG showed typical features of REM sleep (Guilleminault & Gelb, 1995). 
The onset of cataplexy is variable, but in a sample of young narcoleptics (14-23 years), 
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49% of the cases developed cataplexy simultaneously with EDS (Passouant et al., 1976). 
Cataplexy seems to decrease with age (Guilleminault et al., 2006). 
SLEEP PARALYSIS 
Sleep paralysis (SP) has been described as “hypnagogic cataplexy” due to the similarity 
between SP and cataplexy (Yoss et al., 1960). Weir Mitchell, the neurologist, first 
described the condition as “nocturnal paralysis” (Mitchell, 1890). It consists of temporary 
episodes where the patient is incapable of moving although he is aware of his 
surroundings (Yoss et al., 1960). In rare cases, relatives of SP subjects have observed 
temporary breathlessness during sleep paralysis (Yoss et al., 1960) which has been also 
self-reported by the subject (American Academy of Sleep Medicine, 2005).  
Cheyne has proposed that SP can be divided in three categories according to the type of 
hallucinations related to it (Cheyne, 2005). These are intruder, incubus and vestibular-
motor experiences. Intruder experiences are characterized by the sense of a presence 
with the feeling of being touched and hearing noises. Incubus experiences are 
characterized by the sensation of suffocation, bodily pressure and thought of imminent 
dead. Both of them include high levels of fear. Vestibular experiences are different 
because they include sensations of linear and angular acceleration in the form of floating, 
flying and falling. In this type, patients experience out of body experiences, seeing oneself 
from an external point and motor movements. This one is less correlated with fear 
(Cheyne, 2005). SP has been associated with sleep onset REM which is consistent with 
the vivid dreams that are reported (Hishikawa, 1975). Isolated incidence of SP can occur 
in healthy persons who have no symptoms of narcolepsy and may differ among ethnic 
groups (Dahlitz & Parkes, 1993). Isolated SP is not associated with the HLA haplotype 
typical for narcolepsy (Dahlitz et al., 1993). 
HYPNAGOGIC HALLUCINATIONS 
Hypnagogic hallucinations (HH) are dream like, often fear-provoking hallucinations that 
characteristically occur at sleep onset (American Academy of Sleep Medicine, 2005) 
during the phase between wakefulness and sleep. The hallucinations are usually visual 
with reports of seeing people or animals, but can also be tactile, auditory or vestibular such 
as a sense of sudden falling (Scammell, 2003). 
The explanation for the association of hallucinations with sleep paralysis has been 
hypothesized as a link with gamma loop (motoneuron which control muscles) suggesting a 
reflex contraction of the entire muscles (Kryger, Roth & Dement, 2005). 
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The hallucinations in narcolepsy are different than the kind of hallucinations that people 
with schizophrenia experience (Dahmen, Kasten, Mittag & Muller, 2002), as well as 
hallucinations that go along with bipolar depression, depression with psychotic symptoms 
and Morvan´s Syndrome (Jouvet, 1998). The differences in type, quality and body posture 
dependence of hallucinations between narcoleptics and schizophrenics do not support the 
hypothesis of a common pathophysiological mechanism such as REM intrusion for 
hallucinations (Dahmen & Kasten, 2001). 
Symptoms similar to narcolepsy can be associated with psychiatric disorders. Curt 
Rosenthal described in 1934 hallucinations and some kind of “sleep paralysis” similar to 
the real sleep paralysis in narcolepsy which were related to fear. This is known in German 
as “halluzinatorisch - kataplektisches Angstsyndrom” (Hallucinatory- Cataplectic Anxiety 
syndrome) and occurs in the context of schizophrenia (Bassetti, Billiard & Mignot, 2007).  
Further, HH is well recognized in Parkinson’s disease (Barnes, Connelly, Wiggs, Boubert 
& Maravic, 2010).  
NOCTURNAL SLEEP DISTURBANCES 
Narcolepsy patients have normal amounts of sleep over 24 hours but disrupted nighttime 
sleep (American Academy of Sleep Medicine, 2005). Patients show a polyphasic sleep, 
with preserved circadian rhythms and with a homeostatic sleep regulation (Plazzi, Serra & 
Ferri, 2008). Broughton demonstrated that patients with good or relatively normal nighttime 
sleep still have a pathological daytime sleepiness. According to this, nocturnal 
disturbances would be just a little contributor for sleepiness during the day (Broughton, 
Dunham, Weisskopf & Rivers, 1994). 
OTHER SYMPTOMS ASSOCIATED WITH NARCOLEPSY 
? Cognitive impairment: 
Narcoleptic patients frequently complain about impaired memory. A Canadian study shows 
that narcoleptic patients do not have a memory deficit compared to controls. They interpret 
the subjective memory deficit as a motivational problem (Aguirre, Broughton & Stuss, 
1985). The authors suggest that when the test is shorter and challenging the patients may 
stay alert (Aguirre et al., 1985). 
In another study measuring cognitive impairment of 700 narcoleptics, researchers found 
that 38% subjectively reported moderate or severe memory problems, 39% had problems 
with forgetfulness, 40% with concentration and 26% with general learning (Smith et al, 
1992).   
Theoretical part-23 
Some authors have gathered evidence that narcolepsy patients have a decreased 
cognitive performance in comparison with controls due to the complaints of memory 
problems (Fulda & Schulz, 2001) but until now it is not clear if decreased cognitive 
performance is due to the daytime sleepiness or if is due to the pathophysiology of the 
illness. Researchers at the University of Bochum reported that narcoleptics showed a mild 
verbal memory deficit and increased forgetting rates, which may be explained by a 
reduced encoding efficiency (Naumann, Bierbrauer, Przuntek & Daum, 2001). This 
reduction is probably because patients with narcolepsy need to use cognitive resources to 
stabilize vigilance levels at the same time (Naumann et al., 2001). 
? Obesity and eating disorders: 
Obesity is another feature of narcolepsy already distinguished by Daniels (Daniels, 1934). 
Different authors (Kok et al., 2003; Hara et al., 2001; Schuld et al., 2000) report an 
increased BMI in patients with narcolepsy. Some of them suggest that a higher BMI is 
related to the pathological link that involves hypocretin deficiency in narcoleptic patients 
(Schuld et al., 2000). Although hypocretin deficiency should theoretically be a predictor of 
a reduced food intake, this is not the case (Willie, Chemelli, Sinton & Yanagisawa, 2001), 
probably due to multiple factors involved in the pathology of narcolepsy. Narcoleptic 
patients are prone to develop obesity while idiopathic hypersomnia patients are less 
obese. This supports the hypothesis that destruction of hypocretin neurons is involved in 
the pathogenesis of obesity in narcolepsy (Kok et al., 2003). This link between narcolepsy 
and obesity is consistent also with animal models of narcolepsy (Hara et al., 2001).  
Bixler mentioned that several studies have shown that obesity is associated with reduced 
nocturnal sleep (Bixler et al., 2005). The above mentioned study evidently could be linked 
to the poor night’s sleep in narcolepsy and the high BMI, which is well documented in the 
literature (Chabas et al., 2007; Kok et al., 2003; Dahmen, Bierbrauer & Kasten, 2001; 
Krahn, Moore & Altchuler, 2001b). 
Obesity in narcoleptics can also be explained by eating disorders. According to a Dutch 
study, there is a high prevalence of narcoleptic patients with cataplexy reporting symptoms 
of eating disorders such as craving for food or binge eating behavior (Fortuyn et al., 2008). 
The exact mechanism associating narcolepsy with obesity is still unknown. 
? Olfactory dysfunction: 
Recently, investigators linked narcolepsy with olfactory dysfunction. The study, performed 
with only 20 patients, suggests that olfactory dysfunction may be a predictor of local 
degeneration of hypocretinergic mucosa cells (Stiasny-Kolster, Clever, Moller, Oertel & 
Mayer, 2007). This is remarkable because olfactory dysfunction is one of the first signs of 
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a neurodegenerative disorder. In line with this finding, a recent French study showed that 
patients with Parkinson disease (PD) could suffer from cataplexy episodes (Arnulf et al., 
2000). The Francophone study and other two studies simultaneously reported that there is 
a loss of hypocretin cells in Parkinson patients. The similarities with Parkinson patients are 
not only related to the possible olfactory dysfunction but also with the typical EDS and to a 
lesser extent to the hallucinations present in Parkinson patients. Moreover, another link 
with PD is REM-behavior disorder, which was described in narcolepsy patients, especially 
in children (Nevsimalova, Buskova, Kemlink, Sonka & Skibova, 2009b; Arnulf et al., 2000)  
2.2.4. Etiology  
HLA ASSOCIATION 
The family of genes called human leukocyte antigens (HLA) located on chromosome six 
codes for mechanisms that trigger an immune response. In the case of narcolepsy, a 
specific variant of the HLA gene DQB1 has been identified to be strongly associated with 
this sleep disorder (Langdon, Welsh, van, Vaughan & Parkes, 1984). 
Initially, this association was believed to be with HLA DR2, later the association most 
closely linked to narcolepsy was found to be HLA DQB1*0602 (Honda et al., 1986). 
Recently, a study reported that the haplotype DQB1*0603 is a protective HLA haplotype in 
narcolepsy vulnerability. This haplotype is seldom seen in patients with narcolepsy and is 
recognized as one of the main protective alleles against autoimmune disorders such as 
diabetes type 1 and rheumatoid arthritis (Hor et al., 2010). 
NEUROTRANSMITTER HYPOCRETIN 
In 1998, two different research groups identified a new neurotransmitter in the 
hypothalamus relevant to narcolepsy. One group named it “orexin” due to its role in food 
intake (Sakurai et al., 1998) and the other group “hypocretin” because it is similar to the 
hormone secretin and due to its hypothalamic origin (De Lecea et al., 1998). 
Hypocretin 1 is a 33 amino-acid peptide (3562Da) and hypocretin 2 (2937Da) has 46% of 
the amino-acids identified in the sequence of hypocretin 1 (Korotkova, 2003). These 
peptides are produced only by a cluster of neurons in the posterior half of the lateral 
hypothalamus (Saper, Scammell & Lu, 2005). 
Hypocretin (Hcrt) regulates sleep and wakefulness. The hypocretinergic system is involved 
in other functions like the regulation of food intake, autonomic control, sensory control and 
energy balance (Baumann & Bassetti, 2005). Narcolepsy with cataplexy and positive HLA 
DQB1*0602 is linked with low or undetectable levels of Hcrt (Nishino et al., 2000). 
Theoretical part-25 
HYPOCRETIN IN NARCOLEPSY 
The first experimental studies regarding Hcrt system were carried out in animal models of 
narcolepsy. Lin et al (1999) observed that in canine narcolepsy is due to the mutation of 
Hcrt-2 and this result in an REM sleep abnormality such as cataplexy (Lin et al 1999). 
Hcrt-2 knockout mice show a typical narcolepsy behavior (Willie et al., 2001). As a 
consequence of the experimental studies of Hcrt in the animal narcolepsy model, the 
human narcolepsy model began to be studied. Nishino and collaborators first reported low 
levels of Hcrt-1 in around 90% of narcolepsy patients with cataplexy and HLA type 
DQBI*0602 (Nishino et al., 2000). 
Using the Fos protein as a index of neuronal activity, it was demonstrated that Hcrt 
neurons are activated only when there is motor activity during wakefulness and inactive 
during slow wave sleep. Therefore the Hcrt system would be predominantly involved in the 
enhanced arousal of motor activity mediated by histamine (Torterolo & Vanini, 2003). A 
subpopulation of Hcrt neurons is active during REM sleep. 
The main function of Hcrt system is probably the facilitation of the motor system which 
accompanies the wakefulness. This was confirmed by Kiyashchenko and collaborators 
(2002) who, using microdyalisis, described an increase of the release of Hcrt during motor 
activity (Kiyashchenko et al., 2002).  
HYPOCRETIN DESTRUCTION 
The destruction of Hcrt neurons either genetically or with chemical toxins, is, 
hypothetically, the cause of facilitated REM sleep (Scammell, 2003). The probable place 
where the neurons are destroyed was recently reported. The study revealed that a lesion 
in the ventral lateral periaqueductal gray neurons increased REM sleep at night, but does 
not trigger cataplexy (Kaur et al., 2009). In most of cases, it is a destruction of the 
hypocretinergic neurons that causes a low level of Hcrt-1 (Torterolo, Yamuy, Sampogna, 
Morales & Chase, 2003). However, a Norwegian study revealed that only 72% of patients 
with NC+ had low levels of Hcrt (≤134pg/ml) (Heier et al., 2007). The difference in the 
study results is not clear, but could be due to the ethnically diverse patient population or 
due to the inclusion of some patients in the cataplexy group who had the so called 
“pseudocataplexy” (Krahn, Hansen & Shepard, 2001a). 
Recently, a study showed that not only narcolepsy with cataplexy loses Hcrt cells but also 
narcolepsy without cataplexy. However, the depletion is not as much as those levels found 
in patients with cataplexy (Thannickal, Nienhuis and Siegel, 2009). Thannickal based his 
study only on two postmortem brains specimens of patients with narcolepsy without 
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cataplexy. The small sample is because it is difficult to obtain such brain samples and 
therefore, this study needs replication. 
AUTOIMMUNE HYPOTHESIS FOR THE HYPOCRETIN DEFICIENCY 
In addition to genetics, an autoimmune process could explain the above mentioned Hcrt 
destruction. This hypothesis is supported by a study suggesting a streptococcal infection 
and a recently published study regarding antibodies. 
? Streptococcal infections: 
Several patients have claimed that environmental factors triggered narcolepsy, but few 
studies directly tested this hypothesis. Recently, Aran and fellow researchers, in a sample 
of 200 patients with recent onset of narcolepsy in comparison with age matched controls, 
showed that the rate of increased antistreptococcal antibodies is increased in narcoleptic 
patients (Aran et al., 2009). The presence of streptococcal infections could start or cause 
an autoimmune response resulting in the destruction of Hcrt neurons.  
? Tribbles homolog-2: 
Recently, the research group of Tafti in Switzerland found evidence that supports the 
hypothesis that narcolepsy is an autoimmune disorder. They report that sera from 
narcolepsy patients with cataplexy had higher Tribbles homolog-2 (Trib2) specific antibody 
levels compared with healthy controls, patients with narcolepsy without cataplexy, 
idiopathic hypersomnia, multiple sclerosis or other inflammatory diseases. Additionally, 
they found a positive correlation between Trib2 and cataplexy (Cvetkovic-Lopes et al., 
2010).  
VOXEL-BASED MORPHOMETRY STUDIES 
Several studies have investigated structural brain changes in the hypothalamus of 
narcoleptics. Three of them revealed areas of reduced gray matter in the hypothalamus of 
narcoleptics (Kim et al., 2009; Buskova, Vaneckova, Sonka, Seidl & Nevsimalova, 2006; 
Draganski et al., 2002). The remaining studies found no structural abnormalities in the 
hypothalamus of patients with narcolepsy (Brenneis et al., 2005; Overeem et al., 2003; 
Kaufmann, Schuld, Pollmaecher & Auer, 2002). Interestingly, among the studies without 
significant abnormalities, one researcher’s group found a reduction in bilateral cortical gray 
matter but not subcortical gray matter alterations (Kaufmann et al., 2002).  
2.2.5. Pathophysiology 
An explanation for cataplexy, sleep paralysis and hypnagogic hallucinations is that 
narcoleptic patients have abnormal manifestations of REM sleep that intrude into 
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wakefulness (Scammell, 2003). The pathophysiology of cataplexy seems to be an 
imbalance between pontine monoaminergic and cholinergic neuronal populations 
(Overeem, Lammers & van Dijk, 2002). The cataplexy event is produced by the activation 
of the neural systems responsible for the typical REM without muscular tonus during 
wakefulness (Torterolo et al., 2003). Researchers have found an increase in postsynaptic 
dopamine type 2 receptors in the amygdala with an impairment of dopamine discharge in 
dogs (American Academy of Sleep Medicine, 2005). Other brain regions such as the basal 
forebrain/anterior hypothalamus play a role in the modulation of cataplexy. 
THE FLIP-FLOP SWITCH MODEL: EXPLANATION OF THE WAKE-SLEEP TRANSITIONS 
A flip-flop switch is a circuit to design two stable states with immediate transitions. This 
kind of circuit tends to avoid transitions states. This is because when one of the states 
begins to decline, the other one will rapidly increase and the system will “flip” to the 
alternative state. The existence of such a flip-flop switch explains the sudden transition 
sleep-wakefulness. Humans and animals spend no more than 1 to 2% of each day in a 
transition state. There are two reasons of adaptation for the sleep wake system of the flip-
flop switch. First, it is because it would be dangerous for an animal to have an impaired 
attention during wakeful behavior. Second, it would be inefficient to use the time spent 
sleeping in a half wake state. The flip-flop circuit would involve the VLPO (ventrolateral 
preoptic nucleus) and monoaminergic cell groups (Saper et al., 2005). 
? Hcrt and state stability: 
Hcrt neurons have ascending and descending projections in the cerebral cortex. There are 
mutual projections between VLPO and Hcrt neurons but VLPO neurons do not express 
receptors of Hcrt. Consequently, Hcrt neurons can reinforce the arousal system but do not 
inhibit VLPO neurons. This is called an asymmetrical relationship. This asymmetric link 
can stabilize the change flip-flop, preventing unwanted transition into sleep (Saper et al., 
2005). The flip-flop switch is relatively unstable but Hcrt neurons help to stabilize this 
switch. 
? Flip-flop switch in narcoleptics with hypocretin deficiency: 
Narcoleptic patients have EDS and will take several naps during the day. This is because 
they do not have the influence of Hcrt neurons in the VLPO. Therefore, it is hypothesized 
that the flip-flop switch is destabilized in narcoleptics (Saper et al., 2005). 
The flip-flop system explains sleepiness in patients with Hcrt deficiency but does not 
explain sleepiness in patients without Hcrt deficiency. 
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CATAPLEXY AS AN ATAVISM (REAPPEARANCE OF ANCESTRAL CHARACTERISTICS) OF TONIC 
IMMOBILITY. 
A different hypothesis considers cataplexy as a form of tonic immobility. Tonic immobility 
(TI) is an animal response, described when an animal is confronted with an extreme risk. 
The EEG shows that the animal is totally awake similar to cataplexy episodes and the 
animal may fall asleep after long-lasting immobility (Overeem et al., 2002). The authors 
recognize that TI does not occur in humans. Nonetheless, cataplexy and TI share the 
strong emotional trigger. This hypothesis needs further confirmation.   
2.2.6. Epidemiology  
The most important study was performed in Finland with 11,354 subjects; the researchers 
found that the prevalence of narcolepsy in the population was 0.026% (Hublin et al., 1994). 
Other studies in England, France, the Czech Republic and the USA show a similar 
prevalence of about 0.02 to 0.067%. The center for narcolepsy at Stanford University 
suggests that the prevalence of narcolepsy with cataplexy is within a range of 0.02 and 
0.18% (Nishino, Okura & Mignot, 2000). 
In general, the prevalence of narcolepsy in Europe and North America is estimated to be 
about 1 in 3000 (0.03%). In South America there are no data on the prevalence until now. 
Interestingly, in Japan, the prevalence is much higher: between 0.16 and 0.18% while in 
Israel it is considerably lower at about 0.002%. 
According to Billiard, the methodology used in the studies of prevalence performed in 
Japan is a matter of discussion. In contrast, the data from Israel are consistent with the low 
rate of HLA-DQB1*0602 found in the Jewish population. Nonetheless, it is still necessary 
to perform population studies to establish such low prevalence (Billiard et al., 2006). 
Narcolepsy (as a whole) is more common in men than in women with a prevalence rate of 
1.8:1 in narcolepsy. In narcolepsy with cataplexy, the male predominance is lower (1.4:1) 
but is still present (Silber, Krahn, Olson & Pankratz, 2002). This study confirmed previous 
findings reported by Roth (Roth, 1980). With respect to age at onset, in narcolepsy with 
cataplexy there is evidence for a bimodal distribution with two peaks, the first one 
occurring at 14.7 years and the second one at 35 years of age (Dauvilliers et al., 2001). 
The onset of narcolepsy is not correlated with sex or HLA type (Longstreth, Jr., Koepsell, 
Ton, Hendrickson & van Belle, 2007). 
2.2.7. Diagnosis 
Regarding to the clinical diagnosis, the definite presence of cataplexy is the specific 
symptom which characterizes narcolepsy with cataplexy (Table 2). In the case of doubtful 
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cataplexy, the patient with two or more SOREMP on the MSLT should be included in the 
category non cataplexy. It is known that some of these patients will develop cataplexy later 
on (American Academy of Sleep Medicine, 2005). A cataplexy episode should be 
differentiated from the common experience of muscle weakness during sport or when 
laughing uncontrollably. Additionally some subjects feel weak after stressful events which 
should be not considered cataplexy. Cataplexy must be differentiated from hypotension, 
transient ischemic attacks, drop attacks, akinetic seizures, neuromuscular disorders, 
vestibular disorders, sleep paralysis and psychological or psychiatric disorders. In 
psychiatric disorders, cataplexy should be carefully differentiated from a pseudocataplexy 
(Krahn et al., 2001a), for instance, in the context of a conversion disorder (American 
Psychiatric Association, 2000). 
Patients with narcolepsy can have other diagnoses such as obstructive sleep apnea, 
periodic limb movement disorder or behaviorally induced insufficient sleep syndrome. 
However, this does not explain the symptom of excessive daytime sleepiness. 
Regarding to the diagnosis using the MSLT, when two or more SOREMP along with mean 
sleep latency shorter than 8 minutes are found (Table 2) without the explicit presence of 
cataplexy, the diagnosis is narcolepsy without cataplexy and when SOREMP are less than 
two, the diagnosis of idiopathic hypersomnia must be kept in mind. Patients with 
narcolepsy do not normally have long episodes of sleep during the day, which is more 
typical for idiopathic hypersomnia with long sleep time. 
2.2.8. Treatment of narcolepsy  
Sleepiness and cataplexy persist throughout life and often improve after retirement 
probably due to better management of activities and napping schedules (Dauvilliers et al., 
2004). Although medication can increase alertness, avoiding cataplexy and diminishing 
nocturnal disturbances to the patients, there is no complete cure for narcolepsy.  
MEDICATION USED FOR EXCESSIVE DAYTIME SLEEPINESS AND IRRESISTIBLE EPISODES OF SLEEP 
According to the guidelines of the European Federation of Neurological Societies (EFNS) 
for the treatment of EDS and irresistible episodes of sleep, modafinil should be the first-
line therapy and the second-line should be methylphenidate. In case of high severity of 
these symptoms, the combination of modafinil and sodium oxybate is recommended 
(Billiard et al., 2006). 
? Amphetamines and amphetamine-like CNS stimulants:  
The treatment with stimulants (ephedrine and amphetamine) began in 1931 by Dr. Janota 
in patients with narcolepsy (Daniels, 1934). 
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The mechanism of action of amphetamines is dependent on the dose. If it is used at low 
doses, the effect is to discharge dopamine and, to a lesser extent, norepinephrine and 
serotonine. If it is used at high doses, the result is a monoaminergic decrease with an 
inhibition of the reuptake (Billiard et al., 2006).  
The adverse effects are similar to those previously described by Yoss and Daly: irritability, 
hyperactivity, mood changes, headache, palpitations, sweating, tremors, anorexia and 
insomnia (Yoss & Daly, 1959). Side effects of some medication perhaps influenced the 
results of psychopathological findings in patients with narcolepsy. For instance, in MMPI, 
elevations in the scales psychasthenia or schizophrenia (Kales et al., 1982) may be biased 
not only by the physical symptoms but also by the use of stimulants.  
? Methylphenidate: 
Yoss and Daly (1959) accurately described the treatment with methylphenidate 
hydrochloride with a daily dosage of 40 to 80mg in 60 patients with narcolepsy and 
followed some of them for eight to 27 months. They report side effects such as 
nervousness, anorexia, insomnia, tachycardia and in some rare cases skin rash (Yoss et 
al., 1959). The action is the same as for amphetamine with the difference that there is no 
reuptake (Billiard et al., 2006). 
The adverse effects are similar but with the considerations that clinically it seems to be 
slightly better than amphetamines and there is a smaller decrease of appetite and an 
increase in blood pressure (Billiard et al., 2006). 
? Modafinil: 
The way of action of modafinil is not completely understood. The possible mechanisms of 
action are associated with adrenergic alpha-1 stimulation, interactions of the dopamine 
systems and the compromise of serotonergic/GABAergic mechanisms (Billiard et al., 
2006). 
Some adverse effects described are headache, nausea and rhinitis in a range of 11 to 
13% compared with 2 to 3% in the placebo group (US modafinil in narcolepsy multicenter 
study group, 2000). Modafinil affects the mood in narcoleptics and a randomized study 
shows that modafinil improved mood also in healthy subjects and had a significant effect in 
positive life scale events (Taneja, Haman, Shelton & Robertson, 2007). Studies also show 
that narcolepsy patients under treatment with modafinil report improvement in 
psychological well-being and self-esteem between other variables (Beusterien et al., 
1999).  
In a study about the effect of modafinil on fatigue, mood and quality of life in narcoleptics, 
a significant improvement in vigor and cognition was reported (Becker, Schwartz, Feldman 
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& Hughes, 2004). In addition, the authors found a reduced fatigue in the patients assessed 
by the Profile of Mood States. Besides, in the Short Form Health Survey (SF-36) specific 
improvements were seen in vitality, role-physical and social functioning (Becker et al., 
2004). Side effects of stimulants include insomnia, headaches, anxiety and palpitations 
(Mitler, Aldrich, Koob & Zarcone, 1994). It has been argued that stimulants may complicate 
some psychiatric and interpersonal problems of patients with narcolepsy. But side effects 
may be less pronounced with modafinil in comparison to other stimulants (Mitler et al., 
1994). To a lesser extent, there are also negative reports using modafinil. Recently, a case 
was reported about a patient with narcolepsy with cataplexy and HLA-DQB1*0602 with 
pathological gambling associated with modafinil. The 39-year-old patient had no 
psychiatric history or medical co morbidity except narcolepsy but did have a prior history of 
minor gambling. When modafinil was interrupted, the gambling habits disappeared 
although somnolence increased (Tarrant, Cavanna & Rickards, 2010). The authors 
suggest that due to the potentiation of the dopaminergic system, modafinil can have as a 
side effect pathological gambling in individuals with a predisposition for this kind of impulse 
control disorder. Another case-report describes a narcoleptic patient without cataplexy who 
developed a psychotic episode under 500mg of modafinil. The patient’s dosage was 
increased (settled in 400mg divided on two doses per day) because of a test to assess the 
capacity to drive (Wu, Jones, Ryan, Michail & Robinson, 2008). The authors mention three 
other similar reports of modafinil inducing psychosis. 
? Phenelzine: 
Phenelzine is a non-selective inhibitor of the monoamine oxidase (MAO) and the treatment 
has the potential risk of a hypertensive crisis if the patient consumes too much food 
containing tyromine or dopamine. This is therefore an inadequate long-term treatment. 
? Selegiline: 
Selegiline is an irreversible MAO-B selective inhibitor and is metabolized in 
methamphetamines, amphetamine and desmethylselegiline. The use of selegiline is 
restricted due to possible sympathomimetic (substances that mimic the effects of the 
sympathetic nervous system) side effects and interaction with other drugs (Billiard et al., 
2006). 
? Gamma-hydroxyburate (GHB) also known as Sodium oxybate: 
GHB is produced naturally in the body and is the most recent medication approved for the 
management of narcolepsy patients. Currently, this represents an alternative treatment for 
hypersomnia, cataplexy and a poor night’s sleep. GHB is a neurotransmitter or 
neuromodulator present in the central nervous system that possibly acts to silence 
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dopaminergic neurons (Billiard et al., 2006). GHB was discovered in 1960 and became 
renowned for its therapeutic value as well as for being a substance open to abuse. In 
1979, Broughton and Mamelak recommended the prescription of GHB as a treatment for 
cataplexy (Broughton & Mamelak, 1979). During the 1980´s, GHB increased in popularity 
for the use in weight loss, bodybuilding and the treatment of sleeplessness. Also it was 
known as a substance used in sexual assaults. The adverse effects are nausea, nocturnal 
enuresis, confusional arousals and headache (Billiard et al., 2006). Recently, Rossetti and 
his team reported two cases of young male narcolepsy-cataplexy patients (18 and 25 year 
old) who developed depression after sodium oxybate in combination with Modafinil 
(Rossetti, Heinzer, Tafti & Buclin, 2010). 
Both cases recovered completely after sodium oxybate discontinuation. The case is 
interesting as modafinil itself is known to produce nervousness (Mitler et al., 1994) and 
suggests that the combination of both medications might trigger depression in vulnerable 
subjects. The mechanism of action may be associated with the GABA-B receptors 
although the exact pathway remains unclear (Rossetti et al., 2010).  
MEDICATION USED FOR CATAPLEXY  
GHB and clomipramine (a non specific monoamine uptake inhibitor) are indicated for 
cataplexy. All other medications are off-label. 
? Gamma-hydroxyburate (GHB):  
GHB reduces cataplexy in a large number of patients. The cessation of GHB in the 
placebo group produced an increase in the number of cataplexy episodes compared to 
those patients who continued on treatment. As previously mentioned (see above in 
medication used for EDS), GHB has adverse effects but patients do not report tolerance 
(Billiard et al., 2006). 
? Non-specific monoamine uptake inhibitors: 
For the control of cataplexy episodes, tricyclic antidepressants like imipramine, 
desmethylimipramine, clomipramine and protriptylin have been used. 
Clomipramine is the most evaluated treatment for cataplexy and demonstrated efficacy. 
The adverse effects are typical for anticholinergics which include dry mouth, sweating, 
weight increase, tachycardia, constipation, hypotension, impotence and difficulty urinating 
(Billiard et al., 2006). 
? Newer antidepressants for cataplexy: 
The newer antidepressants for cataplexy are selective serotonin reuptake inhibitors 
(including femoxetine, fluoxetine and fluvoxamine). The daily doses are higher than for 
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tricyclics and the effects are less marked. Side effects include central nervous system 
excitation, gastrointestinal troubles, movement disorders and sexual dysfunctions (Billiard 
et al., 2006). Noradrenalin uptake inhibitors (viloxazine) reduce cataplexy and have few 
side effects. Serotonin and noradrenalin reuptake inhibitors (venlafaxine) do not have the 
side effects of tricyclic antidepressants. The adverse effects are increased heart rate and 
blood pressure. 
BEHAVIORAL TREATMENTS FOR EDS AND CATAPLEXY 
It is recommended that the patient take naps according to his or her daily activities and 
that he or she maintain a regular sleep schedule (Billiard et al., 2006). Naps can increase 
alertness and decrease the use of stimulants in some patients (Bassetti, 1999). 
TREATMENT OF ADDITIONAL SYMPTOMS OF NARCOLEPSY -HALLUCINATIONS, SLEEP PARALYSIS 
AND POOR NIGHT SLEEP- 
The treatment for HH and SP is a therapy for REM-associated phenomena, therefore the 
recommendation is the same as for cataplexy. Nonetheless, there are few studies based 
on evidence. For nocturnal sleep disturbances, the use of benzodiazepines or non-
benzodiazepines is recommended. Patients under treatment with modafinil report a 
notable improvement. Currently, the best option for night sleep disturbances is GHB 
(Billiard et al., 2006). 
Theoretical part 
2.3. Idiopathic hypersomnia 
2.3.1. History of the diagnosis of idiopathic hypersomnia  
After narcolepsy was relatively well described, a diagnostic problem become visible with 
those patients who where excessively sleepy, although did not meet the criteria for 
narcolepsy.  
In Prague, Bedrich Roth described for the first time a syndrome with a characteristic of 
excessive daytime sleepiness, prolonged sleep and sleep drunkenness but without sleep 
attacks, cataplexy, sleep paralysis, or hypnagogic hallucinations (Roth, 1980). Due to the 
typical drunkenness, Roth coined the term “hypersomnia with sleep drunkenness” or 
“independent sleep drunkenness” (Roth, 1980). Roth described two clinical forms of 
idiopathic hypersomnia called monosymptomatic and polysymptomatic. The first referred 
to patients with marked non-imperative daytime sleepiness with sleep attacks with a length 
of 30 minutes to several hours. The second included also daytime sleepiness but in co-
occurrence with abnormally prolonged nocturnal sleep with rapid falling asleep and sleep 
drunkenness upon awakening (Roth, 1975). This condition is now known as idiopathic 
hypersomnia (IH) and was defined in 1979 in the first International Classification of Sleep 
Disorders (Table 3) (American Sleep Disorders Association, 1991).  
Until now, this diagnosis is an issue of discussion. This matter was re-discussed during the 
revision of ICSD-2 by the task force in 2007. Currently, the diagnosis of IH is separated in 
two conditions: IH with long sleep time and without long sleep time. Some members of the 
American Academy of Sleep Medicine proposed to integrate IH without long sleep time 
with narcolepsy without cataplexy but this suggestion was not accepted (Billiard, 2009). 
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Table 3. Diagnostic criteria of idiopathic hypersomnia (IH) according to the 
International Classification of Sleep Disorders-first version (ICSD-1) (American 
Sleep Disorders Association, 1991). 
 ICSD-1 diagnostic criteria of idiopathic hypersomnia  
A. A complaint of prolonged sleep episodes, excessive sleepiness or excessively deep 
sleep 
B. Presence of a prolonged nocturnal sleep period or frequent daily sleep episodes 
C. The onset is insidious, and typically before age 25 years 
D. The complaint is present for at least six months 
E. The onset does not occur within 18 months of head trauma 
F. Polysomnography demonstrates one or more of the following: 
1. A sleep period that is normal or prolonged in duration  
2. Sleep latency less than 10 min. 
3. Normal REM sleep latency  
4. An MSLT that demonstrates sleep latency less than 10 min. 
5. Less than two sleep-onset REM periods 
G. Absence of any medical or psychiatric disorder that could account for the symptom  
H. Does not meet the diagnostic criteria of any other sleep disorder causing excessive 
sleepiness, e.g. narcolepsy, obstructive sleep apnea syndrome or posttraumatic 
hypersomnia 
 
2.3.2. Classification: idiopathic hypersomnia with and without long sleep 
time 
In IH with and without long sleep time, sleep drunkenness and few or not awakenings 
during sleep are typical characteristics. The difference between the condition with long 
sleep time and without is the sleep time. If it is prolonged, which means more than 10 
hours, the condition is called with long sleep time but if the sleep time is not prolonged, 
which means more than 6 hours but less than 10 hours, then the condition is called without 
sleep time (Table 4). 
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Table 4. Diagnostic criteria of idiopathic hypersomnia (IH) according to the 
International Criteria of Sleep Disorders-second version (ICSD-2) (American Sleep 
Disorders Association, 2005). 
ICSD-2 diagnostic criteria of idiopathic hypersomnia (IH). 
 I. Criteria for IH with long sleep time. 
A. The patient has a complaint of excessive sleepiness occurring almost daily for at 
least three months 
B. The patient has prolonged nocturnal sleep time (more than 10h) documented by 
interview, actigraphy or sleep logs. Waking up in the morning or at the end of 
naps is usually laborious 
C. Nocturnal polysomnography has excluded other causes of daytime sleepiness 
D. The polysomnogram demonstrates short sleep latency and a major sleep period 
that is prolonged to more than 10h in duration 
E. If an MSLT is performed following overnight polysomnography, a mean sleep 
latency of less than 8 min is found and fewer than two SOREMP are recorded 
Mean sleep latency in IH with long sleep time has been shown to be 6.2±3 min 
F. The hypersomnia is not better explained by another sleep disorder, medical or 
neurological disorder, mental disorder, medication use or substance use 
disorder 
 II. Criteria for IH without long sleep time 
A. The patient has a complaint of excessive sleepiness occurring almost daily for at 
least three months 
B. The patient has normal nocturnal sleep (greater than 6h but less than 10h) 
documented by interviews, actigraphy or sleep logs 
C. Nocturnal polysomnography has excluded other causes of daytime sleepiness 
D. The polysomnogram demonstrates a major sleep period that is normal in 
duration (greater than 6h but less than 10h) 
E.  An MSLT following overnight polysomnography demonstrates a mean sleep 
latency of less than 8 min and fewer than two SOREMP. Mean sleep latency in 
IH has been shown to be 6.2±3 min 
F. The hypersomnia is not better explained by another sleep disorder, medical or 
neurological disorder, mental disorder, and medication use or substance use 
disorder 
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2.3.3. Clinical symptoms 
This sleep disorder presents the characteristics of severe excessive daytime sleepiness 
with not-refreshing naps of up to three or four hours, a major sleep episode prolonged to at 
least 10 hours typically even 12 to 14 hours with few or no awakenings. The patients have 
problems waking up in the morning or at the end of a nap with sleep drunkenness upon 
awakening (Billiard, 2009; American Academy of Sleep Medicine, 2005). Although these 
symptoms are features of IH and narcolepsy, they are also present in other illness such as 
psychiatric disorders and hypersomnia linked to other neurological disorders (Kryger et al., 
2005). Some IH patients have spontaneous improvement for more than 6 months. 
However this cannot be predicted because the clinical and polysomnographic features are 
similar between individuals who improve and those who do not (Anderson, Pilsworth, 
Sharples, Smith & Shneerson, 2007).  
EXCESSIVE DAYTIME SLEEPINESS, NAPS AND SLEEP EFFICIENCY 
Unlike in narcoleptic patients, EDS in idiopathic hypersomniacs is not imperative yet 
permanent (American Academy of Sleep Medicine, 2005). The consequence is frequent 
naps that are not refreshing. Some patients report that they avoid the naps as much as 
possible because of the subsequent sleep drunkenness; nonetheless, this can increase 
automatic behaviours (Kryger et al., 2005). Although planned naps are unfavourable, 
authors mention that some IH patients can have short and refreshing naps (Bassetti et al., 
1997). The sleep of IH patients is typically undisturbed. In comparison with narcoleptics, 
the sleep efficiency of IH is significantly better (Anderson et al., 2007), with fewer 
awakenings and reduced wake duration (Bruck & Parkes, 1996). 
SLEEP DRUNKENNESS 
Sleep drunkenness is a typical symptom of IH and is characterized by a difficulty to wake 
up. It is associated with automatic behavior, confusion and recurrent returns to sleep 
(Anderson et al., 2007). Patients commonly report that they do not awake with clocks 
(American Academy of Sleep Medicine, 2005) which render it necessary to use other 
creative ways to get out of bed. The sleep inertia also called the “time to get going” can be 
considerably long during the morning (Kryger et al., 2005). 
OTHER ASSOCIATED SYMPTOMS 
IH patients often have SP and HH although these symptoms are commonly described in 
narcoleptics (Vernet & Arnulf, 2009; Bassetti et al., 1997). Associated symptoms are 
headaches; orthostatic hypotension with syncope and peripheral vascular complaints 
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(Raynaud´s type phenomena with cold hands and feet) but normally they do not require 
medical care (Bassetti et al., 1997). A study shows evidence that IH, particularly with long 
sleep time, is associated with evening type (chronotype) and young age (Vernet et al., 
2009). 
2.3.4. Etiology  
The etiology is unknown. In contrast to narcolepsy, the disorder is not related to certain 
HLA types or Hcrt levels and a precipitating factor has not been identified. Guilleminault 
(2001) suggests the possibility that IH is a consequence of undiagnosed encephalitis but 
this is difficult to investigate.  
2.3.5. Pathophysiology  
Little is known about the pathophysiology of IH with and without long sleep time. A 
Norwegian study affirmed that narcolepsy patients without cataplexy could not be 
distinguished of IH by biochemical findings (Heier et al., 2007). There is evidence that IH 
patients have normal Hcrt-1 concentrations in the cerebrospinal fluid and a decreased 
histaminic transmission (American Academy of Sleep Medicine, 2005). A Czech study 
found a lower nocturnal level of melatonin in IH compared with controls (Nevsimalova et 
al., 2000). The same group found a phase delay in the rhythm of melatonin and cortisol 
secretion in patients with polysymptomatic form of IH (Nevsimalova et al., 2009). 
Kanyabashi and collaborators found decreased histamine in the cerebrospinal fluid in 14 
IH patients (Kanbayashi et al., 2009).  
Regarding polysomnography data in IH patients, a research group hypothesized that there 
is a decreased slow wave sleep during the first two sleep cycles, suggesting that non 
restorative night sleep might be the cause of EDS (Sforza, Gaudreau, Petit & Montplaisir, 
2000). However, this finding requires replication. Studies exist that have documented a 
consistent familial predisposition to IH with long sleep time (Billiard et al., 2001a). 
2.3.6. Epidemiology 
IH is a rare condition whose prevalence is unknown but is estimated to be about 10 times 
less than narcolepsy. There is no sex predominance (American Academy of Sleep 
Medicine, 2005) but one study reports a female: male ratio of 1.8:1 (Bassetti et al., 1997). 
The beginning of the illness is in the first two decades of life (Anderson et al., 2007; Haba-
Rubio, 2005; Kryger et al., 2005; Bassetti et al., 1997; Bruck et al., 1996). 
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2.3.7. Diagnosis 
For the diagnosis of IH, the minimal criteria are a complaint of EDS, difficulty waking up in 
the morning or after a nap, duration at least six months, exclusion of other conditions that 
can explain the cause of the symptoms and the absence of a recent (within 18 months) 
head trauma. For the exclusion of conditions that may cause the symptoms of IH, it is 
necessary to perform sleep studies such as PSG and the patient must complete sleep 
diaries. The manual of sleep disorders advises for the correct interpretation of PSG that 
the recordings should be performed when the patient is free of drugs that influence sleep 
for at least 15 days. Seven days before, the sleep wake schedule must be standardized 
and nocturnal PSG must be performed on the night immediately preceding the MSLT 
(American Academy of Sleep Medicine, 2005). 
An alternative method to diagnose IH is a continuous 24-h polysomnography where the 
subject is allowed to sleep ad libitum (Latin word that means “at will”). However, this 
method is until now not standardized with a large number of patients and normal controls 
to become reliable (Bastuji & Garcia-Larrea, 1999). Another method to assess sleep 
drunkenness is using evoked potentials but this technique has some inconveniences due 
to the inter-subjects variability (Bastuji et al., 1999). 
DIFFERENTIAL DIAGNOSIS 
IH is not easy to diagnose clinically since a variety of other causes of hypersomnia must 
be excluded. For instance, mood disorders, chronic fatigue syndrome, post-viral infections, 
endocrine disorders and other forms of excessive daytime sleepiness which are due to 
perturbed nocturnal sleep (Nevsimalova et al., 2000). Patients with the disorder may need 
a monitoring of esophageal pressure during sleep to exclude upper airway resistance 
syndrome and must have a psychiatric evaluation in order to exclude another reason for 
daytime sleepiness such as a medical or mental disorder that could explain the symptoms 
(ICSD-10). The presence of multiple brief arousals occurring periodically during PSG may 
suggest a need for monitoring esophageal pressure (American Academy of Sleep 
Medicine, 2005). 
Mood disorders are part of the differential diagnosis of IH. This criterion is part of a 
dilemma because if hypersomnia symptoms come before the beginning of mood changes, 
it is not diagnosed (Billiard, 2001). Because of the similarity of the symptoms in some 
cases IH can be confused with “atypical depression” (Haba-Rubio, 2005). Therefore, it 
should be checked whether the onset of EDS is associated with a depressive or 
hypomanic state (Roth, 1980). Sleep drunkenness is uncommonly related with narcolepsy 
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without cataplexy and can be a symptom also in subjects under sleep deprivation 
diagnosed with a phase delay syndrome (Nevsimalova et al., 2000). 
2.3.8. Treatment of idiopathic hypersomnia 
In keeping with the guidelines of the European Federation of Neurological Societies 
(EFNS), the treatment of IH is the same described for EDS in narcolepsy without cataplexy 
(see treatment for EDS). In IH the response to stimulants is variable and side effects such 
as headaches, tachycardia or irritability are reported (American Academy of Sleep 
Medicine, 2005). 
Theoretical part 
2.4. Depression 
2.4.1. Historical aspects of depression  
Depression or melancholia is a clinical syndrome that has been recognized for over 2000 
years, yet there are still major unresolved issues related to its nature, classification and 
etiology. The term melancholia, at the beginning used synonymously with depression, 
comes from the Greek words meaning “black bile” (Beck, 1967). Hippocrates gave the first 
clinical description of melancholia in the fourth century B.C. (Beck, 1967). According to 
Hippocrates, the black bile was secreted by the spleen and was responsible for darkening 
the mood. He hypothesized that this was the cause of melancholia. Hippocrates describes 
melancholia as “food aversion, desperation, insomnia, irritability and worry, accompanied 
by a characteristic sad mood”. Afterwards, Hippocratic text associated melancholia with 
fear (Sadek & Nemeroff, 2000). 
Robert Burton, who wrote “Anatomy and melancholia” in 1621 suggested that melancholic 
persons are born from melancholic parents and identified some environmental factors in 
the development of depression (Sadek et al., 2000).The Danish neurologist Carl Lange in 
1886 was one of the earliest to establish the term depression to psychological medicine 
(Benca et al., 1997). 
2.4.2. Classification and different names for depression  
The classification of depression has been in constant change along the years and these 
changes are associated with the assumed causes and response to different treatments. 
Between 1905 and 1915, the German psychiatrist Emil Kraepelin created a new 
nosological system to organize psychiatric disorders and defined the expressions 
dementia praecox and involutional melancholia (Wong & Licinio, 2001). During the history 
of depression, there has been a huge change in the classification, moving from a 
descriptive strategy based on Kraepelin´s ideas and the American Psychiatric Association 
to more interpretative strategies such as Freud´s theories (Wong et al., 2001).  
Some classifications were endogenous versus reactive, melancholic versus non- 
melancholic, psychotic versus neurotic and major versus minor depression (Cobo-Gómez, 
2005). Martin Roth and colleagues developed the distinction in endogenous and 
exogenous or reactive depressions (Wong et al., 2001). Endogenous occurred in the 
absence of environmental factors and exogenous or reactive depression is seen as the 
response to external stressors. However, depression often appears with biological and 
environmental variables (Benca et al., 1997). The division of endogenous and reactive 
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depression had the primary focus on the treatment. Another classification is primary and 
secondary depression. The term primary is used when it does not appear after another 
psychiatric illness, while secondary is used when it occurs following or during another 
psychiatric illness (Cobo-Gómez, 2005). 
CONCEPT OF ENDOGENOMORPHIC DEPRESSION 
In 1974, Donald Klein, an American psychiatrist who introduced a difference between 
neurotic and endogenophormic depression proposed a model mixing categorical and 
dimensional constructs (Klein, 1974). This concept, which refers to the “doctrine of the two 
depressions”, distinguishes between the melancholic depression and non-melancholic 
depression (Shorter, 2007). Neurotic depression has the features low self-esteem, feelings 
of helplessness, irritability, anger, unhappiness and histrionic attitude. The concept of 
endogenomorphic depression which can or cannot be precipitated results “in a sharp, un-
reactive pervasive impairment of the capacity to experience pleasure or to respond with 
affect to the anticipation of pleasure …” (Klein, 1974). Indeed, this refers to anhedonia or 
the loss of pleasure which seems to be a central feature of major depression (Stein, 2008). 
DEFINITION OF DEPRESSION WITH MELANCHOLIC AND WITH ATYPICAL FEATURES 
The category referred to as melancholic features was proposed to describe patients with 
loss of the ability to feel pleasure in almost all activities (anhedonia) and the lack of 
reactivity to stimuli that were a source of satisfaction for the person (mood non-reactivity). 
Furthermore, the patient should have at least one of the following symptoms: depression is 
worst during the morning, waking up early in the morning at least 2 hours earlier every 
day, psychomotor retardation or agitation, significant anorexia or loss of weight, excessive 
guilt or feelings of inadequacy. In contrast, the atypical features of depression are mood 
reactivity in response to real and/or positive situations. Additionally, major depression or 
dysthymia must be present, as well as two of the following four associated symptoms: 
significant increase of weight or appetite, hypersomnia, leaden paralysis (feeling of arms 
or legs heavy or inert), long term pattern of sensitivity to interpersonal rejection that has a 
significant negative effect in the social or work relations. The sensitivity to be rejected 
appears with an early onset and continues throughout life. In patients with atypical 
depression, the presence of personality disorders such as avoidant personality disorder 
and anxiety disorders such as social phobia is more frequent (American Psychiatric 
Association, 2000). 
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THE CONCEPT OF DEPRESSION ACCORDING TO AARON BECK 
Beck argues that depression can be understood as a paradox. The paradox is because of 
the huge contrast between the self-image of the person with depression and the objective 
facts (Beck, 1967). This means that in spite of the patient’s idea, there is no objective 
evidence or as Beck wrote: “no logical demonstration of the irrationality of these ideas” 
(Beck, 1967 p.24). It makes sense that Beck, having obtained solid training in 
psychoanalysis before his fundamental contributions to cognitive therapy, suggests that 
depression is contradictory with one of the concepts from psychoanalysis, the so called 
pleasure principle which states that people seek satisfaction and minimal pain (Beck, 
1967). 
According to this US-American psychiatrist, depression may be defined by some attributes 
such as an alteration of mood characterized by sadness, loneliness and apathy, and a 
negative self-concept associated with self-reproach and self-blame. Other aspects are 
regressive and self-punitive wishes together with vegetative changes and modification in 
activity level. In the development of depression, one central aspect is the negative self-
concept or low self-esteem. Following Beck, this is “the tendency to extract personally 
relevant meanings from unpleasant situations … of depression-prone individuals” (Beck, 
1974, p.9). The cause of an adverse situation can have different possible explanations but 
the depressed patient will opt for those that are due to a defect in him or herself. 
Another aspect is self-reproaches and self-criticism. As previously mentioned, Beck 
explains this characteristics of depression using some concepts from psychoanalysis. 
Freud proposed that the depressed patient has hostility toward the “loved object” but he 
did not allow himself to feel this hostility and therefore turned this anger upon himself. The 
goal of this self-blame is self-rejection similar as he would do were he rejecting another 
person. The patient reacts feeling hurt, sad and humiliated (Beck, 1974). In depression, 
the person has lost the capacity to respond with mirth to happy situations replacing them 
with apathy or sadness, also in anger to situations that normally would exasperate this 
person. 
The phenomena of depression can be recognized in exploring the theme of loss, where 
the person has cognitive distortions regarding evaluations of his world, himself and his 
future. The depressed patient will exaggerate or misinterpret the loss or will give an 
extravagant meaning to the loss. Beck mentions in his cognitive model “certainly when the 
loss of appetite or sleep occurs as the result of a debilitating physical illness it does not 
produce the other symptoms of depression” (Beck, 1974, p.5). This suggests that for Beck, 
the depressive symptoms in patients with a physical illness are not necessarily the source 
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of core symptoms of depression. The concept of depression for Beck is more related to a 
melancholic depression. The vegetative symptoms of interest in this study related with 
hypersomnia are focused on the tendency to morning awakenings, loss of appetite and 
weight loss.  
THE CONCEPT OF DEPRESSION ACCORDING TO WILLIAM ZUNG 
Zung was interested in depression as an emotional disorder. He focused on the questions 
of how it is possible to diagnose depression, how it is possible to assess the changes in 
the severity of depression when patients are being treated, whether some physiological 
changes are features of depression and if it is possible to associate some brain structure 
with the behavioral dysfunctions of depression (Zung, 1978). In the seventies, Zung 
recruited patients with depression and found diverse opinions about what a depressive 
disorder is. He decided to reduce the large list of symptoms into four basic categories that 
he denominates “(1) psychic-affective, (2) physiological (3) psychomotor (4) 
psychological”. In each category he included symptoms that would be possible to 
associate with brain structure. 
Zung proposed the following formula to investigate psychopathology: I=i1 +i2 +…+in +x +r. 
“I” represents the Indicator of psychopathology; the investigator can use signs and 
symptoms as indicators of change in quality and quantity. The ies correspond to the 
methods of measurements performed. The numbers down (sub index) of the “i´s” 
correspond to the number of techniques used; this can be subjective, semi objectives and 
objectives. X corresponds with the experimental noises, which according to the author 
represent all that cannot always be controlled such as the intelligence of the subject, the 
affect or emotional situation of the person at the moment of the test, the motivation, the 
adaptation or the amount of learning, habituation or satiation, the introspection which is the 
cognitive elaboration of the subject. Zung mentions that motivation and affect are also 
under the influence of the pre-morbid personality, cultural background and experimental 
environment. The r symbolizes the residues which are all the unmeasured 
psychopathology which remains unaccounted for (Zung, 1973). In developing his 
questionnaire, the author included the most common characteristics of depression with the 
purpose of minimizing the symptoms related with somatic anxiety and in an effort to 
maintain depression and anxiety as two different units. He operationalized depression with 
four criteria: (1) Pervasive affective disturbance, (2) Physiological disturbances: diurnal 
variation was conceptualized as an exaggeration of the symptoms in the morning with 
relief at the end of the day, sleep with early and frequent waking. In the item sleep, the 
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author states that the problems of falling asleep are more typically present in anxiety and 
early awakening and is more representative of patients with depression, (3) Psychomotor 
disturbances and (4) Psychological disturbances: confusion, emptiness, hopelessness, 
indecisiveness, irritability, dissatisfaction, personal devaluation and suicidal rumination 
(Zung, 1973). 
ASSESSING DEPRESSIVE SYMPTOMS: ZUNG SELF-RATING DEPRESSION SCALE (SDS) AND BECK 
DEPRESSION INVENTORY (BDI) 
Both authors developed a scale to assess depressive symptoms based in their concept of 
depression. Zung’s concept of depression is a melancholic type of depression and is 
slightly more focused on aspects related with the vegetative dimension of depression than 
Beck. There are some differences in the content of questions between SDS and BDI, 
although, according to Hautzinger (1995), both tests show a high correlation of rho= .72 
(Spearman´s rank correlation coefficient). The number of questions is almost the same; 
only BDI has one more question. The differences in the questions’ content are slight, and 
when comparing both tests, SDS has five questions that are not equally asked in BDI, 
such as diurnal variation, tachycardia, confusion, psychomotor agitation and emptiness. 
BDI also has five questions that are not present in the SDS, all of which are related with 
the cognitive dimension of depression like failure, guilt, punishment, self-blame and feeling 
ugly. 
2.4.3. Diagnosis of depression according to DSM-IV and ICD-10 
The International Statistical Classification of Diseases and Related Health Problems (ICD-
10) published by the World Health organization and the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV- TR) published by the American Psychiatric Association are 
manuals for mental disorders during adulthood, childhood and adolescence (Schulte-
Markwort M., 2003). Both are official classification and coding systems in most of the 
countries with systematic records of psychiatric diagnoses. 
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Table 5. Diagnostic criteria of Major Depressive Disorder (MDD) according to the 
International Statistical Classification of Diseases and Related Health Problems [ICD-10] 
(World Health Organization, 1992). 
ICD-10 criteria of major depressive episode 
Marked tiredness after only slight effort is common. Individuals usually suffer from 
depressed mood, loss of interest, enjoyment and reduced energy leading to 
increased fatigability and diminished activity. Other symptoms are: 
A. Reduced concentration and attention. 
B. Reduced self-esteem and self-confidence.  
C. Ideas of guilt and unworthiness (even in mild type episode). 
D. Bleak and pessimistic views of the future.  
E. Ideas or acts of self-harm or suicide.  
F. Disturbed sleep. 
G. Diminished appetite. 
 
DSM-IV is widely used in North and South America. DSM-IV is more a rule description 
while ICD-10 -the European system- is more like a guideline description. The DSM-IV 
system generally follows more psychopathologic principles while the chapters of ICD-10 
are structured pathogenetically (Schulte-Markwort M., 2003). 
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Table 6. Diagnostic criteria of Major Depressive Disorder (MDD) according to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV- TR) (American 
Psychiatric Association, 2000) 
DSM-IV criteria of major depressive episode 
A. Five or more of the following symptoms are present during the same two week period and 
represent a change from previous functioning; at least one of the symptoms is either 
depressed mood or lost of interest or pleasure 
1. Depressed mood most of the day, nearly every day, as indicated by either subjective report 
or observation made by others 
2. Markedly diminished interest or pleasure in all or almost all activities most of the day nearly 
every day (as indicated for either subjective account or observation made by others) 
3. Significant weight loss when not dieting or weight gain or decrease or increase in appetite 
nearly every day 
4. Insomnia or hypersomnia nearly every day 
5. Psychomotor agitation or retardation nearly every day (observable by others, not merely 
subjective feelings of restlessness or being slowed down) 
6. Fatigue or loss of energy nearly every day 
7. Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) 
nearly every day (not merely self reproach or guilt about being sick) 
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a 
specific plan, or a suicide attempt or a specific plan for committing suicide 
B. The symptoms do not meet criteria for a mixed episode (maniac and depressive) 
C. The symptoms cause clinically significant distress or impairment in social, occupational or 
other important areas of functioning 
D. The symptoms are not due to the direct physiological effects of substance or a general 
medical condition (e.g. hypothyroidism) 
E. The symptoms are not better accounted for by bereavement, that is, after the loss of a loved 
one, the symptoms persist for longer than 2 months or are characterized by marked 
functional impairment, morbid preoccupation with worthlessness, suicidal ideation, 
psychotic symptoms or psychomotor retardation 
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The presence of symptoms of depression does not automatically indicate that a person 
would be diagnosed as being clinically depressed. There are different criteria organized to 
assure an accurate diagnosis. For depressive episodes of all three grades of severity 
(mild, moderate and severe) a duration of at least 2 weeks is required for the diagnosis but 
the ICD-10 suggests that shorter periods may also be reasonable if symptoms are 
“unusually severe and of rapid onset” (World Health Organization, 1992). 
One of the cardinal symptoms of depression is sleep disturbance. In some cases where 
depression is accompanied by hypersomnia rather than insomnia, such patients report 
increased duration of nocturnal sleep, often with problems in waking up and increased 
napping. This hypersomnia tends to occur in bipolar patients during major depressive 
disorder (Benca, Obermeyer, Thisted & Gillin, 1992). In patients with hypersomnia who 
have somatic symptoms of depression the diagnosis may be difficult. Some symptoms in 
narcolepsy patients and in patients with depression can be indistinguishable. In particular, 
these are reduced energy leading to increased fatigability and diminished activity, reduced 
concentration and attention due the excessive daytime sleepiness and fragmented night 
sleep. 
2.4.4. Severity of depression according to DSM-IV and ICD-10 
The clinical presentation of the symptoms may vary from person to person. The two 
manual systems described above (ICD-10 and DSM-IV), have different criteria to classify 
whether the severity or degree of depression is mild, moderate or severe (Table 7). 
 
Table 7. Depression severity criteria according to DSM-IV and ICD-10. 
Depression                 DSM-IV criteria                                            ICD-10 criteria 
Severity 
Mild 1. Depressed mood or loss of interest/pleasure 
+ four other depressive symptoms.  
2. Minor social/occupation impairment. 
1. Two typical symptoms. 
2. Two other core symptoms. 
Moderate 1. Depressed mood or loss of interest/pleasure 
+ four or more other depressive symptoms. 
2. Variable social /occupational impairment. 
1. Two typical symptoms. 
2. Three or more other core 
symptoms. 
Severe 1. Depressed mood or loss of interest/ pleasure 
+ four or more depressive symptoms. 
2. Major social /occupational impairment-or with 
psychotic features. 
1. Three typical symptoms 
2. Four or more other core 
symptoms. 
Also sub typed as with or 
without psychotic symptoms. 
From Depression by Lam and Mok (2008, p.29), Oxford University Press, Copyright 2008. 
Reprinted with permission.  
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2.4.5. Core symptoms of depression 
ANHEDONIA  
Anhedonia is a core symptom of depression. Ribot defined anhedonia in 1897 as the loss 
of the capacity to experience pleasure (Loas, 1996). In the beginning of the last century, 
Myerson (1922) suggested a state permanent of anhedonia together with low energy, 
pessimism and introspection. Afterwards he used the expressions of “constitutional 
anhedonia” and “anhedonic constitutional personality”. With the term constitutional, the 
author means not only hereditary but also environmental factors. Genetic studies confirm 
this hypothesis. For example, Kendler found that in 29 pairs of twins the correlation for 
anhedonia was higher in the monozygotic twin pairs (r=.94) than in the dizygotic twins (r=-
.18). The personality is characterized by low sensation seeking, avoiding emotional 
involvement and sometimes huge interest in work activities. ICD-10 and DSM-IV support 
the notion that anhedonia is a symptom of pre-schizophrenia personality and is a 
recognized negative symptom of this psychopathology. 
PSYCHOLOGICAL VARIABLES ASSOCIATED WITH ANHEDONIA 
Loas (1996) described the association between anhedonia and psychological variables, 
such as displeasure capacity, introversion, autonomy, dysfunctional attitudes and 
sensation seeking (Loas, 1996). Displeasure capacity refers to the inhibitory role of 
anhedonia in negative emotions such as anger, sadness, irritation or fear. Introversion 
shows a positive correlation with anhedonia in healthy subjects. Autonomy is related to 
attitudes and aims, giving a high value to independence and freedom to the detriment of 
close interpersonal relationships. This is, according to the cognitive therapy of Beck, a 
vulnerability factor for depression. When an autonomous person confronts a problem, 
which is perceived as a loss of control, he or she will tend to protect him or herself by 
withdrawing from the environment. The characteristic of autonomous subjects becoming 
depressed is similar to the concept of endogenomorphic depression, defined for the first 
time by Klein. For this author anhedonia is the central symptom of depression (Klein, 
1974). 
Dysfunctional attitudes are, according to Beck´s cognitive theory, a substrate of 
depression. Beck in a life interview says that his idea about dysfunctional attitudes began 
during a clinical interview with a patient. Dr. Beck asked him, just as an intuitive idea, what 
he was thinking about his conflict right at that moment of their dialogue. The patient told 
him that he constantly thought he was boring, tedious and unintelligent. Beck asked him if 
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this was only during that interview but the patient revealed that it happened when talking 
with other persons as well (video life interview to Aaron Beck in DGPPN, Berlin, 2009) 
From this and other patients, Beck and Weismann derived a questionnaire called 
Dysfunctional Attitudes Scale (DAS) which attempts to predict subsequent depressive 
episodes. The Physical and Anhedonia Scales (PAS) correlates with DAS. The last 
variable is sensation seeking, which is related with the necessity to maintain high levels of 
cortical activation or arousal (Loas, 1996). Once again, the sensation seeking scale shows 
a correlation with PAS. 
SLEEP DISTURBANCES 
Poor sleep is a fundamental aspect of depression; sleep-disturbances in depression 
include insomnia, the more common form and hypersomnia (Jindal & Thase, 2004). 
Kraepelin mentioned the association of depression with hypersomnia for the first time in 
1904 (Roth et al., 1975). A strong correlation exists between excessive daytime sleepiness 
and depression consistent with larger epidemiological studies. An epidemiological study 
with 1007 adults aged 26 to 35 years showed a significant connection between severity of 
excessive sleepiness and MDD. The authors report an association of daytime sleepiness 
with employment, marital status, snoring and MDD remaining when hours of sleep and 
other determinants of daytime sleepiness were held constant (Breslau, Roth, Rosenthal & 
Andreski, 1996). Nevertheless, in a previous study the same authors did not find support 
for an association between hypersomnia and major depression, meaning that hypersomnia 
is not a cause for developing a depression, although it could be associated (Benca et al., 
1992).  
Frequently, patients with major depression-unipolar complain about insomnia, but 
hypersomnia symptoms are reported mostly by patients with bipolar and seasonal affective 
disorder (Benca et al., 1992). Sleepiness implies an increased vulnerability to fall asleep 
but the complaint about sleepiness is frequently used to describe physical tiredness for 
example in depression (Hublin, Kaprio, Partinen, Heikkila & Koskenvuo, 1996). A study 
performed in Idaho, USA, using the ESS  to evaluate the symptoms of excessive 
sleepiness in major depressive disorder (MDD), found that approximately half of the 
patients with MDD also experience excessive sleepiness (Lundt, 2005). Sleep 
disturbances are an important component of depression, but on the other hand, 
depression is not an obligatory component in hypersomnia patients, although some 
studies demonstrate a high prevalence of depressive symptoms in hypersomnia patients 
(Dauvilliers et al., 2009). 
Theoretical part-51 
SLEEP DISTURBANCE AS A PREDICTOR OF RECURRENT DEPRESSION 
Disturbed nocturnal sleep is a characteristic symptom of depression. After an effective 
treatment, most of the symptoms will disappear while REM sleep abnormalities are 
maintained. The persistence of sleep disturbance after the recovery of the other symptoms 
can be a predictor of recurrence of depression (Modell & Lauer, 2007). Reduced REM 
latency is a biological marker of major depression and correlates inversely with the 
severity of symptoms (Kupfer & Foster, 1972) although during normal aging, REM sleep 
begins to shorten, this process is pronounced in patients with depression (Modell et al., 
2007).  
DEPRESSION AS CAUSE OR AS CONSEQUENCE 
Some authors question whether depression is a cause for sleep disorders or if depression 
is the origin of sleeps abnormalities. Many people with depression fail to display short 
REM sleep latency, reduced slow wave sleep (SWS) or sleep disruption (Kryger et al., 
2005). Studies in psychiatric disorders such as schizophrenia, mood disorders, anxiety 
disorders, borderline personality disorder, eating disorders and alcoholism, reported a 
short or reduced REM latency. The same has been reported in patients after the end of 
treatment with REM sleep suppressing drugs such as benzodiazepines and 
antidepressants or during alcohol withdrawal (Nishino, Taheri, Black, Nofzinger & Mignot, 
2004). In a study within the Finnish population, approximately 25% of patients with 
excessive daytime sleepiness had BDI scores suggesting a state of moderate to severe 
depression (Hublin et al., 1996).  
In the sleep centers, the differential diagnosis of depression is frequent. A Dutch study 
regarding the prevalence of depressive feelings in patients diagnosed in a center for sleep 
and wake disorders found that depression symptoms occurred in more than half of 
patients with psychophysiological insomnia, inadequate sleep and wake hygiene, sleep 
state misperception and periodic limb movement disorder, or restless legs syndrome 
(Vandeputte et al., 2003). However, they report that moderate to severe depression was 
found only in 3.5% of the patients using BDI. This study suggests that mood disorders are 
common in patients with sleep disorders and the authors recommend performing a 
depression scale in the daily routine of diagnosing and treating sleep disorders 
(Vandeputte et al., 2003). Consistent with this study, another author, also based on self 
rating questionnaires, reported that 67% of patients from a sleep centre reported an 
episode of depression within the previous 5 years and 26% described themselves as 
depressed at presentation (Mosko et al., 1989). 
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2.4.6. Problems in the diagnostic of depression related to hypersomnia 
DSM-IV-TR and ICD-10 take into account self reported sleep disturbances, instead of 
using an objective parameter. In contrast, the International Classification of Sleep 
Disorders [ICSD-2] (American Academy of Sleep Medicine, 2005) recommends a PSG to 
probe the reduced sleep efficiency and the increased numbers of arousals during the 
night. ICSD-2 is the only manual that includes the discussion about time in bed but none of 
these three classification systems include the amount of hours of sleep in the context of a 
depression (Kaplan et al., 2009). 
Table 8. Criteria for hypersomnia related to another mental disorder according to 
DSM-IV-TR. 
A.  
The predominant complaint is excessive sleepiness for at least 1 month as 
evidenced by either prolonged sleep episodes or daytime sleep episodes that 
occur almost daily.  
B.  
The excessive sleepiness causes clinically significant distress or impairment 
in social, occupational or other important areas of functioning.  
C.  
The hypersomnia is judged to be related to another Axis I or II disorder 
(MDD, dysthimic disorder) but is sufficiently severe to warrant independent 
clinical attention.  
D.  
The disturbance is not better accounted by another sleep disorder 
(narcolepsy, breathing- related sleep disorder, parasomnia) or by an 
inadequate amount of sleep.  
E.  
The disturbance is not due to the direct physiological effects of a substance 
(drug of abuse, medication) or a general medical condition.  
 
The criterion C for non-organic hypersomnia in the ICD-10 is noteworthy because around 
30% of the normal population present hypnagogic hallucinations or sleep paralysis in the 
absence of excessive daytime sleepiness (Table 8).  
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Table 9. Criteria for non-organic hypersomnia according to ICD-10 
A.  EDS or sleep attacks, not accounted for by an inadequate amount of sleep, 
and/or prolonged transition to the fully aroused state upon awakening (sleep 
drunkenness).  
B.  Sleep disturbance occurring daily for more than one month or for recurrent 
periods of shorter duration, causing either marked distress or interference with 
social or occupational functioning.  
C.  Absence of auxiliary symptoms of narcolepsy (cataplexy, sleep paralysis, 
hypnagogic hallucinations) or of clinical evidence for sleep apnea (nocturnal 
breath cessation, typical intermittent snoring sounds)  
D.  Absence of any neurological or medical condition of which daytime 
somnolence may be symptomatic.  
 
In the proposed DSM-V (2010), which is still in revision, hypersomnia included the 
category of narcolepsy without cataplexy, while narcolepsy with cataplexy is referred to as 
Hcrt deficiency. Both hypersomnia/narcolepsy without cataplexy and narcolepsy with 
cataplexy/Hcrt deficiency have the criteria C: “do not occur exclusively during the course of 
another mental or medical disorder but may occur simultaneously with these disorders”. 
This new proposal, not yet official but programmed for 2013, would broaden the diagnosis 
of hypersomnia in patients with depression and will probably revive the dilemma of those 
patients with IH and depression. 
2.4.7. Epidemiology  
Depression is a common but a serious condition. Around 13% of the population will 
experience an episode of MDD during their lifetimes (Table 10). Depression is the leading 
cause of disability in developed countries and the fourth leading cause of disability 
worldwide (Lam & Mok, 2008).  
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Table 10. Prevalence of major depressive disorder in studies performed in the 
general population of several countries according to the criteria from DSM-IV and 
ICD-10. 
Location (study) Criteria Current/1 month 12 month Lifetime 
Prevalence rates (%) 
Europe (ESEMeD) DSM-IV - 3.9 12.8 
Germany DSM-IV 5.6 10.7 17.1 
Netherlands (NEMESIS) DSM-III-R 2.7 5.8 15.4 
UK(NSPM) ICD-10 2.1   
Canada DSM-IV - 7.4 - 
USA (NCS-R) DSM-IV  6.6 16.2 
USA (NCS) DSM-III-R 4.9  17.1 
Australia DSM-IV 3.2 - - 
Australia ICD-10 3.3 - - 
Japan DSM-III-R - 1.2 2.9 
From Depression (p. 4) by Lam and Mok, 2008, New York, Oxford University Press, 
Copyright 2008. Reprinted with permission. 
DEPRESSION BY SEX AND AGE 
? Sex: 
Women are more depressed than men, the lifetime prevalence of depression is 1.6 to 3.1 
higher in women than in men (Lam & Mok, 2008). The prevalence of MDD ranges from 
2.6% to 5.5% for men and between 6% and 11.8% for women. The difference in the 
prevalence of depressive symptoms is much higher than MDD, with rates from 10% to 
19% in men and 18% to 34% in women (Loue & Sajatovic, 2008). In the global burden of 
disease study (Murray & Lopez, 1998), depression is the leading cause of disability among 
all diseases in women “and accounted for 41.9% of their [women] disability burden from 
neurological and psychiatric disorders as compared to 29.3% among men” (Blehar, 2006). 
There are many interpretations for these differences between men and women, one being 
that men experience similar depressive symptoms but attempt to cope with them in a 
different way such as substance abuse and antisocial behavior, which is more prevalent in 
men than in women (Loue et al., 2008). 
The theories on stressful life events explain the difference as being caused by the 
tendency women have of taking care of and being concerned for others, which increases 
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the exposure to adverse life events and as a result leads to depression. Another theory is 
associated with rumination. Ruminative thinking maintains a negative emotion and is more 
frequent in females than in men (Blehar, 2006).  
? Age: 
Sex differences already begin during adolescence and aggravate at the onset of 
menstruation, diminishing after menopause (Lam et al., 2008). In German adolescents 
screened in Munich and Bremen, the male: female ratio of depression is 1:7 (Kuehner, 
2003). Nowadays, depression is the second cause of disability in the age category 15-44 
years. By the year 2020 depression will be the second cause of disability for all ages and 
both sexes (American Psychiatric Association, 2000). The mean age for the depression 
onset is 26 years old. An earlier age for the onset of depression is associated with higher 
levels of medical co-morbidity, greater depressive symptom severity and a more negative 
view of life and self, among other characteristics (Zisook et al., 2007). Depressive 
symptoms differ with age. In childhood there tends to be more somatic complaints 
combined with irritability and withdrawal, while during adolescence, symptoms appear 
more atypical, such as hypersomnia and overeating. In the elderly, melancholic features 
as anhedonia or a lack of reactivity are more present (Lam et al., 2008). 
2.4.8. Theories about depression related to sleep abnormalities  
The precise pathogenesis of depression is still unknown but there are multiple processes 
that can explain it, biological, psychological and social factors are involved (Lam et al., 
2008). Here the principal theories about depression related with sleep disturbances will be 
described.  
TWO PROCESS MODEL OF SLEEP REGULATION: DEFICIENCY OF PROCESS S 
Borbely proposed a model of sleep regulation integrating two processes: the process S 
and the process C (Borbely, 1982). The first one is sleep dependent and describes a 
physiological correlate of increase and decrease of sleep necessity. The second is 
independent of sleep and is controlled by a circadian oscillator. According to this model, 
the combined action of both processes determines the need and duration of sleep. The 
author exposes that the increase of process S during wakefulness is deficient in 
depression (Borbely, 1982). This means that depressive patients accumulate process S 
slowly. The classical problems of patients with depression in initiating and maintaining 
sleep are an attribute of low need of sleep, which is a consequence of a low level of 
process S. 
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Figure 3. Two process model of sleep in depression. The interrupted curve represents 
process S and C in a healthy control, and the continuous curve represents it in a 
depressive patient. In the left part, a regular sleep waking cycle is represented and in the 
right part the situation under sleep deprivation is shown. The shading corresponds to the 
sleep periods of a depressive patient (Borbely, 1987, p.23).  
 
The hypothesis of Borbely consists of two parts:  
A. The deficiency in process S can explain the sleep disturbances in depression: the sleep 
in depressives is characterized by a prolongation of sleep latency, more night awakenings 
and the premature end of sleep (Figure 3). The diminished process S will determine a 
superficial and short sleep. Typical changes are the reduction of slow wave sleep and 
alterations in the REM sleep patterns. Process S is by definition measured from the EEG 
activity of SWS in NREM sleep. It has been suggested that the increase in REM activity is 
also due to the inhibition of process S. Typical features of sleep in patients with depression 
are the short REM latency and a longer first REM period. 
B. A causal relation between the level of S and depressive symptoms is postulated to 
account for the antidepressant action of sleep deprivation: sleep deprivation decreases 
depressive symptoms because the low level of process S is normalized with the 
prolongation of wakefulness. Nevertheless, this effect has a short duration because the 
level of S is again reduced by the next sleep period (Borbely, 1987).  
CHOLINERGIC- AMINERGIC IMBALANCE 
Janowsky and his collaborators originally proposed the hypothesis of cholinergic-aminergic 
imbalance in depression in 1972 (Janowsky, el Yousef, Davis & Sekerke, 1972). REM 
sleep has been suggested to be promoted by cholinergic activation and inhibited by 
aminergic activation. The imbalance could also be responsible for reductions in total sleep 
time and in sleep efficiency (Benca, 2000). This theory suggests an imbalance of the 
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neurotransmitters acetylcholine, serotonin and norepinephrine. Janowsky and 
collaborators proposed that the aetiology of mood disorders is influenced by cholinergic 
and adrenergic factors. These authors thought that depression is a disease of central 
cholinergic predominance and mania a disease of central adrenergic (or serotonergic) 
predominance (Janowsky et al., 1972). This theory of a high cholinergic and low 
monoaminergic neurotransmission has been supported by several experiments (Adrien, 
2002). According to this hypothesis, depressive patients are sensitive to the cholinergic 
muscarinic agonists that provoke REM (Nishino et al., 2004). One critical point of this 
theory is that it does not explain the antidepressant effect of sleep deprivation.  
INCREASED REM SLEEP PRESSURE 
Patients with depression have sleep abnormalities already at the beginning of the disease. 
Vogel has postulated that depression may be caused by excessive amounts of REM sleep 
and a decrease in REM sleep pressure (Vogel, 1999). In line with this theory, sleep 
deprivation and especially REM sleep deprivation have antidepressant effects (Borbely & 
Wirz-Justice, 1982). The finding that antidepressants suppress REM sleep for long periods 
supports this hypothesis. According to Vogel, two lines of evidence disclose the 
relationship between REM sleep and depression (Vogel, 1999): 
A. Depression has sets of REM sleep abnormalities: the studies suggest that REM sleep is 
disinhibited during depression.  
B. Sleep deprivation: REM sleep deprivation has the effect of improved depressive 
symptoms. Some antidepressant drugs improve depression by arousal type deprivation of 
REM sleep.  
Evidence for this theory is the known REM rebound following the interruption of REM sleep 
deprivation or tricyclic antidepressants, although some antidepressants do not reduce 
REM sleep. This suggests that REM suppression is not always a necessary effect (Nishino 
et al., 2004).  
CIRCADIAN PHASE ADVANCE 
This theory suggests that in depressed patients, the circadian oscillator controlling REM 
sleep and temperature are phase advanced. Wehr and cols. in 1979 tested the hypothesis 
of a phase advance of the circadian sleep-wake cycle, revealing that an advancement of 
the sleep-wake schedule of 6 hours in maniac depressed patients causes a remission of 
the symptoms (Wehr, Wirz-Justice, Goodwin, Duncan & Gillin, 1979). In the 
polysomnography analysis, they were able to show that after this phase advance, several 
indices approach normal values. In addition, this study shows that the antidepressant 
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effect of the phase advance is transitory and the authors make an analogy with the 
circadian desynchronization triggered by jet lag in normal subjects (Wehr et al., 1979).  
HYPOTHALAMIC-PITUITARY- ADRENAL (HPA) AXIS DYSREGULATION  
There is evidence showing that the relationship between sleep and the HPA axis is 
bidirectional. This means that HPA hormones influence sleep and that alterations on sleep 
affect the discharge of these hormones (Steiger, 2002). During the sleep period, low and 
higher levels of secretion of adrenocorticotropin (ACTH) and cortisol will occur. 
Corticotropin releasing hormone (CRH) impairs sleep, augments vigilance and promotes 
REM sleep. A REM period, especially during the first four sleep cycles, is associated with 
a decrease in cortisol levels. Furthermore, ACTH and cortisol were higher in a group of 
normal subjects with short sleep in comparison with those with long sleep.  
Cortisol secretion is sex dependent; women have a higher secretion of cortisol compared 
to men. In addition, there is a positive correlation between age and cortisol levels in female 
patients with depression. In depression there are well-described endocrine changes 
revealing elevated cortisol and ACTH although the circadian pattern is preserved (Steiger, 
2002). Some studies show a causal connection between superficial sleep, low growth 
hormone (GH) and HPA hyperactivity in depression, supporting that HPA is a state marker 
of depression in adults (Steiger, 2002). After recovery of depression, the changes in sleep 
such as superficial sleep and REM sleep disinhibition will persist together with blunted GH 
secretion. 
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2.5. Hypersomnia and depression  
2.5.1. Similarities 
DAYTIME SLEEPINESS 
Patients with depression and hypersomnia have the main complaint of being “tired” but 
sleepiness and fatigue are distinct phenomena (Shen, Barbera & Shapiro, 2006). The 
measurements of fatigue are mainly subjective and the measurements of sleepiness are 
subjective and objective. In hypersomnia, the patient has a complaint of excessive daytime 
sleepiness, which is conceptually different to the fatigue experienced by a patient with 
depression. Therefore, the concept fatigue is not included in the diagnostic criteria of 
hypersomnia although the expression could be used by the patient to explain his or her 
daytime sleepiness. Fatigue is the consequence of prolonged physical activity. In contrast, 
sleepiness does not necessarily imply a previous physical activity and can decrease after 
a sleep period (Cluydts, De Valck, Verstraeten & Theys, 2002). 
SHORT REM SLEEP LATENCY 
Changes in the sleep pattern are associated with depression in a classic study involving 
sleep onset rapid eye movement (SOREM) in patients with depression (Kupfer et al., 
1972). Owing to the short REM latency reported in narcolepsy, researchers grounded the 
idea that depression might be endogenous to narcolepsy (Roth et al., 1975). Although, 
narcolepsy patients with short REM sleep latency and with all the symptoms of the illness 
are not invariably depressed (Kryger et al., 2005), this hypothesis was supported by other 
common features such as nocturnal sleep disruption and increased REM density (Serra, 
Montagna, Mignot, Lugaresi & Plazzi, 2008; Aldrich, 1992; Broughton et al., 1981).  
The comparison of narcolepsy and depression has been done in the structure of sleep due 
to the apparent similarities in REM. An American study compared nocturnal sleep in 
patients with narcolepsy and depression (Reynolds, III, Christiansen, Taska, Coble & 
Kupfer, 1983). The authors found that 60% of the sample did not meet the criteria for any 
present or past psychiatric disorder and narcoleptics reported less frequently a history of 
depression compared to depressive patients. Polysomnography revealed that Non-REM 
(NREM) sleep differences and sleep continuity measures are the most authentic 
differences between narcoleptic and depressive patients regardless of age or SOREM 
positivity. This suggests that sleep in depression is different from sleep in narcolepsy 
(Reynolds, III et al., 1983). The researchers leave open the possibility that depression is 
inherent to narcolepsy but the results plainly support the idea that depression might be a 
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reaction to the imperative sleepiness. Another study, performed in Germany, addressed 
the same issue but with the hypothesis that narcolepsy and depression share a common 
mechanism of REM sleep disinhibition at sleep onset (Pollmaecher, Mullington & Lauer, 
1997). The researchers concluded that narcolepsy and depression do not have a common 
pathophysiology of REM sleep disinhibition and showed that REM sleep disinhibition is not 
caused by depressive symptoms. Unfortunately, the authors of the study excluded 
narcolepsy patients with past or current major depressive disorder.  
The American and the German researchers found that narcoleptic patients exhibit shorter 
sleep onset latency, longer sleep period and total sleep times, as well as higher amounts 
of stage 1 and awakenings than depressives. However, the German study differed with the 
American one in the higher REM density and the shorter mean REM latency described in 
narcoleptics (Pollmaecher et al., 1997; Reynolds, III et al., 1983). The differences are 
probably due to the selection criteria regarding the inclusion of only narcoleptics with 
cataplexy in the German study. 
COGNITIVE DEFICIT 
The psychomotor retardation and decreased concentration can be very similar in 
hypersomnia patients and in those with depression. The cause for the cognitive deficit in 
hypersomnia patients is mostly attributable to the instability of vigilance, which is 
normalized when better controlled by medication (Aguirre et al., 1985). Cerebral imaging 
studies in depressives show a dysfunction in the dorsolateral prefrontal cortex, the 
amygdala and hippocampus (Jouvent, 2008). Fossati hypothesized that cognitive deficits 
in MDD can be explained by an increasing effort to maintain a high performance level prior 
to the presentation of a demanding task (Fossati, 2008). 
WEIGHT INCREASE 
An increased body mass index is frequent in patients with hypersomnia and at least in 
narcolepsy patients it is independent of gender and medication, which suggests a 
disturbance in food intake, metabolism, or in both (Schuld et al., 2000). Yet some studies 
have found differences in the body mass index within the spectrum of hypersomnia 
(Dauvilliers et al., 2009; Martinez-Rodriguez, Iranzo, Casamitjana, Graus & Santamaria, 
2007). There has been a disagreement in the literature as to whether there is a connection 
between obesity and mood disorders. In patients with depression, obesity is specifically 
associated with females and in depression with atypical symptoms, abdominal obesity is 
associated with depression in females and males. However, in the opposite scenario, most 
overweight and obese persons do not have mood disorders (McElroy et al., 2004). Another 
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study showed that obesity measurements were associated with depressive symptoms and 
found that women were maybe more influenced by body size than their current amount of 
body fat, while for men, depressive symptoms were relatively unrelated to diverse 
measures of obesity. Nevertheless, it is of high interest that in sleep disorders, the percent 
of fat was more associated with fatigue than with depression (Lim et al, 2008). 
2.5.2. Possible causes of depression in narcolepsy and idiopathic 
hypersomnia 
CHRONIC ILLNESS 
The association between chronic illness and depression is widely reported in the literature 
(Moussavi et al., 2007; Cavanaugh, 1984). Recently, the WHO corroborated that 
depression occurs more frequently in persons with physical illness rather than in those 
without illness. Depression and physical illness share some common symptoms of 
depression. Moreover, physical symptoms of depression may not only confound but also 
perhaps add to the diagnosis of depression. 
Clark et al analyzed the internal consistency of the BDI responses from two different 
patient samples: medical inpatients and psychiatric inpatients. They tried to test whether 
BDI items explore a single underlying dimension of depressive severity and if some, but 
not all, BDI scales items measured depressive severity well in both samples of patients. 
The authors found that the two symptoms related to the subject’s pleasure capacity were 
the most relevant symptoms in both samples. These are anhedonia (item D) and social 
anhedonia (item L) (Clark, vonAmmon & Gibbons, 1983). Several authors have highlighted 
the need to distinguish between somatic symptoms and the cognitive component of 
depression especially in medical populations. Beck suggested that somatic symptoms 
should be cautiously treated when they can be attributed to the medical condition (Beck, 
1967). 
A polysomnographic study aimed to differentiate patients with IH versus those with 
psychiatric hypersomnia and found that psychiatric hypersomnia should be a disorder of 
hyperarousal and IH a disorder of hypoarousal (Vgontzas, Bixler, Kales, Criley & Vela-
Bueno, 2000). The authors emphasized that psychiatric hypersomnia patients show a 
lower sleep propensity than persons with IH (Vgontzas et al., 2000). 
Some studies have tried to eliminate somatic items from depression rating scales, arguing 
that in patients with physical illness, the scores obtained are inflated by bodily symptoms 
(Clark et al., 1983). Nonetheless, some authors have disagreed because this would 
diminish the diagnostic properties of the test. According to DSM-IV, major depressive 
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disorder (MDD) can be associated with chronic medical illness. Up to 20 or 25% of the 
patients with specific chronic illness, for example: diabetes, heart attack, stroke, and 
carcinoma will present MDD during the illness (American Psychiatric Association, 2000). In 
this context, it can be expected that a similar percentage of patients with narcolepsy or IH 
will display MDD.  
STRESSFUL LIFE EVENTS 
Depressive symptoms can have their origin in a stressful event in a person’s life. Orellana 
et al (1994) reported that in narcoleptics, the weight of life events in the year preceding the 
beginning of EDS and cataplexy was higher than life events reported by controls in the 
equivalent year. Indeed, some patients connect the onset of narcolepsy with a stressful 
event such as a major change in sleeping habits, a major personal injury or illness, and 
major changes in the health of a family member, among others (Orellana et al., 1994). 
Although that study was searching for the association between stressful life events and 
illness onset, this also could suggest that narcolepsy patients can have depressive 
symptoms not only due to the impact of the illness but also due to other stressful events 
that occurred in the years preceding the onset of illness. 
DELAY OF DIAGNOSIS  
Patients with narcolepsy usually will visit several doctors until they have a diagnosis. A 
study in a normal population found that a high frequency of medical visits is an aspect that 
increases the chance of patients to be misdiagnosed as depressed (Perez-Stable, 
Miranda, Munoz & Ying, 1990). Even today, narcoleptic patients often have to see several 
physicians until the correct diagnosis is made (Paterack & Faria, 2009). This has been 
confirmed by a study showing that narcoleptic patients are often misdiagnosed with 
depression (Kryger, Walid & Manfreda, 2002). 
RESTLESS LEGS SYNDROME (RLS) IS ASSOCIATED WITH DEPRESSION AND NARCOLEPSY 
Recently, a multicenter study reported a higher prevalence of RLS in NC+ patients (14.7%) 
in comparison with age matched controls (3%) (Plazzi et al., 2010). Because there is a 
well documented high prevalence of depressive symptoms in RLS patients (Winkelmann 
et al., 2005), this could suggest that an increased rate of depression in narcoleptic patients 
might be related to the presence of RLS in this population. Plazzi and his team found that 
depression is not a predictor for having or not having RLS but rather the opposite, namely 
that it is possible that RLS may play a role in depressive symptoms as in other RLS 
patients without narcolepsy (Plazzi et al., 2010). 
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SEXUALITY PROBLEMS IN NARCOLEPTIC PATIENTS 
Severe sleepiness can result in loss of sexual and libidinal drive, thereby causing 
psychological distress. There are few studies focused on the sexual activity of narcolepsy 
patients in spite of the psychosocial importance (Bruck, 2001). An old study found that all 
women with narcolepsy of the sample (n=10) suffered from anorgasmia. The author 
suggests that an explanation can be aversive learning, producing a phobia of orgasm. Roy 
hypothesized that women with narcolepsy avoided sexual intercourse to prevent cataplexy 
(Roy, 1976). Karacan et al reported in 1992 that men with narcolepsy frequently 
experienced erectile problems (Karacan et al., 1992). In a more recent study, from 29 
patients with narcolepsy-cataplexy only 3 reported cataplexy during sexual intercourse and 
orgasm (2 females, 1 male) (Poryazova, Khatami, Werth & Bassetti, 2009). In conclusion, 
narcoleptic patients report problems with sexual life but this it seems to be not necessarily 
associated with cataplexy. 
SELF-HELP GROUP 
Many patients with narcolepsy and patients with depression participate in a self-help 
group. They receive social support which may improve depressive symptoms (Karp, 
1992). The participation in a self-help group could be also a disadvantage for patients 
because according to the theory of Coyne, the interpersonal process can contribute to the 
development of depression (Haeffel, Voelz, Joiner, 2007). Coyne postulates that some 
mildly dysphoric persons (not depressed) who excessively look for reassurance and have 
little social support can be vulnerable to develop depressive symptoms. This author states 
that this group of patients would be more susceptible to diminished social support or to 
perceive less social aid and therefore be more prone to have depressive symptoms 
(Coyne & Bolger, 1990).  
In the literature on narcolepsy, others have mentioned this point, arguing that perhaps only 
narcoleptics with severe symptoms would participate in a self-help group but at the same 
time, patients could improve their status of health (Daniels et al., 2001). 
The importance of a support group has been documented due to their ability to normalize 
the participants’ feelings and experiences. The following is a comment of one patient cited 
by Alaia: “Having narcolepsy has been a lonely experience. Only recently have I come to 
know others with it. A support group through the 40+ years would have helped me cope so 
much. Family and friends have understood, but they do not really know my feelings and 
frustration…only persons with it (narcolepsy) can understand” (Alaia, 1992).  
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HYPOCRETIN DEFICIENCY AND DEPRESSION 
Hcrt plays an important role in the regulation of complex behaviors such as feeding, 
sleeping and being awake. Hcrt can modulate the mesocorticolimbic dopamine circuit and 
therefore seems to be implicated in the pathology of schizophrenia, depression, addiction 
(Borgland & Labouebe, 2010) and panic anxiety (Johnson et al., 2010).  
A loss of Hcrt neurons is believed to be the cause of narcolepsy in humans (Peyron et al., 
2000; Thannickal et al., 2000). There is sufficient evidence that this deficiency of Hcrt is 
present in patients with narcolepsy with cataplexy, but a smaller amount of evidence for 
narcoleptics without cataplexy (Thannickal, Nienhuis & Siegel, 2009). These findings 
suggest that in patients with narcolepsy with cataplexy depression may be caused or 
augmented by Hcrt deficiency. The connection between depression and Hcrt is due to the 
hypocretinergic innervations in all the important areas of the brain implicated in the 
neurobiology of depression. This topic can be analyzed from at least two points of view. 
The first one is due to the role of Hcrt in the aminergic and cholinergic cell groups 
(Salomon et al., 2003). The second one is related to the fact that both narcolepsy and 
depressive patients are treated with agents that increase monoaminergic activity and 
affect the physiology of sleep (Salomon et al., 2003). 
It has been hypothesized that deficiency of Hcrt is related to psychiatric symptoms such as 
depression (Ganjavi & Shapiro, 2007). Low levels of Hcrt in narcolepsy are associated with 
depression but, on the other hand, there is no important decrease in the CSF Hcrt baseline 
levels in depressive patients (Salomon et al., 2003). Hcrt most likely takes part in the 
regulation of the monoaminergic tone that is high during wakefulness and diminishes 
sleep. Monoaminergic tone decreases during REM sleep (see 2.4.8 Theories about 
depression related to sleep abnormalities) and Hcrt is active during wakefulness and REM 
sleep and inactive during rest and non REM sleep. In narcolepsy, low Hcrt would decrease 
monoaminergic activity, provoking sleepiness and short REM sleep latency. 
According to the hypothesis of Janowski, REM is promoted by cholinergic activation and is 
inhibited by aminergic activation (Janowsky et al., 1972). Hence, Hcrt deficit in narcoleptic 
patients could cause an imbalance of the aminergic and cholinergic systems. The 
cholinergic-aminergic imbalance has been described in depression and in narcolepsy. In 
both diseases, there are indicators of a deficiency in the monoaminergic 
neurotransmission and an increased sensitivity to muscarinic-M2-cholinergic agonists 
(Mamelak, 2009). Salomon and colleagues examined levels of Hcrt in 14 depressed 
subjects before and after antidepressant treatment. In patients with depression, a small 
variation of Hcrt-1 in CSF during the day is reported but the authors also suggest that Hcrt 
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deficiency is an improbable cause for depression (Salomon et al., 2003). This would be an 
argument against the difference between patients with and without cataplexy (with or 
without Hcrt deficiency). Antidepressant drugs which are also anticataplectic drugs will 
improve the monoaminergic transmission and will re-establish the balance between 
noradrenergic and cholinergic transmission (Mamelak, 2009).  
ROLE OF HYPOCRETIN IN OBESITY 
Hcrt deficiency in narcoleptic patients is associated with abdominal obesity (Kok et al., 
2003). Zhang, in an animal model, confirmed that Hcrt ligand deficiency could be one of 
the critical factors in the tendency for obesity in narcolepsy. However, multiple other 
factors are also likely to affect this phenotype, and a sex specific alteration of leptin-Hcrt 
signaling may be involved (Zhang, Zeitzer, Sakurai, Nishino & Mignot, 2007).  
Dauvilliers (2003) found no association between CSF Hcrt-1 level and sex, body mass 
index, severity of cataplexy, mean sleep latencies in MSLT and the number of SOREM 
periods. He confirmed prior findings showing that Hcrt-1 levels are significantly reduced or 
indetectable in patients with cataplexy, but not in narcolepsy without cataplexy, where the 
levels are within the normal range (Dauvilliers, 2003). 
2.5.3. Prevalence of depression in narcolepsy 
Depression is considered common in narcolepsy (Daniels et al., 2001; Goswami, 1998; 
Broughton et al., 1994; Merrit et al., 1992). One of the first studies regarding narcolepsy 
and depression reported that 17 narcoleptics out of a group of 100 were depressed (Roth 
et al., 1975). The same study found that in narcolepsy patients without cataplexy, 
depression occurred in 28.6% of the cases, while in narcolepsy with cataplexy they found 
depression in 17.2% of the cases. In IH, the occurrence of depression was 26.1%. 
Furthermore, the authors reported a relatively frequent occurrence of depression in the 
families of the patients suffering from depression associated with IH or narcolepsy (Roth et 
al., 1975). In 1992, a North-American study found that the prevalence of depressive 
symptoms in narcolepsy patients was 49%. Additionally, it was reported that although the 
drugs used by narcoleptic patients could have an effect on mood, in the sample studied 
this was not a factor that affected depressive symptoms. Younger patients experienced 
significantly more depressive symptoms, as well as narcoleptics with less education and 
lower income levels. Narcoleptics who are married experienced significantly less 
depressive symptoms (Merrit et al., 1992). 
Another study describes the health status and psychosocial aspects of narcolepsy patients 
in the UK compared with normative data using BDI and SF-36. The authors found in BDI 
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that 56.9% of 305 subjects had some degree of depression (Daniels et al., 2001). A 
Brazilian study using BDI and HAM-D, reported that in a sample of 12 narcoleptic patients, 
3 patients showed depressive symptoms in BDI and 5 patients in HAM-D. Only one patient 
reported severe depressive symptoms according to both questionnaires (Adda et al., 
1997). All these investigations remain controversial because of the enormous differences 
in the prevalence of depression. Consequently, it is not yet clear whether depression is a 
genuine comorbidity of narcolepsy, or if the finding of an increased rate of depressive 
symptoms is merely an assertion artifact. 
NO EVIDENCE OF CULTURAL DIFFERENCES  
The psychosocial impact of narcolepsy was the same in populations from North America 
(Canada and USA), Japan and the Czech Republic (Czechoslovakia at the time of the 
study) demonstrating that the genetic origin or cultural experiences have no significant 
influence (Broughton et al 1983). Suicidal thoughts were more common in Japanese 
patients, whose culture has a tradition of using suicide as a means of escape. Driving 
accidents were significantly less frequent in the Czech Republic probably because of the 
severe restrictions and penalties for driving narcoleptics (Broughton et al., 1981). 
 PERSONALITY 
Using MMPI, one study found higher scores in the scales for schizophrenia, depression, 
and hysteria (Kales et al., 1982). Another study reported that also scales hypochondriasis 
and psychasthenia were elevated (Ramos-Platón, 1998). Others found that only the scales 
of hysteria and hypomania are significantly elevated in patients with narcolepsy compared 
with controls (Jara, Loubat & Castillo, 2003). As Kales mentions, some items of MMPI may 
not distinguish between symptoms of narcolepsy and daily life feelings, but there is no way 
to reduce the elevation of scales due to content related with physical symptoms (Kales et 
al., 1982).  
In 1990, Stepanski et al compared a group of 56 narcoleptics with patients diagnosed with 
excessive daytime sleepiness of other causes. Both groups showed greater scores using 
MMPI (Stepanski, Markey, Zorick & Roth, 1990). The results suggest that the 
psychopathology related to narcolepsy is not specific and may be generalized to other 
disorders with excessive sleepiness. Beutler et al (1981) found that narcoleptics are most 
often characterized by personality patterns which emphasize coping with stress by 
sensitization to sources of anxiety and social withdrawal compared to the control group 
(Beutler, Ware, Karacan & Thornby, 1981). Narcoleptics were distinguished from controls 
as being relatively more depressed, anxious, fatigued and having less vigor. Moreover, 
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Broughton in another study discovered that narcoleptic patients are more anxious and 
emotionally changeable than normal controls (Broughton, 1976). 
2.5.4. Prevalence of depression in idiopathic hypersomnia 
A study performed in Montpellier that compared dysthymic patients who complained of 
excessive night and daytime sleepiness with IH patients found that patients with dysthymia 
did not have reduced mean sleep latency on the MSLT. However, they exhibited an 
abnormal macrostructure of sleep with enhanced sleep stage 1 and a decreased stage 3 
and 4 (Dolenc, Besset & Billiard, 1996). Roth reported that in patients with IH, the 
prevalence of psychiatric symptoms is circa 50% and specifically for depression between 
14 to 26% (Roth, 1980; Roth et al., 1975). One study found that the prevalence of 
psychiatric symptoms was 57% (Bassetti et al., 1997) It seems that psychiatric symptoms 
in IH patients are reactions to chronic illness but at the same time the symptoms of IH 
have common characteristics with psychiatric symptoms (Bassetti et al., 1997). Bassetti 
and Aldrich suggested that there are three arguments to maintain the link between IH and 
mood disorders: (a) Fluctuations of EDS and psychiatric complaints with intensification of 
EDS in winter or during menstrual period, (b) Hypersomnia is commonly reported by young 
depressed patients who spend 16-20 hours in bed per day and (c) Patients with 
depression frequently sleep longer when they are allowed to sleep as much as they want, 
which is significantly more than in the controls (Bassetti et al., 1997). Supporting this 
results, Chellappa (2006) evaluated EDS related with depression, and examined the 
association with severity of depression and suicide ideation. The authors reported that 
daytime sleepiness in outpatients with depressive disorder is related with suicide ideation 
(Chellappa, 2006). 
One study with a considerable number of IH patients used depression as an exclusion 
criterion (Anderson et al., 2007), which decreased possibilities for a psychiatric approach. 
Only in the absence of a depression is it possible to diagnose IH with short or long sleep 
time. This can be a bias in the studies of IH. Billiard et al (2001) reported that IH patients 
with mood disorders are often excluded from the diagnosis spectrum because of the 
criteria “no medical or mental disorders as a possible cause of the symptoms” (Billiard, 
2001). 
2.5.5. Key references related to depression and daytime sleepiness 
To provide an insight into the pertaining literature, table 33 (in appendix) shows crucial 
work concerning the topic of narcolepsy, idiopathic hypersomnia and depression. The 
papers are listed in alphabetical order of the first author. The majority of studies are 
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prospective (62%). After the division narcolepsy with and without cataplexy in 2005, the 
studies are principally focused in patients with cataplexy. The following review of the 
literature, summarized in the table, shows that although patients have depressive 
symptoms and have a low quality of life (which includes some items regarding depression) 
most of the studies fail to probe whether they have a major depressive disorder (MDD).  
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2.6. Research questions and hypothesis 
Depression and depressive symptoms are consistently reported as a problem for 
narcoleptic patients in various studies, but the lifetime prevalence of depressive disorders 
based on internationally accepted diagnostic criteria is not increased, as pointed out in the 
previous section. This obvious discrepancy leads us to hypothesize that depression in 
narcoleptics is a phenomenon that can be differentiated from the symptoms in patients 
with MDD by a distinct constellation of single symptoms (Hypothesis I). Depending on 
varying sets of criteria, these symptoms may or may not result in the formal diagnosis of a 
depressive disorder. Accordingly, the key question of this dissertation is: 
ARE DEPRESSIVE SYMPTOMS OF NARCOLEPTIC PATIENTS DIFFERENT FROM THE DEPRESSIVE 
SYMPTOMS OF NON-NARCOLEPTIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER? 
The main hypothesis implicitly presupposes that narcoleptic patients are indeed more 
depressed than a comparable control group from the general population (Hypothesis II). 
Given the large variance in previous results on this topic, this hypothesis was to be tested 
in a first step. This was formulated as a first research question: 
 
ARE NARCOLEPTIC PATIENTS MORE DEPRESSED THAN CONTROLS FROM THE GENERAL 
POPULATION? 
In the latest version of the International Classification of Sleep Disorders, the diagnosis of 
narcolepsy has been split into two distinct subcategories, and the delimitation against IH 
was changed. This may in many ways influence the characteristics and the distribution of 
depressive symptoms. Therefore, an additional step of analysis was introduced to lay the 
foundation to approach the primary research question. Based on previous research, it was 
hypothesized that narcoleptics with cataplexy show more depressive symptoms than those 
without cataplexy (Hypothesis III), and that IH patients are equally depressed as 
narcolepsy patients without cataplexy (Hypothesis IV). This resulted in a second research 
question: 
DO THE TWO NEWLY DIFFERENTIATED FORMS OF NARCOLEPSY (WITH AND WITHOUT CATAPLEXY) 
AND IH DIFFER WITH RESPECT TO THE DEGREE OF DEPRESSIVE SYMPTOMS? 
To answer these questions, a first study was performed with the title: “Depressive 
symptoms in narcolepsy with and without cataplexy and in IH” (Study I).  
For methodological reasons, an approach with self-rating scales was chosen to compare 
depressive symptoms between depressed narcoleptic patients and patients with primary 
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depression. The type of depressive symptoms narcoleptic patients report may be different 
from those seen in primary depression. Physical symptoms may elevate the scores 
obtained by narcoleptic patients. Consequently, it is expected that depressed narcoleptics 
report less cognitive symptoms than patients with primary depression with equal mean 
scores in the same rating scales (Hypothesis V). 
In terms of a research question, this was worded as:  
ARE SELF-REPORTED DEPRESSIVE SYMPTOMS IN PATIENTS WITH NARCOLEPSY DIFFERENT FROM 
THOSE IN PATIENTS WITH A PRIMARY DEPRESSIVE EPISODE, WHEN INTENSITY OF DEPRESSION IS 
CONTROLLED? 
To address this question, a second study was performed with the title “Narcoleptics with 
depressive symptoms compared with patients with primary depression” (Study II).  
Based on the results of study II, the analysis of the specific symptom constellation was 
followed up concentrating on the BDI, which had proven to be the most promising 
candidate for a factor analysis. A large number of factor analysis studies have been 
performed in many depressed and non-depressed populations, and in various medically ill 
populations. Despite the extensive use of BDI in narcoleptic patients, so far, this method of 
statistical analysis has not been previously explored on this population. This resulted in the 
following research question: 
WHAT ARE THE CENTRAL ITEMS OF BECK DEPRESSION INVENTORY (BDI) THAT EXPLAIN THE 
SCORES OBTAINED BY NARCOLEPTICS?  
Different studies using BDI factor analyses have identified three factors: (1) negative 
attitudes toward self, (2) performance impairment and (3) somatic disturbances. 
The expectations are that in narcoleptic patients the components related to somatic items 
of BDI will be more relevant when compared to components associated with cognitive 
items. (Hypothesis VI). Accordingly, a third study was performed with the title: “Factor 
analysis of Beck Depression Inventory in patients with narcolepsy” (Study III). 
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3. EMPIRICAL PART I: “DEPRESSIVE SYMPTOMS IN NARCOLEPSY WITH AND WITHOUT 
CATAPLEXY AND IDIOPATHIC HYPERSOMNIA” 
3.1. Introduction  
Narcolepsy is a chronic sleep disorder first described by Westphal more than 130 years ago 
(Westphal, 1877). Over time, it has been a matter of discussion as to whether or not the symptom 
of cataplexy should be necessary to diagnose narcolepsy. Notably, in 15% of the cases, cataplexy 
will develop more than 10 years after the onset of sleepiness (Yoss et al., 1960). In the second 
edition of the ICSD (ICSD-2) two forms of narcolepsy, with (NC+) or without cataplexy (NC-), are 
distinguished (American Academy of Sleep Medicine, 2005). The difference between both is the 
definitive presence of cataplexy in the first form and absent or questionable cataplexy in the second 
form (American Academy of Sleep Medicine, 2005). Narcolepsy without cataplexy is distinguished 
from IH based on the presence of two or more sleep onset REM periods in the MSLT. IH is divided 
into two groups, depending on whether the duration of night sleep is more than 10 hours or not, 
referred to as IH with long sleep time or without long sleep time, respectively. 
An association between narcolepsy and depression was observed in 1975 when Roth and 
Nevsimalova reported that 17 narcoleptics out of a group of 100 were depressed, as assessed by 
clinical interviews (Roth et al., 1975). This is higher than the prevalence of major depression in 
Europe, which is between 3.1% and 10.1% (Wittchen & Jacobi, 2005). After these studies, several 
authors using a variety of diagnostic systems and assessment scales reported depressive 
symptoms in 6% to 56% of the narcolepsy patients (Rovere et al., 2008; Vandeputte et al., 2003; 
Daniels et al., 2001; Adda et al., 1997; Broughton et al., 1994; Merrit et al., 1992; Kales et al., 1982; 
Roth, 1980; Sours, 1963). A study performed with a structured interview found that only 7% of NC+ 
patients met criteria for depressive disorder not otherwise specified according to DSM-IV (Vourdas 
et al., 2002) while Daniels found that 56.9% of patients were on the border of a depression (BDI 
>10 points), and 15.1% were at least mildly to moderately depressed (BDI >20 points) (Daniels et 
al., 2001). The variation in these studies could reflect unlike assessments, the use of different 
research instruments, varying cut-off scores or specific questions in the psychometric tests related 
to sleep and overlap between symptoms of depression and narcolepsy.  
Five out of the nine symptoms of Major Depressive Disorder according to DSM-IV (American 
Psychiatric Association, 2000) are common symptoms of narcolepsy, including fatigue, 
psychomotor retardation, decreased concentration, hypersomnia and weight increase. 
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Nonetheless, the high rates of depressive symptoms in narcolepsy suggest a relevant relation 
between these two disorders. In the discussion of possible causes, several lines of evidence have 
been mentioned. The core question, brought up more than 45 years ago (Sours, 1963), of whether 
the psychiatric findings are epiphenomena or if they are inherent to the disease, remains 
unanswered.  
The distinction between NC+ and NC- raises the question of whether there is a difference in 
depressive symptoms between both groups. Most authors reported no significant differences 
between narcoleptics NC+ and NC- in quality of life scales such as the SF-36 scale or in 
depression (e.g. BDI) scores (Morrish, King, Smith & Shneerson, 2001). A Japanese study with 
drug naïve patients showed that quality of life did not differ across different categories of 
hypersomnia of central origin (NC+, NC-, and IH without long sleep time) (Ozaki et al., 2008). In 
contrast, the “Harmony study”, performed in France with medicated patients found that NC+ 
patients have more depressive symptoms than a combined group of NC- and IH (Dauvilliers et al., 
2009). Several studies suggest that narcolepsy patients have many limitations and difficulties 
managing their daily activities (Goswami, 1998; Broughton et al., 1994) and untreated narcoleptics 
with or without cataplexy do not differ in terms of quality of life. Others found that the impact of 
narcolepsy in daily life is unrelated to medication (Rovere et al., 2008; Dodel et al., 2007; Ervik, 
Abdelnoor, Heier, Ramberg & Strand, 2006; Vignatelli et al., 2004; Daniels et al., 2001; Beusterien 
et al., 1999). Usually, antidepressant medication in narcolepsy patients is given for cataplexy and 
not to diminish depressive symptoms. Therefore, the prescribed dose is low. There is no clear 
evidence that antidepressants improve the quality of life (Vignatelli et al., 2004). Whether stimulants 
will diminish depressive symptoms is not well established. Amphetamines can increase anxiety and 
in some patients can lead to mania (Roy, 1976) but modafinil has been associated with 
improvement in quality of life and mood in narcolepsy patients (Becker et al., 2004).  
Hcrt deficiency is mainly observed in NC+ (Nishino et al., 2000). The interest to compare both 
groups is increasing because this peptide plays a role in modulating the reward system in the brain 
in addition to regulating appetite, metabolism and sleep. Therefore, Hcrt may be relevant in 
depression (Ganjavi et al., 2007). A direct comparison of depressive symptoms in NC+, NC-, IH 
and a sex and age matched control group has not been performed yet. Given these considerations, 
depressive symptoms in narcoleptic and IH patients and controls were assessed. Furthermore, a 
comparison of depression scores of patients with and without cataplexy and IH were performed. 
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3.2. Methods 
3.2.1. Participants 
Eighty-six narcolepsy patients of Caucasian origin were studied (46 women, 40 men, age range 19 
to 78 years) and a total of 15 patients with IH were studied (three women, 12 men) (Table 4).  
Diagnosis according to ICSD-2 criteria (American Academy of Sleep Medicine, 2005) was 
established in the  Sleep Disorders Centre, department of Psychiatry, Psychosomatics and 
Psychotherapy, University Medical Centre Regensburg (n= 36) or in another German sleep 
laboratory, based on polysomnography (PSG) and Multiple Sleep Latency Test (MSLT). Patients 
were rated NC+ when a history of current or past definite cataplexy was present (n = 65). No 
specific exclusion criteria were applied.From the narcoleptic sample, 70% were members of the 
German narcolepsy association, a patient support group. 
All IH patients were diagnosed in the sleep centre in Regensburg according to the ICSD-2 criteria. 
Because of the small number of patients the group was not divided into the categories of with or 
without long sleep time as recommended by the ICSD-2.There was a significant difference in age 
between the whole sample of controls and IH patients. Therefore, from the sample of controls, a 
sub sample was regrouped to match each IH patient.Each narcoleptic patient was matched to a 
control subject of the same sex and equal age (± five years). The matching variables were chosen 
because these are known predictors of depressive symptoms (Slone et al., 2006). 
The ethics committee of the University of Regensburg approved the study. All patients and controls 
signed informed consent. 
CONTROL GROUP 
The control group for the narcoleptic patients group was composed by 86 healthy subjects. From 
them (86 subjects) 15 were matched to the IH patients group for statistic comparison. This group of 
15 subjects was called IH controls (Table 12). The purpose of this extraction of the control group 
was to have groups similarly distributed by age. The control group (86 subjects) was recruited from 
volunteers among the employees of the Psychiatric University Hospital, students of the University 
of Regensburg and visitors of a senior citizen center in Regensburg. Exclusion criteria for controls 
were use of hypnotics, antidepressants, current diagnosis of depressive disorder, Restless Legs 
Syndrome according to ICSD-2, and insomnia complaints (Pittsburgh Sleep Quality Index [PSQI] 
(American Academy of Sleep Medicine, 2005; Buysse, Reynolds, III, Monk, Berman & Kupfer, 
1989) score > 5, or > 8 points for subjects 60 years or older (Eser, Khorshid & Cinar, 2007; 
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American Academy of Sleep Medicine, 2005)). Although a diagnosis of depression was an 
exclusion criterion, controls with depressive symptoms were not excluded of the sample to avoid a 
bias. 
3.2.2. Procedure and questionnaires 
Following a prospective study design, self-administered questionnaires were given to the patients 
during their visit in the sleep disorders centre in Regensburg or at a meeting of the German 
narcolepsy association. The scales used were the German versions of Beck Depression Inventory 
(BDI), Zung Self-rating Depression Scale (SDS), Global Impression of Severity of Depression 
(GSD), Profile of Mood States (POMS) and Epworth Sleepiness Scale (ESS), and a questionnaire 
on demographic data and symptoms, diagnosis, and pharmacological treatment.  
BECK DEPRESSION INVENTORY (BDI) 
The BDI is a self-rating scale, which is comprised of 21 questions related to depressive symptoms. 
For each item, the possible score ranges from 0 to 3 points, resulting in a possible total score from 
0 to 63 points. The score increases with the severity of depression and originally is graded as 
follows: from 0-9 points: no or minimal depression, 10-14 points: on the border of depression, 15-20 
points: mild depression, 21-30 points: mild to moderate depression, 31-40 points: moderate to 
severe depression, and 41-63 severe depression (Hautzinger, 1991; Beck, Ward, Mendelson, Mock 
& Erbaugh, 1961). The first version of the test was used because the second one version (Kühner, 
Bürger, Keller & Hautzinger, 2007) was not yet available in the German language at the beginning 
of the study.  
 
Table 11. Items of Beck Depression Inventory (BDI) according to Beck et al. (1961) 
BDI items 
A. Sadness K. Irritability 
B. Hopelessness L. Social anhedonia 
C. Sense of failure M. Indecisiveness  
D. Anhedonia N. Change of body image 
E. Guilt O. Push to work  
F. Expectation of punishment P. Insomnia  
G. Self hate Q. Fatigue  
H. Self blame R. Loss of appetite 
I. Suicidal ideation S. Loss of weight  
J. Crying spells T. Health worries  
  U. Loss of libido 
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ZUNG SELF-RATING DEPRESSION SCALE (SDS)  
The SDS consists of 20 items. The scores for each item are 1 to 4 points, so the minimum score is 
20 and the maximum score is 80 points.The scores were graded following the original cut off values 
from Zung: 20-39 points: normal, 40-47: mild depression, 48-55 points: moderate depression and 
56-80 points: severe depression (Zung, 1965). 
 
Table 12. Items of Zung Self-Rating Depression Scale (SDS) according to William Zung 
(1965). 
Items SDS 
1) I feel down-hearted and blue  11) My mind is as clear as it used to be 
2) Morning is when I feel the best 12) I find it easy to make decisions  
3) I have crying spells or feel like it 13) I am restless and can´t keep still 
4) I have trouble sleeping at night  14) I feel hopeful about the future 
5) I eat as much as I used to 15) I am irritable than usual 
6) I still enjoy sex 16) I find it easy to make decision  
7) I notice that I am losing weight  17) I feel that I am useful and needed  
8) I have trouble with constipation  18) My life is pretty full 
9) My heart beats faster than usual 
(tachicardia)  
19) I feel that others would be better off if I were 
dead  
10 I get tired for no reason 20) I still enjoy the things I used to do 
 
In a secondary analysis, items specifically related to sleep in BDI and SDS (“sleep items”) were 
excluded. These items were in BDI „I can sleep as well as before” and “I do not get more tired than 
usual” and in SDS “I have trouble sleeping at night” and “I get tired for no reason”. 
GLOBAL IMPRESSION OF SEVERITY OF DEPRESSION (GSD) 
The GSD is a visual analogue scale (range 0 to 10) with the question “Do you feel depressed” with 
expressive faces at each one of the extremes, with low values corresponding to depressive 
feelings. GSD was performed in this study based on the validated scales used in pain research 
studies (Wewers & Lowe, 1990). This was used to compare the subjective feelings of depression of 
narcoleptic patients without mentioning the field of sleepiness. 
PROFILE OF MOOD STATES (POMS) 
The POMS consists of 65 items grouped into five negative and one positive mood dimension. As 
for time frame, the question “How have you been feeling during the past week including today?“ 
was used. The subscales are tension-anxiety (9 items), depression (15 items), anger-hostility (12 
items), vigor-activity (8 items) fatigue (7 items), and confusion-bewilderment (7 items) (McNair, Lorr 
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& Droppleman, 1992). The total of mood disturbance score (TMD, range 0 -200) is calculated by 
adding all the negative mood dimensions and subtracting the positive one (vigor). In some 
analyses, the focus was on the subscale depression of POMS because it is specifically related to 
depressive symptoms. 
EPWORTH SLEEPINESS SCALE (ESS) 
Daytime sleepiness was assessed with the ESS. The ESS asks about the tendency to fall asleep 
during eight different situations that are commonly encountered in daily life, yielding a score range 
of 0-24, 11 points or over was considered indicative of pathological sleepiness (Johns, 1991). The 
normative value of the German version of the ESS for healthy controls is 6.6±3.5 [mean± SD] 
(Sauter et al., 2007).  
3.2.3. Statistical analysis 
Data analyses were processed using the Statistic Package for Social Sciences 16.0 (SPSS). The 
significance level was set to .05 for all analyses. The effect size is reported because “a result 
statistically significant at conventional levels is not necessarily “practically significant” as judged by 
the magnitude of the effect” (Rosenthal, Rosnow & Rubin, 2000, p.4). Cohen´s d was carried out to 
calculate the effect size. To address the problem of multiple comparisons, the Bonferroni correction 
was carried out where indicated. A square root transformation was performed in some cases of 
variables with non-Gaussian distribution. Sex and age matched groups were compared by Mann 
Whitney U-test. For categorical variables, the Pearson Chi-square test followed by Fisher’s exact 
test was employed. The effect and interaction of type of drug and sex was evaluated by analysis of 
variance (ANOVA). For post-hoc comparison, tests not assuming equal variances (Games-Howell) 
were used. 
The associations between the sleep related items in BDI and SDS, and the ESS were analyzed 
with the Spearman correlations. Bilateral tests for significance were used in all cases. The Pearson 
Chi-square test was employed to contrast the hypothesis of independence between two categorical 
variables (levels of depressive symptoms) followed by Fisher’s exact test.  
A multiple linear regression analysis using the backward method was conducted to explore and 
quantify the relation between the depressive symptoms and multiple independent variables such as 
age, sex, use of stimulants, antidepressants, combination of stimulants and antidepressants, the 
illness duration, cataplexy symptom, severity of sleepiness, body mass index, age at the onset of 
narcolepsy and diagnosis age. IH patients were not included in this analysis because the goal of 
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the regression was to analyze the effect of cataplexy, which is specific to narcolepsy. The backward 
method includes all the independent variables and then proceeds to eliminate each variable one at 
a time. A logistic regression was used to confirm the results obtained in the linear regression, 
because some of the variables were dichotomous. For this analysis, the variables of depressive 
symptoms were transformed into yes (BDI > 9, SDS > 39) or no. We analyzed by age group (19-29, 
30-39, 40-49, 50-59, 60-69 and 70-78 years old) and body mass index (BMI) classification 
according to the WHO (Underweight<18.50, normal range 18.50-24.99, overweight ≥25-29.99 and 
obese ≥30) (World Health Organization, 2000). 
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3.3. Results 
3.3.1. Demographic and clinical characteristics 
AGE, SEX, BODY MASS INDEX 
The difference between sexes in the control group was not significant (p>.05). In the BDI test, the 
control group scores were in the normal range with a percentage of participants arranging a higher 
level referred to by Beck as “on the border of a depression” without a diagnosis of MDD. This was 
part of the exclusion criteria (see methods). The total scores are represented in the Table 14. 
COURSE OF THE ILLNESS 
Patients with IH had shorter illness duration than narcoleptics because almost all were younger 
than patients the comparison group. 
 
Table 13. Demographic and clinical characteristics of study sample. 
Group Age M ± SD 
Sex 
female: 
male 
Body Mass  
Index (in kg/m²)
M ± SD 
Age at onset  
of excessive 
sleepiness 
 M ± SD 
Illness  
duration 
(in years) 
M ± SD 
Years living 
without  
diagnosis 
 M ± SD 
NC+ 
n=65 45.4 ± 16.4 35:30 29.5 ± 6.2 21.4 ± 10.1 27.5 ± 16.2 14.2 ± 1.6 
NC- 
n=21 51.7 ± 15.2 11:10 28.5 ± 4.4 23.2 ± 13.2 26.5 ± 17.6 20.4 ± 3.6 
IH 
n=15 31.6 ±12 3:12 24.0±3.5 19.6±12.4 12.4±7.8 10.2±8.5 
C (NC+ & 
NC-) n=86 45.2 ± 16.5 46:40 23.8 ± 4.0 NA NA NA 
C (IH) 
n=15 33.5 ±12 3:12 23.9±2.7 NA NA NA 
NC+, narcoleptics with cataplexy; NC-, narcoleptics without cataplexy; IH, idiopathic hypersomnia 
patients; C (IH), matched control group for IH patients; C (NC+ & NC-), matched control group for NC+ 
and NC- patients; M, arithmetic mean; SD, standard deviation; NA, not applicable. 
 
Depressive symptoms in narcolepsy and idipopathic hypersomnia - 79 
 
MEDICATION USE  
Sixteen patients were unmedicated for narcolepsy at the time of the study (NC+: 10, NC-: 6), 39 
were using stimulants only (NC+: 27, NC-: 12), eight (all NC+) were taking anticataplectics only, 
and 20 NC+ patients were taking both (stimulants and anticataplectics). Three NC- patients were 
taking antidepressant medication in combination with stimulants, one of them for recurrent 
depression and the other two for unknown reasons. The anticataplectic drugs used were tricyclic 
antidepressants (n=12), selective serotonin reuptake inhibitors (n=8), serotonin-norepinephrine 
reuptake inhibitors (n=5), norepinephrine reuptake inhibitors (n=8), monoamine oxidase inhibitors 
(n=1), and sodium oxybate (n=6). Eight patients were taking a combination of two anticataplectic 
drugs. The stimulant drugs used were modafinil (n=46), methylphenidate (n=9), fenethylline (n=1) 
and pemoline (n=1). Twenty-nine patients were not taking stimulants at the time of the study. These 
had been just diagnosed (n=8) or had chosen not to use stimulants at this time. 
EPWORTH SLEEPINESS SCALE (ESS) 
Daytime sleepiness (measured by ESS scores) was compared between patients groups and 
controls (Figure 4). Although all but 16 patients were taking medication against narcolepsy and 57 
were taking stimulants, the ESS-score at the time of the study was in the normal range (below 11 
points) for only five patients (5.8%), with a mean of 16.7 points (Standard deviation (SD) 3.9 range 
4 to 23 points). Patients on stimulants showed the same mean as the rest (ON stimulants: ESS-
score mean=16.7, SD= 3.8; OFF stimulants: ESS-score mean=16.6, SD=4.0, p>.05). In the control 
group, the ESS mean score was 5.1, SD 3.3, with 10.5% scoring more than 10 points. This is 
similar to the normative values of the German version of ESS for healthy controls (See methods).  
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Figure 4. Average of scores in the Epworth Sleepiness Scale (ESS). Higher scores indicate a 
higher level of impairment. Lines denote the median values; box denotes specific interquartile 
range. Maximum and minimum scores are indicated by the upper and lower markers, respectively 
(See interpretation of boxplots in section appendix). 
3.3.2. Depressive symptoms – Univariate analysis 
COMPARISON NARCOLEPTIC PATIENTS WITH, WITHOUT CATAPLEXY, IDIOPATHIC HYPERSOMNIA  
No significant differences between NC+ and NC- in the total scores in BDI, SDS, GSD, TMD or any 
of the subscales of POMS were found. The analysis shows that NC+ and NC- have significantly 
lower scores in the subscale Fatigue than IH (Figure 5). In addition, NC- have significantly lower 
scores in the subscale Confusion than IH, however NC+ shows no significant differences with NC- 
or IH (Table 14).  
NC+ women showed a significant increase in depressive symptoms compared to men. This 
difference was neither present in NC- nor in controls. Nevertheless, no significant differences were 
found in BMI by gender. 
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Table 14. Depression, mood ratings and sleepiness in narcoleptics with and without cataplexy and 
diopathic hypersomnia patients. i
 
Measure  NC+ (n=65) 
M ± SD 
NC- (n=21) 
M ± SD 
IH (n=15)  
M ± SD 
Kruskal 
Wallis 
(df=2) 
p value 
 
Depression BDI 11.8 ± 8.8 7.8 ± 6.0 11.6±10.8 2.78 .25 
 BDI –sleep 
items 
9.8±7.8 6.1±5.4 10.1±10.1 4.03 .13 
 SDS 40.2± 10.0 37.1± 7.8 39.1±11.3 1.40 .50 
 SDS – 
sleep items 
34.9±9.4 32.3±7.3 34.6±11.1 0.99 .61 
 GSD 2.9 ± 2.6 2.9 ± 2.6 3.3±3.0 0.23 .89 
Mood POMS- 
TMD 
39.3±37.3 27.5±21.7 53.2±41.9 3.60 .17 
 Tension 11.7±6.7 8.9±4.5 11.7±8.7 3.27 .19 
 Depression 13.3±12.9 7.8±7.7 16.9±15.8 4.10 .13 
 Anger 10.1±7.5 9.2±6.3 11.4±9.4 0.17 .92 
 Vigor 16.1±6.2 18.0±5.3 13.5±6.6 3.77 .15 
 Fatigue 
 
11.7±6.1 10.8±4.5 15.7±5.5 7.32 .03* 
 Confusion 8.6±5.0 6.8±4.0 11.1±5.1 7.05 .03* 
Sleepiness ESS 16.6 ± 3.8 16.8 ± 3.8 14.1±4.3 3.60 .10 
NC+, narcoleptics with cataplexy; NC-, narcoleptics without cataplexy; IH, idiopathic 
hypersomnia patients; Kruskal-Wallis Test; this is a non-parametric test here performed to 
compare NC+, NC- and IH. M, arithmetic mean; SD, standard deviation; BDI, Beck Depression 
Inventory (21 item version); BDI-sleep items, BDI scores excluding 2 sleep items (see 
Methods); SDS, Zung Self-Rating Depression Scale; SDS-sleep items, SDS scores excluding 
2 sleep items (see methods); GSD, Global impression of Severity of Depression; POMS, 
Profile of Mood States; TMD, Total Mood Disturbance; ESS, Epworth Sleepiness Scale; **: 
significance level= .01 after Bonferroni correction (k=5, adjusted for comparison of BDI, SDS, 
GSD, POMS (total) and ESS ).  
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To avoid the problem of multiple comparisons, a one factor ANOVA with post hoc was 
performed. The Levene tests shows that the variance is equal (p>.05), therefore the Tukey 
post-hoc test was performed confirming that fatigue and confusion are significantly 
different between the groups. 
 
Table 15.
 
 Depression and mood ratings in narcoleptic patients with and without cataplexy. 
Measure  NC+ (n= 65) 
M ± SD 
NC- (n= 21) 
 M ± SD 
U p value
 
Depression BDI 11.8 ± 8.8 7.8 ± 6.0 -1.70 .09 
 BDI –sleep items 9.8±7.8 6.1±5.4 -2.01 .04 
 SDS 40.2± 10.0 37.1± 7.8 -1.10 .26 
 SDS – sleep items 34.9±9.4 32.3±7.3 -.96 .33 
 GSD 2.9 ± 2.6 2.9 ± 2.6 -.12 .89 
M, arithmetic mean; SD, standard deviation; U, computed value Mann-Whitney U-Test; NC+, 
narcoleptics with cataplexy; NC-,narcoleptics without cataplexy; BDI, Beck Depression 
Inventory (21 item version); BDI-sleep items, BDI scores excluding 2 sleep items (see 
methods); SDS, Zung Self-Rating Depression Scale; SDS-sleep items, SDS scores 
excluding 2 sleep items (see Methods); GSD, Global impression of Severity of Depression; 
POMS, Profile of Mood States; TMD, Total Mood Disturbance; ESS, Epworth Sleepiness 
Scale; **: significance level= .01 after Bonferroni correction (k=5, adjusted for comparison of 
BDI, SDS, GSD, POMS (total) and ESS ). 
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Figure 5. Average of scores in the six subscales of Profile of Mood States and in the total 
mood disturbance (total of subscales excluding Vigor). Higher scores indicate a higher 
level of impairment. 
SEVERITY OF DEPRESSION  
In BDI and SDS, the distribution among the graded categories of depression severity 
showed no significant differences between the NC+ and the NC- groups (Pearson Chi-
square, Fisher’s exact test, p >.05). The distribution over the graded score groups of the 
BDI and the SDS was clearly different between narcoleptics and controls (BDI: Pearson 
Chi-squared=27.03 p<.0001, Fisher’s exact test=27.84 p<.0001, SDS: Pearson Chi-
squared=38.21 p<.0001, Fisher’s exact test=40.15 p<.0001). 
In BDI, none of the narcoleptic patients were in the “severe depression” group, but three 
patients (3%) scored “moderate to severe depression”. In SDS, seven patients (8%) 
scored in the highest category (“severe depression”), and 10 patients (12%) had 
“moderate depression”. Only about half of the patients scored normal values in SDS and 
BDI. In the control group, 94 % (SDS) or 90 % (BDI) were in the normal range, while the 
remainder scored in the range of mild depression (Figure 6 and 7). None of the 
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narcoleptics showed severe depression in the BDI, and none of the controls had more 
than mild depression in either of the scales.  
 
 
Figure 6. Graded distribution of depressive symptoms in narcoleptics with and without 
cataplexy, idiopathic hypersomniacs and controls according to Beck Depression Inventory. 
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Figure 7. Graded distribution of depressive symptoms in narcoleptics with and without 
cataplexy, idiopathic hypersomniacs and controls according to Zung Self-rating 
Depression Scale. 
 
As not substantial differences between NC+ and NC- were found, both groups were 
combined for subsequent analyses. 
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Table 16. Depression and mood ratings in narcoleptic patients and control 
subjects. 
 Measure Narcoleptic patients 
(n= 86) M ± SD 
Controls (n=86) 
M ± SD 
U 
Depression BDI 10.8 ± 8.4 3.8 ± 3.9 -6.25**** 
 BDI - sleep items 8.9 ± 7.4 3.2±3.5 -5.98**** 
 SDS 39.4 ± 9.7 28.1 ± 6.2 -6.73**** 
 SDS - sleep items 34.3 ± 8.9 25.5±5.8 -6.29**** 
 GSD 2.9± 2.6 1.0 ± 1.6 -5.59**** 
Mood  POMS - TMD 36.4±34.4 2.0±21.9 -6.35**** 
 Anxiety 11.1±6.4 5.5±4.5 -5.77**** 
 Depression 12.0±12.1 4.0±6.3 -5.70**** 
 Anger 9.9±7.2 5.4±5.3 -4.47**** 
 Vigor 16.6±6.0 21.0±6.2 -4.40**** 
 Fatigue 11.6±5.8 4.4±4.6 -6.78**** 
 Confusion 8.2±4.9 3.8±2.9 -6.01**** 
M, arithmetic mean; SD, standard deviation; U, computed value Mann Whitney test; BDI, 
Beck Depression Inventory (21 item version); BDI-sleep items, BDI scores excluding 2 sleep 
items (see Methods); SDS, Zung Self-Rating Depression Scale; SDS-sleep items, SDS 
scores excluding 2 sleep items (see Methods); GSD, Global impression of Severity of 
Depression; POMS, Profile of Mood States; TMD, Total mood disturbance; ****p<.0001. 
 
COMPARISON -NARCOLEPTIC PATIENTS AND CONTROLS 
Patients with narcolepsy revealed a significantly higher level of depressive symptoms in 
the total scores of BDI, SDS and GSD than controls (p<.0001 for all scores). This 
difference remained significant when the sleep items in BDI and SDS were excluded. In 
the POMS, narcoleptics scored higher on the TMD and on all negative sub scales, and 
lower on the positive sub scale (vigor). As expected, the ESS score was significantly 
higher in the narcoleptics (Figure 4).  
CORRELATION BETWEEN ESS AND DEPRESSIVE SYMPTOMS IN PATIENTS AND CONTROLS 
In narcoleptics, BDI items correlating with ESS scores were: item L Social withdrawal 
(r=.26, p=.002), item 0 Retardation (r=.25, p=.02), item Q Fatigability (r=.25, p=.02). The 
item P Insomnia showed a statistical tendency which was not significant (r=.21, p=.052). 
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In controls, BDI items correlating with ESS scores were: item B Hopelessness (r=.23, 
p=.03), G Dislike of self (r=.23, p=.03), N Change of body image (r=.36, p=.001), Q 
Fatigability (r=.27, p=.01) and U Loss of Libido (r=.25, p=.02). There was no correlation 
between ESS and items of BDI and SDS in the sample of 15 IH patients. 
 
Table 17. Correlation between Epworth sleepiness scale and Beck Depression Inventory 
items in narcoleptic, idiopathic hypersomnia patients and controls. 
Beck Depression 
Inventory (BDI) items 
Narcoleptic  
patients  n=86 
Healthy controls 
n=86 
Idiopathic hypersomnia 
patients n=15 
rho 
Sadness .15 .12 -.05 
Hopelessness .21  .23* -.27 
Sense of failure .07 .01 -.15 
Dissatisfaction .09 .06 .41 
Guilt -.06 .08 .09 
Punishment .05 .02 .08 
Dislike of self .07  .23* -.03 
Self accusation -.09 .17 .37 
Suicidal ideation .15 0 -.05 
Crying spells .04 .08 .10 
Irritability .03 .11 .13 
Social withdrawal .26* .20 .36 
Indecisiveness .03 -.04 .42 
Body image .14  .36** .44 
Push to work  .25* .11 -.17 
Insomnia .21 .12 .26 
Fatigability .25 .27* .03 
Loss of appetite -.01 .05 .21 
Loss of weight .01 -.03 .36 
Healthy worries .00 .08 .07 
Loss of libido .11 .25* .40 
rho, Spearman´s rank correlation coefficient; *p value<.05; **p value<.01. After Bonferroni 
correction p value is considered significant when <.0024, (alpha divided by the number of tests 
(k= 21). 
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In narcoleptic patients, the items of SDS correlating with ESS scores were: I feel down and 
blue (r=.22, p=.04), I get tired for no reason (r=.33, p=.002), my mind is as clear as it used 
to be (r=.26, p=.01) and I find it easy to do the things I used to (r=.29, p=.008). In controls, 
no items of SDS correlate with ESS scores.  
 
Table 18. Correlation between Epworth sleepiness scale and Zung Self rating Depression 
scale items in narcoleptic patients, controls and idiopathic hypersomnia patients. 
Items of SDS Narcoleptics 
patients 
n=86 
Healthy 
controls 
n=86 
Idiopathic 
hypersomnia patients 
n=15 
r 
Depressed affect .22* .01 .13 
Diurnal variation .04 -.08 .03 
Crying spells .05 .18 .11 
Sleep disturbance .21 .00 -.03 
Decreased appetite .03 .01 .51 
Decreased libido .17 .16 .25 
Weight loss -.02 .07 .46 
Constipation -.01 .18 .19 
Tachycardia .03 -.01 .32 
Fatigue .33* -.01 .36 
Confusion .26* .14 .38 
Psychomotor retardation .29** .07 .12 
Psychomotor agitation .17 .07 .45 
Hopelessness .03 .12 .03 
Irritability .15 .08 .29 
Indecisiveness -.00 .06 -.20 
Personal devaluation .10 .19 -.07 
Emptiness .01 -.08 -.32 
Suicidal rumination .19 0 .13 
Dissatisfaction .15 -.04 .42 
SDS, Zung Self-rating Depression Scale; r, sample correlation coefficient of Pearson. After 
Bonferroni correction p value is considered significant when <.0025, (alpha divided by the 
number of test k= 20) 
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CORRELATION OF ESS AND DEPRESSION SUBSCALE OF POMS 
As predicted, the subscale fatigue correlates with ESS. Similarly as in BDI and SDS, 
there was no correlation between ESS and POMS (total and subscales) in the sample 
of 15 IH patients. 
 
Table 19. Correlation between Epworth sleepiness scale and Profile of mood states in 
arcoleptics, idiopathic hypersomnia patients and healthy controls. n
 
POMS Narcolepsy  
patients 
 n=86 
Healthy 
controls 
n=86 
Idiopathic  
hypersomnia 
patients 
n=15 
r 
TMD  .24* .22* .34 
Tension- anxiety .14 .22* .40 
Depression- dejection .24* .27* .34 
Anger-hostility .20 .15 .18 
Vigor-activity -.17 -.16 -.22 
Fatigue-inertia, .28* .16 .15 
Confusion-bewilderment  .17 .09 .31 
POMS, Profile of Mood States; TMD; Total mood disturbance (calculated 
as total of subscales excluding Vigor); r, sample correlation coefficient of 
Pearson; *p<.05 
  
EFFECT SIZE  
The effect size is a measure of the power of the relationship between two variables in a 
statistical population. In consequence, the effect size is a complement of inferential 
statistics such as p-values. According to Cohen "effect sizes of .20 are small, .50 are 
medium, and .80 are large enables us to compare an experiment’s effect-size results to 
known benchmarks” (Thalheimer, W. & Cook, S., 2002) (Table 20). 
Depressive symptoms in narcolepsy and idiopathic hypersomnia-90 
 
Table 20. Effect size of the independent groups 
Test Narcoleptics and controls NC+ and NC- 
Cohen´s d Effect-size r Cohen´s d Effect-size r 
BDI 1.07 0.47 0.53 0.25 
SDS 1.39 0.57 0.35 0.17 
GSD 0.88 0.40 0 0 
POMS 1.18 0.51 0.39 0.19 
Anxiety 1.01 0.45 0.49 0.24 
Depression 0.83 0.38 0.46 0.22 
Anger 0.71 0.34 0.13 0.064 
Vigor -0.72 -0.34 -0.32 -0.16 
Fatigue 1.37 0.56 0.17 0.08 
Confusion 1.09 0.48 0.40 0.19 
Anxiety 1.01 0.45 0.49 0.24 
ESS 3.2 0.84 -0.053 -0.026 
BDI, Beck Depression Inventory (21 item version); SDS, Zung Self-Rating 
Depression Scale; SDS-sleep items, GSD, Global impression of Severity of 
Depression; POMS, Profile of Mood States; TMD, Total Mood Disturbance; ESS, 
Epworth Sleepiness Scale; Cohen´s d is defined as the difference between two 
means divided by a standard deviation for the data.  
3.3.3. Variables influencing depression- Multivariate analysis 
CONSTRUCTION OF THE MODEL 
The final model was constructed including each independent variable using the 
backward method. The variables excluded from the final model in BDI, SDS, GSD and 
depression subscale of POMS scores were: Epworth sleepiness scale scores, age at 
onset of sleepiness, illness duration, age at the time of the study, age at diagnosis of 
narcolepsy (in a sleep laboratory), body mass index, symptom of cataplexy, 
participation in the narcolepsy support group and intake of stimulants only. 
Multiple linear regression analysis showed that for BDI and SDS, the same set of 
variables contributed significantly to the final model, which explained 20 to 27% (BDI, 
SDS, GSD and Depression subscale of POMS) of the variance in patients with 
narcolepsy (Table 21). These variables were for BDI, SDS and depression subscale of 
POMS, a combination of drugs (anticataplectic and stimulants) and female sex.  
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In controls, none of the possible predictor variables (age, sex, sleepiness, BMI) were 
associated with depressive symptoms in BDI, SDS or GDS. Only in depression 
subscale of POMS, the variables age and sleepiness (ESS-score) together explained 
13% of the variance (R² =.13, Age: Beta [B] =0.30 p=.005, 95% CI [-0.04,-0.01]; 
Sleepiness [B] =0.24 p=.02, 95% CI [0.02, 0.19]).  
When probed by ANOVA, neither cataplexy nor the interaction of “type of drug” and 
cataplexy had an influence on depressive symptoms. Rather, “type of drug” alone had 
an influence on such symptoms. Post hoc-analysis (Games-Howell) showed that 
narcolepsy patients using stimulants and antidepressants (combination) presented 
more depressive symptoms than those using only stimulants, only anticataplectics or 
unmedicated patients.  
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Table 21. Multiple linear regression models for depressive symptoms in patients with 
narcolepsy 
Independent  
Variables   
Dependent variables 
BDI  SDS 
 
GSD  Depression 
subscale of 
POMS 
B [95%CI] 
Constant 5.536*** 
[3.88, 7.51] 
34.117*** 
[31.36, 36.97] 
0.824*** 
[0.39, 1.44 ] 
4.322***  
[2.34, 6.92] 
Combination A+S 1.476*** 
[0.46, 3.06] 
0.357*** 
[0.07, 0.85] 
- 2.730** 
[0.81, 5.81] 
Only A  - - -2.500** 
[3.88, 0.27] 
- 
Any A at all - - 0.706*** 
[0.17, 1.59] 
- 
Sex (Female) 0.403** 
[0.02, 1.25] 
0.516** 
[0.02, 0.52] 
0.362** 
[0.06, 0.92] 
0.690* 
[0.02, 2.31] 
r²  .241 .201 .270 .222 
F 13.15*** 10.42*** 9.84*** 11.81*** 
Analyses were performed with square root transformed variables, but in the table original 
value are given for better comprehension. Table data correspond to the final model of each 
independent variable, using the backward method; the variables excluded from the final 
model in BDI, SDS, GSD and depression subscale of POMS scores were: Epworth 
sleepiness scale scores, age at onset of sleepiness, illness duration, age at the time of the 
study, age at diagnosis of narcolepsy (in a sleep laboratory), body mass index, symptom of 
cataplexy, participation in the narcolepsy support group and intake of stimulants only; A, 
antidepressants; S, stimulants; r², coefficient of determination unadjusted; BDI, Beck 
Depression Inventory; SDS, Zung Self-Rating Depression; Scale; GSD, Global impression 
of Severity of Depression; Depression subscale of POMS, Profile of Mood Disturbance; B, 
unstandardized Coefficient Beta; CI, confidence interval; * p<.05, ** p<.01, *** p<.001. 
 
LOGISTIC REGRESSION 
The results obtained from the regression analysis were further tested by binary logistic 
regression. Again, the patients using antidepressants and stimulants (combination) and 
females had a higher probability for depressive symptoms independent of cataplexy, 
BMI and age group (Table 22). 
Because of the fundamental effect of antidepressants and stimulants, a logistic 
regression without the patients taking that combination of drugs (n=63) was carried out. 
Also in this analysis, cataplexy does not have an effect on depressive symptoms, 
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(Odds ratio [OR] = 2.05, Standard Error [SE] =1.56, Z=0.94, p=.345, 95%CI [0.46, 9.14] 
but sex plays a significant role (OR=7.72, SE=6.39, Z=2.47, p=.014, 95%CI [1.52, 
39.10]. 
 
Table 22. Logistic regression for patients with narcolepsy with the dependent variables 
BDI and SDS. 
BDI and SDS 
n=86 
Odds Ratio SE Z p value 95% CI 
[LL, UL] 
Sex  8.39 5.78 3.09 .002** [2.17,32.38] 
Age group 0.91 0.17 -0.51 .612 [0.63, 1.31] 
Cataplexy 0.91 0.58 -0.15 .881 [0.26,3.18]  
BMI 1.68 1.14 0.77 .443 [0.44, 6.37] 
Combination 
A+S 
16.2 11.6 3.90 .000*** [4.01,66.12] 
BDI, Beck Depression Inventory, SDS, Zung Self-Rating Depression Scale; 
dichotomized in yes (BDI > 9, SDS > 39) or no; for age group division see 
Methods; BMI, Body Mass Index (kg/m²) BMI classification of adults according 
to WHO see Methods ; A, antidepressants; S, stimulants; SE, standard error; 
LL, lower limits; UL, upper limits; CI, confidence interval;**p<.01***p<.001. 
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4. EMPIRICAL PART II: “NARCOLEPTICS WITH DEPRESSIVE SYMPTOMS COMPARED WITH 
PATIENTS WITH DEPRESSION”. 
4.1. Introduction 
At the beginning of the last century, the etiology of the symptoms of narcolepsy was often 
misunderstood as psychiatric symptoms, probably because it could be not explained as a 
physical disease. For example, in 1924, an Austrian physician, in the heyday of 
psychoanalysis, described a case of a young narcoleptic man who recovered after a 
psychoanalytic treatment (Missriegler, 1941). 
Currently, the etiology of narcolepsy is associated with a deficiency of Hcrt in the lateral 
hypothalamus (Nishino et al., 2000). Hcrt is associated with stress, appetite (Ganjavi et al., 
2007; Taheri & Hafizi, 2002), psychiatric disorders (Borgland et al., 2010) and is involved 
as an antidepressant effect in a model of depression in mice (Lutter et al., 2008). This 
finding has again opened the debate and increased the interest in mood disorders in 
narcolepsy. Recently, a study from the Netherlands reported that anxiety and social 
phobias are more prevalent than depression in patients with narcolepsy (Fortuyn et al., 
2010). This conclusion is not supported by another study showing that patients with panic 
anxiety had a higher CSF Hcrt concentration than patients without panic anxiety (Johnson 
et al., 2010). 
Narcolepsy has been associated with depression for several reasons. One of them is the 
REM similarities at sleep onset. Another reason is that narcolepsy is a chronic illness that 
has a negative impact on the patients’ quality of life.  
Many authors have described the presence of depressive symptoms to different degrees 
in patients with narcolepsy (Dauvilliers et al., 2009; Rovere et al., 2008; Vandeputte et al., 
2003; Daniels et al., 2001; Broughton et al., 1994; Merrit et al., 1992; Kales et al., 1982; 
Broughton et al., 1981; Beutler et al., 1981; Roth, 1980; Roth et al., 1975). Some authors 
have argued that this is an overrepresentation caused by similar symptoms between 
narcolepsy and depression (Vourdas et al., 2002; Adda et al., 1997). The misdiagnosis of 
depression is reinforced because some symptoms in narcoleptics and in patients with 
depression can be identical. Among these symptoms especially are the reduced energy 
leading to increased fatigability and diminished activity, reduced concentration and 
attention due to the excessive daytime sleepiness, increased weight and fragmented night 
sleep (American Psychiatric Association, 2000; American Sleep Disorders Association, 
1991). 
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In the first study of this dissertation, the results confirmed that several but not all patients 
with narcolepsy with and without cataplexy have depressive symptoms independent of the 
presence of cataplexy. Therefore, in this second part, the group of narcoleptics (with and 
without cataplexy) was not divided into these two categories. 
Several studies have compared narcoleptic patients to patients with diseases such as 
obstructive sleep apnea, epilepsy and IH (Broughton et al., 1994). Only two studies have 
compared narcolepsy patients to patients with a diagnosed depression disorder. All of 
these studies are focused on the polysomnography (Pollmaecher et al., 1997; Reynolds, III 
et al., 1983). It is not yet clear if patients with narcolepsy and high scores in questionnaires 
of depression exhibit similarities to patients diagnosed with depression. Furthermore, is not 
well known if the somatic symptoms of depression are inflating the rate of depressive 
symptoms reported in the literature as in other chronic diseases.  
The severity of depressive symptoms in patients with narcolepsy is most frequently 
reported in the range of mild to moderate depression (Dauvilliers et al., 2009; Vandeputte 
et al., 2003). The severity of the symptoms was taken into account. In consequence, this 
study was conducted on patients with mild to moderate depression with the purpose of 
having an equal severity of depressive symptoms. This allowed the analysis of the items 
because BDI item means vary widely and increase at different rates relative to the total 
score (Beck et al., 1988). For example, less “pathological” items reflecting high base rate 
problems (e.g., low self-esteem) approach a maximum level more rapidly than the 
suicidality item, which may not be endorsed unless depression is marked (Aikens et al., 
1999). Furthermore, in medically ill patients, several authors using identical self-rating 
scales have made the distinction between physical symptoms (somatic/vegetative) and 
non-physical symptoms (cognitive/affective). The goal of this second study was to examine 
if there are differences in the self reported depressive symptoms of patients with 
narcolepsy from those with a primary depressive episode. 
4.2. Methods 
4.2.1. Procedure and questionnaires 
The intensity of depression in patients with narcolepsy and depression was controlled. The 
procedure used was to include only patients with mild to moderate depression, defined by 
a score in the BDI between 10 and 40 points. According to this questionnaire, 10 points 
are the minimum score to describe a subject on the border of depression (Hautzinger, 
1991; Beck, 1967; Beck et al., 1961). 
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In BDI, more than 40 points correspond to severe depression. On the one hand, the cut-off 
score of at least 10 points was selected because previous studies show reasonable 
specificity and sensitivity for predicting a depressive episode. On the other hand, 
depressive symptoms in narcoleptics are often presented as moderate. 
The upper limit of 40 points was chosen to reduce the variance in the data. The limit 
seems appropriate, because none of the narcoleptic patients scored more than 40 points 
in BDI. The items of BDI and SDS have been described above (see section 3.2.1.Table 11 
and 12). For the group of narcoleptic patients, data obtained in study 1 were used (see 
section 3.2.2). The depressive patients selected were those with 10 or more points but 
less than 41 points in Beck Depression Inventory. For the group of depressive patients, 
self-administered questionnaires were given to the patients during their regular medical 
visits. These were three validated questionnaires: the German versions of Beck 
Depression Inventory (BDI), Zung Self-rating Depression Scale (SDS), Global Impression 
of Severity of Depression (GSD), Profile of Mood States (POMS) and Epworth Sleepiness 
Scale (ESS). In SDS, the division between somatic and affective dimensions was not 
performed because is not well validated as in BDI (see results 4.3.5) 
A general questionnaire regarding demographic data and questions about symptoms, 
diagnosis, and pharmacological treatment was given to participants together with the 
testing and informed consent.  
4.2.2. Participants 
Thirty-six narcoleptics (10 men, 26 women) with a Beck Depression Inventory (BDI) score 
≥10 points and <41 points were selected from the sample of 86 narcoleptic patients in the 
first study (section 3). In patients with narcolepsy, the mean age at the onset of excessive 
daytime sleepiness (EDS) was 20.5±11.1. All were diagnosed in a Sleep Disorders Center 
according to ICSD-2 criteria (American Academy of Sleep Medicine, 2005). Twenty-nine 
were NC+ and seven were NC-. The age was between 20 and 76 years (mean 
44.7±SD15.5). The mean of body mass index in patients with narcolepsy, according to the 
world health organization (WHO), was in the overweight range (mean 29.6±7.3) and 
41.7% of them had a BMI>30. 
Thirty-four outpatients with depression (12 men, 22 women) were recruited from the 
Bezirksklinikum (Dr. Lübbers, Dipl. Psych. Hauser) and from the private practices of 
psychiatrists in Regensburg (Drs. Eckl, Zacher and Kühnl). Because patients with 
narcolepsy are out-patients, only out-patients with a depressive episode as described 
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above were included. The group of patients with depression was diagnosed with mild or 
moderate depression (Table 23) [F32.0 and F32.1 codes ICD-10].  
The age of the patients was between 19 and 74 years (mean 42.8±SD 14.6). The mean of 
body mass index in patients with depression was in the overweight range (mean 25.3±SD 
4.9), 23.5% of them had a BMI>30. 
 
Table 23. Description of the levels of depression with emphasis on mild to moderate 
depression according to ICD-10 
Classification Description  
Mild depression Episode The individual is normally distressed due to the 
symptoms and difficulties of continuous working 
and social activities but will not discontinue 
functioning entirely (can be with or without a 
somatic syndrome). 
Moderate depression Episode The individual has considerable difficulties 
working, with social activities or activities at 
home.  
 
The control group (11 men, 25 women) was recruited from volunteers among the 
employees of the Bezirkskrankenhaus (psychiatric regional hospital) of Regensburg, 
students of the University of Regensburg and visitors of a senior citizen centre. None of 
the patients or control subjects were paid to participate. The age was between 19 and 78 
years old (mean 44.7±SD 15.8). 
The mean of body mass index in the control group was in the normal range (mean 
23.4±SD 4.5) and only 2.8% of the controls had a BMI>30. Each narcoleptic patient was 
matched to a depressive patient by age (± 3 years), sex and mean score of Beck's 
depression inventory. They were also age (± 3 years) and sex matched with a healthy 
control subject. Exclusion criteria for the controls were the same as for the first study (see 
section 3.2.1). The age range of the whole sample was 19 to 78 years. Age and sex were 
chosen as matching variables because these are known predictors of depressive 
symptoms (Slone et al., 2006). There were no significant differences in the matching 
variables between groups. BMI was significantly different between narcoleptic patients 
(with depressives symptoms) (p=.008) and controls (p<.001). In BMI, there were no 
significant differences between controls and patients with depression (p=.09). 
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4.2.3. Statistical analysis 
The significance level was set to .05 for all analyses (two tailed). To address the problem 
of multiple comparisons, the Bonferroni correction was used when indicated.  
All data were checked for a normal distribution using the nonparametric Kolmogorov-
Smirnov test. Non parametric-tests were employed to assess differences between the 
depressive group and the narcolepsy group (Mann-Whitney test) and for comparison with 
the age matched healthy control group (Kruskal-Wallis test for 3 or more independent 
samples). ANOVA was carried out to explore if depression (BDI, SDS, GSD, POMS) is 
different between women and men (effect of the first factor) and at the same time whether 
different age groups had different scores in depression. This analysis was done on the 
three groups (narcoleptics, depressives and healthy control group). A two-way ANOVA 
was performed to analyze if the dimensions affective/cognitive and somatic in BDI were 
different between groups of patients and if sex or age groups had an effect of interaction 
on these scores. For categorical variables, the Pearson´s chi-square test was employed 
followed by Fisher’s exact test. After comparing the differences in items mean scores, an 
item by item analysis was performed using custom tables. The focus was in the hypothesis 
that the structure of the depressive symptoms in patients with narcolepsy is different than 
in patients with depression. Because multiple tests were performed, the Bonferroni 
adjustment was applied to column proportion tests to ensure that the alpha level (or false 
positive rate) specified on the test statistics tab applies to each set of tests. A post-hoc 
comparison test not assuming equal variances (Games-Howell) was performed when 
needed. Data analyses were processed using the Statistic Package for Social Sciences 
16.0 (SPSS Inc. Chicago, Illinois). 
4.3. Results 
4.3.1. Medication use 
In the narcoleptic group, the anticataplectic drugs were tricyclic antidepressants (TCA, 
seven patients), selective serotonin reuptake inhibitors (SSRI, five patients), serotonin-
norepinephrine reuptake inhibitors (SNRI, one patient), norepinephrine reuptake inhibitors 
(NRI, two patients) and sodium oxybate (three patients). Five patients were taking a 
combination of two anticataplectic drugs (monoamine oxidase inhibitors (MAOI) and SSRI 
(one patient), SNRI plus SSRI (one patient), TCA plus SSRI (one patient) and sodium 
oxybate plus NRI or TCA (one patient). The stimulant drugs used were modafinil (20 
patients), methylphenidate (four patients), and fenethylline (one patient).  
 Narcoleptics with depressive symptoms compared with patients with depression-99 
 
 
In the depression group, the antidepressants were SSRI 11 patients, TCA six patients, 
SNRI six patients and tetracyclic antidepressants (TeCA) two patients. Nine patients were 
not taking antidepressant medication (Figure 8). These patients had been just diagnosed 
t the time of the study. None of the healthy controls were taking antidepressant. a
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Figure 8. Patients with narcolepsy (n=36) and depression (n=34) on or not on medication; 
A, antidepressants; S, stimulants. 
 
4.3.2. Comparison of mean scores and grading distribution of depressive 
symptoms in questionnaires 
MEAN SCORES IN DEPRESSION QUESTIONNAIRES 
As intended, the intensity of depressive symptoms in patients with narcolepsy was similar 
to patients with depression. The mean scores in measures of depression (BDI, SDS and 
GSD scores) for the narcoleptic group were not different from the mean scores for the 
same measures for the depression group. A Mann-Whitney U test did not reject the 
hypothesis of equals mean scores at a 5% significant level (p>.05). Similarly, POMS (total 
of mood disturbances [TMD] and sub scales) showed no significant differences between 
the two groups of patients (p> .05). For all scales (BDI, SDS, GSD, POMS [TMD and 
subscales]) the differences between both patient groups and the healthy controls were 
significant (p> .001). The daytime sleepiness measured by the ESS (mean score) in the 
narcoleptic group (mean=17.6) was higher than in the depressive group (mean=8.2). A 
Mann-Whitney U test demonstrated that this difference was significant (p<.001). The 
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healthy controls had a lower mean ESS score (mean=5.0) than both patients groups 
(p<.001, Table 24) 
 
Table 24. Clinical data, depressive symptoms, Mood (POMS) and sleepiness (ESS) of 
narcoleptic patients, patients with primary depression and healthy controls. 
 narcoleptic 
patients with 
depression¹ 
M ±SD 
(n=36) 
patients with 
depression² 
M±SD 
(n=34) 
 
p value  
¹vs² 
(two- 
tailed) 
Healthy 
control 
group³ 
M ±SD 
 (n=36) 
p 
value 
² vs³ 
 
p 
value  
 ¹vs³ 
 
BMI 
%BMI>30 
29.6±7.3 
41.7 
25.3±4.9 
23.5 
.008 
.020 
23.4±4.5 
2.8 
.09 
<.001 
<.001 
<.001 
ESS  
%ESS>10<16 
%ESS>16 
17.6±3.3 
97.2 
61.1 
8.2±3.6 
32.4 
0 
.001 
.03 
<.001 
5.0±3.2 
11.1 
0 
<.001 
<.001 
0 
<.001 
<.001 
<.001 
BDI 
BDI-sleep items 
18.6±7.3 
15.8±6.6 
19.6±5.9 
16.47±5.6 
.49 
.41 
3.9±4.5 
3.2±3.9 
<.001 
<.001 
<.001 
<.001 
SDS 
SDS-sleep items 
47.5±8.0 
41.9±7.5 
46.8±9.0 
42.3±8.6 
.99 
.63 
28.7±7.3 
26.1±6.9 
<.001 
<.001 
<.001 
<.001 
GSD  4.9±2.4 5.1±2.1 .94 1.2±1.8 <.001 <.001 
POMS (TMD) 61±35.8 67.8±36.2 .27 4.8±22.9 <.001 <.001 
Anxiety 15.2±6.1 16.9±7.1 .15 5.3±1.3 <.001 <.001 
Depression 21.8±12.4 24.4±13.1 .31 5.4±6.8 <.001 <.001 
Anger 13.2±7.5 14.3±8.4 .66 5.3±4.5 <.001 <.001 
Vigor 13.1±6.7 12.2±5.9 .43 19.7±7.4 <.001 <.001 
Fatigue 14.7±6.0 15.2±6.8 .63 4.5±5.2 <.001 <.001 
Confusion 11.4±5.2 10.7±4.9 .54 4.1±3.2 <.001 <.001 
M, arithmetic mean; SD, standard deviation; vs., versus; BDI, Beck Depression Inventory 
(21 item version); BDI-sleep items, BDI scores excluding 2 sleep items (see Methods); 
SDS, Zung Self-Rating Depression Scale; SDS-sleep items, SDS scores excluding 2 sleep 
items (see Methods); GSD, Global impression of Severity of Depression; POMS, Profile of 
Mood States; TMD, Total Mood Disturbance; ESS, Epworth Sleepiness Scale; BMI, Body 
Mass Index( kg/m²), significance level (two tailed)= .01 after Bonferroni correction (k=5, 
adjusted for comparison of BDI, SDS, GSD, POMS (total) and ESS ). The Mann-Whitney or 
Kruskal Wallis tests statistics were performed to compare the groups depending of two or 
three groups.  
 
In the questionnaires, BDI and SDS two items are directly associated with sleepiness. 
These items are: „I can sleep as well as before” and “I do not get more tired than usual” 
and in SDS are “I have trouble sleeping at night” and “I get tired for no reason”.  
 Narcoleptics with depressive symptoms compared with patients with depression-101 
 
 
When these two items were excluded respectively from BDI and SDS, the total scores 
were still higher in the patients with narcolepsy than in controls and patients with 
depression (Table 24). 
GRADING DISTRIBUTION OF DEPRESSIVE SYMPTOMS 
When the clinical grading of the BDI and the SDS scores was applied, the distribution over 
the resulting groups was not different between narcoleptic and depressive patients (BDI: 
Pearson´s chi-square=4.86 p>.05, Fisher’s exact test=4.84 p>.05, SDS: Pearson Chi-
square = p>.05, Fisher’s exact test= p>.05, Figure 9 and 10). 
A significant difference in the grading of BDI and SDS was found between narcoleptics 
and healthy controls. The same result was obtained when comparing depressives and 
controls (p<.05). ANOVA shows that in BDI, SDS and ESS, the difference between groups 
was significant (p<.001). Post-hoc comparisons were performed using the method of 
Games-Howell. When both groups were compared in the grading of ESS (%ESS score 
>10<16 and %ESS>16), depressive patients and controls were found to be significantly 
lower than narcoleptics (p<.001), but no differences between depression group and 
controls were found. Seven narcoleptics and six depressive patients showed severe 
depression in the SDS. In BDI, three narcoleptics and two depressive patients were in the 
„moderate to severe depression” category. None of the patients were in the “severe 
depression” group, and none of the controls had more than mild depression on either of 
the scales.  
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Figure 9. Graded distribution of depressive symptoms in patients with narcolepsy, 
depression and in controls according to Beck Depression Inventory. Patients with 
narcolepsy and primary depressive patients showed no differences. Both patient groups 
are different to healthy controls. 
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Figure 10. Graded distribution of depressive symptoms in patients with narcolepsy, 
depression and in controls according to Zung self-rating Depression scale. Patients with 
narcolepsy and primary depressive patients showed no differences. Both patient groups 
are different to healthy controls. 
4.3.3.  Correlations between different measures of depression 
The narcoleptic, depressive patients and the control group showed a positive correlation 
among all scales of depression used in this study (Table 25). 
 
Table 25. Pearson's correlations between tests assessing symptoms of depression in 
patients with narcolepsy, primary depression and controls. 
Measure Patients with narcolepsy  
n=36 
Patients with depression 
n=34 
Healthy controls 
n=36 
r 
SDS vs. BDI .73** .71** .75** 
SDS vs. GSD .51** .69** .73** 
BDI vs. GSD .41* .69** .56** 
r= Pearson correlation, two sided p value *p<.05, **p<.01. SDS: Zung Self-rating Depression 
Scale, BDI: Beck Depression Inventory, GSD: Global impression of Severity of Depression. 
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No correlation was found between the ESS and the total scores in the depression scales 
(BDI, SDS; GSD) within the groups (Table 26). However, several items correlate with ESS 
points obtained by narcoleptics, patients with primary depression and controls. 
Concerning the correlation between ESS and items of BDI and SDS in the sub-sample of 
36 narcoleptic patients with depressive symptoms, in BDI, there were no items correlating 
with ESS scores in this group. In SDS, the items correlating with ESS scores were: “I get 
tired for no reason” (item 10) and “my mind is as clear as it used to be” (item 11). Both 
items had the same degree of correlation (r=.36, p=.03). 
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Table 26. Spearman correlations between ESS scores and items of BDI in narcoleptics, 
depressive patients, and healthy controls.  
Items BDI Epworth sleepiness scale (total scores) 
Narcoleptic 
patients n=36 
Depression 
 patients n=34 
Controls 
n=36 
rho 
Sadness .31 .38 .18 
Pessimism .14 .29 .34 
Sense of failure -.00 .10 -.13 
Dissatisfaction .06 .16 .16 
Guilt -.17 .19 .09 
Expectation of Punishment -.19 -.22 -.29 
Dislike of self .02 .00 .24 
Self accusation -.10 .09 .21 
Suicidal ideation .11 -.05 0 
Crying spells -.14 .07 .24 
Irritability -.07 .06 .06 
Social withdrawal .20 .28 .28 
Indecisiveness -.20 .01 -.02 
Change of body image .13 -.23 .32 
Push to work  .31 .29 .12 
Insomnia .21 -.13 -.01 
Fatigability .18 .30 .18 
Loss of appetite -.06 .25 .17 
Loss of weight -.07 .13 0 
Health worries -.10 .10 .17 
Loss of libido .03 -.38 .14 
ESS, Epworth Sleepiness Scale; BDI, Beck Depression Inventory; rho, Spearman´s rank 
correlation coefficient. Note: after Bonferroni correction, p value is considered significant when 
<.0024, (alpha divided by the number of test (k= 20). 
 
Concerning the correlation between ESS and items of BDI and SDS in the sample of 34 
patients with primary depression, in BDI, the items correlating with ESS scores were: item 
A “sadness” (r=.38, p=.03) and negative correlation with item U “loss of libido” (r=-.38, 
p=.03). In SDS no items correlated with ESS scores in this group. 
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Concerning the correlation between ESS and items of BDI and SDS in the sample of 36 
matched controls, in BDI only the item B “pessimism” correlated with ESS scores (r=.34, 
p=.04). In SDS, there were no items correlating with ESS scores in this group. 
Finally, a correlation shows that the items “sadness” and “loss of libido” of BDI correlate 
with sleepiness (ESS) (Table 27). 
 
Table 27. Spearman correlations between ESS scores and items of SDS in narcoleptics 
with depressive symptoms, in depressive patients, and in healthy control group. 
Items SDS ESS (total scores) 
Narcoleptic 
patients n=36 
Depression  
patients n=34 
Healthy controls 
rho 
Depressed affect .28 .21 .15 
Diurnal variation .09 .33 .11 
Crying spells -.03 -.11 .21 
Sleep disturbance .21 -.23 -.18 
Decreased appetite .04 -.09 -.16 
Decreased libido .06 -.16 -.05 
Weight loss -.06 .15 .20 
Constipation -.09 .05 .19 
Tachycardia -.18 .16 .08 
Fatigue .36 .32 .08 
Confusion .36 -.01 .25 
Psychomotor retardation .18 .24 -.00 
Psychomotor agitation .18 -.06 .10 
Hopelessness .07 .16 .31 
Irritability .30 .09 .04 
Indecisiveness -.08 .18 .04 
Personal devaluation .18 .14 .25 
Emptiness -.01 -.06 -.14 
Suicidal rumination .10 .09 0 
Dissatisfaction .21 .10 -.02 
ESS, Epworth Sleepiness Scale; SDS, Zung Self-rating Depression Scale;  rho, Spearman´s 
rank correlation coefficient.After Bonferroni correction, p value is considered significant when 
<.0024, (alpha divided by the number of test (k= 21). 
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Table 28. Spearman correlation between ESS (total scores) and POMS (total and sub 
scales) in narcoleptics, depressive patients, and healthy controls.  
POMS ESS (total scores) 
Narcoleptic 
patients 
n=36 
Depressive 
patients 
n=34 
Healthy 
controls 
n=36 
rho 
TMD .25 .21 .30 
Tension- anxiety .32 .24 .26 
Depression- dejection .32 .20 .20 
Anger-hostility .20 .13 .06 
Vigor-activity -.20 -.30 -.31  
Fatigue-inertia, .27 .24 .18 
Confusion-bewilderment .15 .23 .08 
ESS, Epworth Sleepiness Scale; POMS, Profile of Mood States; TMD; 
Total mood disturbance (calculated as total of subscales excluding 
Vigor); rho, Spearman´s rank correlation coefficient. Note: after 
Bonferroni correction, p value is considered significant when <.01 (alpha 
divided by the number of subscales of POMS (k= 5) 
 
4.3.4. Age and sex differences 
When age (as continous variable) was considered in controls (partial correlation), Vigor 
[sub scale POMS] was the unique factor that correlated with ESS scores (r=-.37, p=.03). 
When age was controlled in patients with narcolepsy (partial correlation), Depression and 
Fatigue [sub scales POMS] correlated with ESS (respectively r=.41, p=.01, r=.35, p=.04). 
When age was controlled in patients with depression, it was found for a second time that 
no factor correlated with ESS.  
Women with narcolepsy had higher scores than men with narcolepsy in BDI scores 
excluding items of sleep and in Tension [sub scale POMS]. This difference was significant 
using a Mann-Whitney U test (respectively U=67, p=.03; U=61, p=.01 (two-tailed)). 
Comparing the depression group and controls, no differences were found in any of the 
measures with respect to sex.  
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4.3.5.  Somatic and affective items: differences between groups 
In narcoleptics and depressive patients the scores in cognitive and somatic dimensions 
had a normal distribution using the Kolmogorov-Smirnov test (Cognitive dimension p=.271, 
Somatic dimension p=.122).  
 
 
  
Figure 11. Characteristics of the cognitive dimension of depressive symptoms 
according to the Beck Depression Inventory in narcoleptic [N] (n=36) and 
depressive patients [D] (n=34). The highest score in a single item is three, and
the lowest score is zero.  
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Figure 12. Characteristics of somatic dimension of depressive symptoms
according to the Beck Depression Inventory in narcoleptic [N] (n=36) and
depressive patients [D] (n=34). The highest score in a single item is three, and
the lowest score is zero. 
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Figure 13. Characteristics of depressive symptoms according to the Zung Self-
rating Depression Scale (SDS) in narcoleptic [N] (n=36) and depressive patients 
[D] (n=34). The highest score in a single item is four (i.e. mostly or always), and 
the lowest score is one (i.e. seldom or never).  
 
 
 
Regarding to the differences in the dimensions, both patients groups had higher scores in 
somatic and affective items (Figure 11 and 12) compared to controls (respectively mean 
ranks narcoleptics=68, depressives=72 and controls=22, Kruskal-Wallis [KW] test x² (df 2) 
=59; p<.001; narcoleptics=69.1, depressives=71 and controls=21.4. KW test x² (df 2) =60; 
p<.001).  
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Figure 14. Mean of z scores of narcolepsy and patients group in cognitive and 
somatic dimension of Beck Depression Inventory. The raw scores were 
standarized in z scores. Z scores represents the distance between the raw score 
and the population mean in units of the standard deviation.   The mean of z score is 
negative when the raw score is below the mean and is positive when above. 
 
When the dimensions were tested with a mixed-design ANOVA, the main effect of the 
groups (depressive and narcoleptics) was significant. The depressive group showed 
higher scores in both dimensions (F(1,50)=4.07, MSE=5.85, p<.05, partial-eta-
squared=.075). The variables sex or age group were not significant (respectively F(1,50)= 
.003 , n.s.; F(1,50)=1.33, MSE=1.91, n.s). Moreover, the interactions of these three factors 
(illness group, sex and age group) were not significant (respectively F(1,50)=.29 MSE=.43, 
.s; F(4,50)=.99, MSE=1.43,n.s., F(4,50)=.45, MSE=.65, n.s., F(4,50)=.07, MSE=.10, n.s.). n
 
4.3.6. Differences in the structure of depressive symptoms between 
narcoleptic and depressive patients 
The mean scores of BDI items showed significant differences between narcoleptic and 
primary depressive patients in the item anhedonia and loss of appetite (Mann-Whitney U 
test z=-2.993, p=.003, z=-2.697, p=.007 respectively). The depressive group reported 
higher scores in both items (Figure 15). 
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Figure 15. Mean scores of Beck Depression Inventory items. ** p value<.001. 
 
The mean scores of SDS items showed significant differences between narcoleptic and 
primary depressive patients only in the item fatigue (Mann-Whitney U test z=-3.769, 
p=.0001). As expected narcoleptic patients reported higher scores in the item “I get tired 
for no reason” (Figure 13 and 15) 
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Figure 16. Mean scores of Zung Self-Rating Depression Scale items in 
arcoleptic and depressive patients. *** p value<.0001. n
 
A finer analysis of the answers showed that the results reaching statistical differences 
using the Bonferroni adjustments for multiple answers in BDI were items D, R and T (see 
methods). In item D, dissatisfaction/anhedonia, narcoleptic patients were more likely to 
continue to feel pleasure than before compared to patients with depression. 
For item R, loss of appetite, narcoleptic patients responded more often that their appetite 
was not worse than usual compared to patients with depression, and for the same 
question (second category also significant), patients with depression declared that in fact 
their appetite was not as good as it used to be. 
Finally, for the item T, health worries, narcoleptic patients answered more often that they 
were not worried about physical problems compared to patients with depression who 
mostly answered that they were, in fact, very worried about physical problems..  
The results reaching statistical differences using the Bonferroni method for multiple 
answers in SDS were Items 2 (Morning is when I feel the best), 5 (I eat as much as I used 
to), 6 (I still enjoy sex), and 7 (I notice that I am losing weight) . Patients with narcolepsy 
were less impaired in diurnal variation (2), appetite (5), loss of libido (6) and loss of weight 
(7) than patients with depression. 
Factor analysis of Beck Depression Inventory in patients with narcolepsy 
5. EMPIRICAL PART III: “FACTOR ANALYSIS OF BECK DEPRESSION INVENTORY IN 
PATIENTS WITH NARCOLEPSY”. 
5.1. Introduction 
Depressive symptoms in varying degrees are typically reported in narcoleptics using 
mostly the Beck Depression Inventory (Dauvilliers et al., 2009; Vandeputte et al., 2003; 
Morrish et al., 2001; Daniels et al., 2001; Adda et al., 1997; Pawluk, Hurwitz, Schluter, 
Ullevig & Mahowald, 1995), in addition to other assessment tools (Mosko et al., 1989; 
Beutler et al., 1981; Roy, 1976; Roth et al., 1975). In line with these findings, instruments 
evaluating quality of life have emphasized the presence of a high level of depressive 
symptoms (Ozaki et al., 2008; Dodel et al., 2007; Ervik et al., 2006; Vignatelli et al., 2004). 
Others using structured psychiatric interviews have reported that patients with narcolepsy 
do not meet the criteria for a lifetime depression in a greater degree compared to control 
subjects (Vourdas et al., 2002). These conflicting results suggest that depressive 
symptoms in narcolepsy patients are over represented due to somatic symptoms. 
Nonetheless, the first study of this dissertation shows that even when the questions 
directly related with sleep were excluded, narcoleptics exhibited more depressive 
symptoms than sex and age matched controls. Emmons et al (1987), who found that there 
was no difference in the total BDI scores between medically ill patients and psychiatric 
inpatients, did find significant differences in the cognitive/affective items. In patients 
seeking a surgery for weight loss, Munoz et al (2007) found that patients were more likely 
to display somatic items than cognitive items. This is relevant because of the overlapping 
physical symptoms of depression and obesity. This is similar to the situation of patients 
with narcolepsy, which is even more difficult because most of these patients are 
pathologically sleepy. Furthermore, most of them are obese. An analogous condition is in 
patients with an obstructive sleep apnea syndrome where depressive symptoms are 
widely reported (Kjelsberg, Ruud & Stavem, 2005; Schroder & O'Hara, 2005; 
Sharafkhaneh, Giray, Richardson, Young & Hirshkowitz, 2005; Bardwell, Berry, Ancoli-
Israel & Dimsdale, 1999). A study using BDI found that the association between sleep 
apnea severity and depressive symptoms is related with the subset of somatic items more 
than with cognitive items (Aloia et al., 2005). 
As shown in the first study, women with narcolepsy were more depressed than men. 
Further, women are traditionally believed to be more sensitive to weight than men. These 
beliefs have been probed in the study of Lim et al 2008, who reported that women are 
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more influenced by body size, and that depression scores in men are relatively 
independent of different measures of obesity. It would therefore not be surprising if body 
image played a role in the depressive symptoms of narcoleptics and especially in women. 
Regarding BDI, cut off scores are used to indicate the presence of depression. These cut 
off scores can vary when used in medical populations as a consequence of the overlap 
between symptoms of depression and physical symptoms. Therefore, some authors found 
an overestimation in the prevalence and severity of depression in medically ill patients 
compared with a clinical assessment of depression (Clark et al., 1983). 
Previous research in BDI has identified a two factor approach to depression: the 
cognitive/affective items and somatic items. BDI cognitive/affective represents the sum of 
the first 13 items of the BDI and BDI somatic items is formed by the sum of the scores of 
the last eight items (Beck & Steer, 1993).The purpose is to facilitate find out the primary 
cause of a patient´s depression.The first one describes depressive thoughts, feelings and 
beliefs and the second one reflects the health worries or physical discomfort (Beck et al., 
1961) Somatic items can be less useful in patients with chronic illness but can also help in 
the diagnosis (Cavanaugh, 1984). 
A factor analysis was conducted to explore the relationships among items in the BDI and 
to determine if these relationships can be summarized in a small number of latent 
constructs. The purpose of performing a factor analysis is to reduce the items of BDI to 
explain the results obtained by narcoleptics. The goal is to find the minimal factors that 
clarify most of the information given by narcoleptics in the 21-item version of BDI. 
Beck, Steer and Garbin identified three factors from a review of 13 factor analysis studies: 
Negative attitude toward self, performance impairment and somatic disturbance (Beck, 
Steer & Garbin, 1988).The relevance of this concern is that patients with narcolepsy may 
appear to be depressed based on total scores while, in fact, this is more representative of 
their medical stress rather than cognitive and affective features of depression. Moreover, 
this could be the case not only for the items of BDI specifically related with sleep but also 
for the rest of the somatic items. Factor analysis of the BDI has been reported for many 
psychiatric and non-psychiatric populations. Despite the extensive use of BDI in 
narcoleptic patients, there are no studies investigating the factor structure on patients with 
narcolepsy.  
The BDI was developed to assess depression as a syndrome but not as a nosologic entity. 
This means that depressive symptoms are supposed to be present in affective disorders 
but are not necessarily excluded from, for example, anxiety or schizophrenia. Within the 
same argument, Kendall emphasizes that high scores can also reflect stressful life events 
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or transitory distresses that are not always part of an affective disorder and that individuals 
with very low scores may have other forms of psychopathology such as psychopathy or 
hypomania (Kendall, 1987). The aim was to find the minimal factors that explain 
depressive symptoms in narcoleptic patients and the hypothesis is that the components 
related to somatic items of BDI will be more relevant when compared to components 
associated with cognitive items. 
5.2. Method 
5.2.1. Participants 
The total number of patients was increased to meet the basic requirements of a factor 
analysis. The sample size must be considered in an exploratory factor analysis. The 
recommended is not less than 100 individuals for any analysis. 
The sample was made up of 114 Caucasian narcoleptic patients (62 women, 52 men) with 
and without cataplexy. 28 patients were recruited during the annual meeting of the 
German narcolepsy association (a patient support group). They complemented the sample 
of 86 narcoleptic patients in study 1 (section 3) to run the analysis. All patients were 
diagnosed according to the ICSD-2 and were between the ages of 19-79 years 
(mean=47±.17.2). 
5.2.2.  Procedure and questionnaire 
The Beck Depression Inventory (BDI) is a self-rating scale comprised of 21 questions 
related to depressive symptoms. The score increases with the severity of depression and 
originally is graded as follows: from 0-9 points: no or minimal depression, 10-14 points: on 
the border of depression, 15-20 points: mild depression, 21-30 points: mild to moderate 
depression, 31-40 points: moderate to severe depression, and 41-63 severe depression 
(Hautzinger, 1991; Beck et al., 1961). It has been translated into a variety of languages. A 
German manual is provided by Hautzinger, and its reliability and validity is well 
documented (Hautzinger, 1991). The cognitive/affective items of BDI as identified by Beck 
et al. (1988) are sadness, hopelessness, sense of failure, anhedonia, guilt, punishment, 
self-hate, self-blame, suicidal, crying, irritation, social anhedonia, difficulty in making 
decisions and feeling ugly. The somatic items are a push to work, late insomnia, tiredness, 
loss of appetite, weight loss, health worries and loss of libido. 
5.2.3. Statistical analysis  
An exploratory factor analysis (EFAs) was processed using the Statistic Package for 
Social Sciences 16.0 (SPSS). Components were restricted to those with characteristic 
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roots or eigenvalues > 1. Only variables with rotated loadings ≥.5 are included to generate 
components with unique variables, a only post rotation components are reported with 
percentages of variance explained. The approach used to decide how many factors were 
retained was the statisitical significance test according to Barlett. The extraction method 
performed was a principal component analysis (PCA) and the rotation method used was 
promax with Kaiser Normalization. Promax was selected because it is an oblique method 
which allows factors to correlate with each other, as expected for BDI factors.  
Factor analysis of Beck Depression Inventory in patients with narcolepsy 
5.3. Results  
5.3.1. Somatic and cognitive items of BDI 
The scale reliability (Cronbach`s alpha) for the present study participants was .89, 
indicating a high internal consistency of the items. The mean BDI score for the sample was 
10.9 (SD=8.8, median=9, CI 95% [9.3, 12.5]). The mean for cognitive items 6.5 (SD=6.8) 
and for somatic items was 4.3 (SD=2.6). 
 
Table 29. Descriptive statistics for each item of the Beck Depression Inventory (BDI) in 
patients with narcolepsy (n=114) in descending order. 
Item type Name of the BDI item  M±SD  95% CI [UL, LL] 
Somatic Fatigue 0.99±.85 [0.99, 1.15] 
Somatic Insomnia 0.91±.93 [0.74, 1.08] 
Somatic Push to work 0.86±.66 [0.74, 0.98] 
Somatic Sexuality 0.82±1.01 [0.64, 1.01] 
Cognitive Decisions 0.82±.79 [0.67, 0.96] 
Cognitive Irritable 0.71±.77 [0.57, 0.85] 
Cognitive Self-criticism 0.61±.72 [0.47, 0.74] 
Cognitive Anhedonia 0.55±63 [0.44, 0.67] 
Cognitive Crying spells 0.47±.90 [0.31, 0.64] 
Cognitive Body image 0.46±.86 [0.30, 0.63] 
Cognitive Punishment 0.46±.82 [0.30, 0.61] 
Cognitive Failure 0.42±.75 [0.28, 0.56] 
Somatic Health worries 0.39±.54 [0.29, 0.49] 
Cognitive Sadness 0.38±.64 [0.26, 0.50] 
Cognitive Future 0.37±.74 [0.23, 0.51] 
Cognitive Social anhedonia 0.36±.64 [0.24, 0.48] 
Cognitive Self-disappointment 0.35±.64 [0.23, 0.47] 
Cognitive Guilt 0.33±.63 [0.22, 0.45] 
Cognitive Suicidal thoughts 0.28±.51 [0.19, 0,37] 
Somatic Loss of appetite 0.18±.57 [0.08, 0.29] 
Somatic Weight loss 0.18±.52 [0.08, 0.27] 
 M, Mean ; SD, standard deviation ; CI, Confidence interval ; UL,upper 
limit ; LL lower limit. 
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When the group was divided by sex, women reported more depressive symptoms in the 
cognitive area (Table 30). 
 
Table 30. Comparison of somatic and cognitive items of BDI in narcoleptic patients by sex. 
BDI items Narcoleptic patients U Z p value 
(two 
sided) 
Women n=62 M±SD 
95%CI [LL, UL] 
Men n=52 M±SD  
95%CI [LL, UL] 
Total scores 13.4±10.1 
[10.1, 16.0] 
7.9±5.8  
[6.3, 9.5] 
1078 -3.04 .002 
Somatic items 4.8±3.0 
[4.1, 5.6] 
3.7±2.0 
[3.2, 4.3] 
1274 -1.94 .053 
Cognitive items 8.6±7.8 
[6.6, 10.6] 
4.1±4.3 
[2.9, 5.3] 
1058 -3.16 .002 
M, arithmetic mean; SD, standard deviation; BDI, Beck Depression Inventory; CI, confidence 
interval; LL, lower limit; UL, upper limit, U, Mann –Whitney test statistic, Z, standardized score, 
the value of U divided by its standard error. 
 
5.3.2. Exploratory factor analysis (EFAs) 
The Barlett test of sphericity [Chi-square (df= 210) =1.029E3, p>.001] indicating sufficient 
overlap among Beck items (variables) was used to perform this analysis. The Kaiser-
Meyer-Olkin (KMO) measure of sample adequacy was 0.866, which indicates that the 
factor matrix was adequate for data reduction.  
 
Table 31. Eigenvalues and percentage of variance explained by each component 
of the model. 
Component Eigenvalues % variance % cumulative variance explained 
1 7.11 33.87 33.87 
2 1.86 8.84 42.71 
3 1.41 6.72 49.43 
4 1.25 5.97 55.41 
5 1.19 5.64 61.05 
6* 1.02 4.84 65.89 
Note: Eigenvalues represents the explanatory importance of the factors with respect to the 
variables. *This component comprises only one item and therefore was eliminated. 
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The obtained solution comprised five components model. These first five components 
explained a prudent level of variance (Table 31). The total of variance explained by this 
model is 60.7%. Solutions with more components were unacceptable because contain 
only one item and each component must consist of at least two items.   
 
Table 32. Factor loadings for exploratory factor analysis with promax rotation of Beck 
Depression Inventory (BDI) items. 
 Item BDI 
Negative 
attitude toward 
self 
36% of 
variance 
Negative 
mood  
7.5% of 
variance 
Interpersonal 
relations 
6.1% of 
variance 
Sleep 
5.5% of 
variance 
Eating 
5.1% of 
variance
A
ffe
ct
iv
e 
/C
og
ni
tiv
e 
ite
m
s 
A. Sadness .150 .756 .049 .114 .055 
B. Hopelessness .079 .668 .237 .030 .061 
C. Sense of failure .725 .228 .265 .044 .023 
D. Anhedonia .156 .651 .252 .326 .108 
E. Guilt .710 .219 .049 .072 .024 
F. Punishment .805 .257 .286 .039 .174 
G. Self hate .753 .191 .189 .131 .050 
H. Self blame .909 .219 .017 .121 .201 
I. Suicidal ideation .125 1.013 .306 .019 .043 
J. Crying spells .311 .286 .656 .021 .186 
K. Irritability* .003 .216 .183 .298 .271 
L. Social Anhedonia .064 .270 .659 .031 .032 
M. Indecisiveness* .418 .357 .057 .158 .134 
N. Body image* .327 .187 .330 .141 .203 
So
m
at
ic
 it
em
s 
O. Push to work * .133 .367 .148 .194 .007 
P. Insomnia .013 .148 .285 1.087 .141 
Q. Fatigue .110 .041 .092 .521 .149 
R. Loss of appetite .291 .016 .154 .195 .747 
S. Loss of weight .230 .016 .334 .302 .809 
T. Health worries* .096 .101 .004 .146 .163 
U. Loss of libido .151 .051 .981 .253 .224 
Factor loadings>.50 are in boldface. Items were considered to load on a factor if the rotated 
factor loadings was at least 0.5. *factor loadings<.50. Each component must consist of at least 
two items (here loading refer to pattern coefficients). Porcentage of variance in the data 
accounted by the rotated factor solution. The total of variance explained by this model is 61%. 
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Solutions with fewer factors revealed an inadequate amount of residual variation. The five 
solution generated distinct components, each composed of between two and four items. 
Some items of BDI did not load on a factor with minimum expected (0.5), these items are 
reported with an asterisk (Table 32).  
The first component was called negative attitude toward self, which accounted for the 36% 
of the variance and was composed of five items: self-hate, self-blame, expectations of 
punishment, guilt and sense of failure. The second component, called negative mood, 
explained 7.5% of the variance and was composed of four items: suicidal ideation, 
sadness, anhedonia and hopelessness.  The third component, social interpersonal 
relations, explained 6.1% of the variance and was composed of three items: loss of libido, 
social anhedonia and crying spells.  The fourth component was sleep which made up 
5.5% of the variance. It was composed of the two items insomnia and fatigability. The fifth 
component, eating, explained 5.1% of the variance and was composed of two items: loss 
of appetite and lose of weight.  
Discussion empirical part II 
6. DISCUSSION  
6.1. Discussion empirical part I: “Depressive symptoms in narcolepsy with and 
without cataplexy and idiopathic hypersomnia” 
In this study, the question of whether depression in narcolepsy is an epiphenomenon or if 
it is inherent to the disease itself was attempted to answer. An epiphenomenon is defined 
as “an accidental or accessory event or process occurring in the course of a disease but 
not necessarily related to that disease” (Dictionary Merriam-Webster online, 2010). The 
results provide an argument for depression as an epiphenomenon. A central finding of this 
study is that 40% of the narcoleptic patients were at least mildly depressed as it is for more 
severe depression with at least 15% of the narcoleptic patients experiencing a clinically 
significant level of depressive disorder. This was almost four times as much as in controls. 
The control group was selected from the general population and one of the criteria of 
exclusion was the absence of a current depression diagnosis. However, some participants 
did show a mild degree of depressive symptoms. The proportion of participants with mild 
depression was similar to an unselected general population, in which it is 11% (Oliver & 
Simmons, 1985).  
The use of self-rating scales was preferred for several reasons. The first one is because 
the patients were mostly contacted in different social meetings of the self-help group. In 
consequence, the patients were interviewed for demographic data and filled in the 
questionnaires in a quiet place. Most of them returned the questionnaires during the 
meeting and some of them decided to send it by post later. The second one was the fact 
that the interviews and analysis of the data were done by the same person. For these 
reasons, self-rating scales were an advantage because they decreased the possibility of a 
bias in the analyses and interpretation of the results. In addition, others investigating this 
group of patients have used the same approach before. Therefore, this procedure 
facilitates comparison with quantitative data from previous research studies performed with 
similar approach and equivalent populations. 
6.1.1. Predictors of depressive symptoms 
The major predictors for depressive symptoms were sex (being female) and the intake of a 
combination of stimulants and anticataplectic drugs, while cataplexy and the ESS score 
had no influence. These findings make it unlikely that depressive symptoms in narcoleptics 
are closely linked to the Hcrt deficit, which is predominantly found in NC+ patients. ESS, 
which was assessed under current treatment, may not be a valid indicator for sleepiness in 
this population comprising many medicated patients. Severely affected patients may be 
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more prone to take stimulants and thus reduce their ESS score. It cannot be ruled out that 
the intake of antidepressants in 33% of the narcoleptic sample masked the presence of 
even more depressive symptoms. The findings are in keeping with previous studies, which 
reported that the severity of sleepiness is not related to depression (Nevsimalova, 
Buskova, Kemlink, Sonka & Skibova, 2009; Daniels, King, Smith & Shneerson, 2001). 
Items in BDI and SDS directly related to EDS appeared to have only a minor influence. 
According to Beck's cognitive model (Beck, 1967), depressed narcoleptics could perceive 
themselves without control of their vigilance and sleepiness, and this deficit is attributed as 
a weakness damaging to self-esteem.  
6.1.2. Presence of cataplexy 
Another major result of this study is that despite the psychological impact of cataplexy 
reported by the patients in clinical interviews, depressive symptoms were not associated 
with the presence of cataplexy. The lack of difference between NC+ and NC- in the level of 
depression supports the assumption that the major psychosocial burden in narcolepsy is 
not necessarily associated with the presence of cataplexy. This data are in line with the 
findings of Morrish et al. (2001) who used older criteria for the differentiation between NC+ 
and NC- (Morrish et al., 2001). Another study established that “irresistible episodes of 
sleep” is the major symptom affecting quality of life. There is no significant influence of the 
other symptoms of narcolepsy, such as cataplexy (Dodel et al., 2007).  
These results are also in good agreement with a previous longitudinal study by Bruck and 
Costa (2003) who reported that excessive daytime sleepiness (EDS) had the greatest 
impact on life across the 10-year period of the study compared to other symptoms of 
narcolepsy (Bruck & Costa, 2003). In addition, Vignatelli et al. (2004) found that cataplexy 
does not correlate with the scales of the SF-36 (Vignatelli et al., 2004). A possible 
explanation is that cataplexy is frequently better controlled by medication than EDS. Even 
with the intake of stimulant medication, sleepiness is merely reduced but not eliminated 
(US Modafinil in narcolepsy multicenter study Group, 2000; Broughton & Mamelak, 1979). 
Most but not all other studies found that NC+ patients tend to be sleepier than NC- patients 
(Dauvilliers et al., 2009; Martinez-Rodriguez et al., 2007). This was not the case in this 
sample, perhaps due to pharmacological treatment. The difference in sleepiness between 
NC+ and NC- plus IH patients in the “Harmony study” may be explained by the influence of 
the IH group (Dauvilliers et al., 2009). In fact, in the results, it is possible to detect a 
difference between IH and narcolepsy patients regarding general mood state (fatigue and 
confusion). Consequently this difference supports the idea that it is not appropriate to 
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group IH patients with NC- ones. This finding once more demonstrates the negative impact 
of narcolepsy on psychosocial performance (Broughton et al., 1981), although the results 
revealed a lesser degree of depressive syndrome than some earlier studies (Dauvilliers et 
al., 2009; Daniels et al., 2001). 
6.1.3. Similarities with other studies 
The results furthermore indicate that the pharmacological treatment used in narcolepsy is 
closely associated with depressive symptoms. Supporting this data, Daniels and 
colleagues showed that narcolepsy patients taking stimulants and antidepressants had a 
higher BDI score than patients taking none or only one of these compounds (Daniels et al., 
2001). It is likely that individual personality characteristics influence the decision for drug 
intake. In addition, life circumstances that permit coping strategies such as taking regular 
naps may reduce the necessity to take medications. Simultaneously, this could reduce 
distress and the resulting depression. Of particular concern is the role of sex in depressive 
symptoms. Narcoleptic women were more depressed independent of other factors, which 
is in line with studies performed in the general population (Slone et al., 2006). A 
Norwegian study found that women with narcolepsy experience more social limitations 
than men do. The authors explained this by considering that women are more socially 
active, or that they have the ability to express their experiences more easily (Ervik et al., 
2006). Supporting that notion, an Israeli study found that untreated sleepy women with 
obstructive sleep apnea have higher scores in depression than men (Pillar & Lavie, 1998). 
Another explanation could be that women are more prone to report their symptoms than 
men, which might be due to early socialization, traditional sex roles or differences in social 
standing (Van Wijk & Kolk, 1997). In conclusion, this data suggest that depression is an 
epiphenomenon of narcolepsy, not a primary feature of the disease itself. The results 
reconfirm the psychosocial impact of narcolepsy and the subsequent effect on mood state. 
Sleepiness appears to be the best candidate explaining depressive symptoms, and the 
use of medication to combat it may be a better indicator for this than the ESS score. 
Inevitable sleepiness is a symptom less impressive than cataplexy and for that reason 
often misinterpreted as laziness by peers (Stores, 2006; Kales et al., 1982). This may be 
the reason why depression is associated rather with sleepiness than with cataplexy 
(Vignatelli et al., 2004). Since sex and a combination of antidepressants and stimulants 
contributed to depressive symptoms, future research should focus on the role of 
psychotropic drug intake and sex for depression in narcolepsy. Furthermore, depressive 
symptomatology in narcoleptic patients needs to be studied in more detail. 
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6.2. Discussion empirical part II: “Narcoleptics with depressive symptoms 
compared with patients with depression”. 
6.2.1. Sleepiness 
As expected, there is a significant difference in the ESS total scores between narcoleptic 
and depressive patients. However, the sleepiness present in narcolepsy is considered 
conceptually different from tiredness, fatigue and sleep disturbances characteristic to 
depression (Lessov-Schlaggar, Bliwise, Krasnow, Swan & Reed, 2008). The fact that a 
group of patients with depression has clinically relevant high scores in the ESS is 
consistent with previous studies (Ferentinos et al., 2009; Lundt, 2005) which found that 
one fourth to half of the patients with depression experience on average moderate daytime 
sleepiness (ESS>10 points). However, it is not possible to assume that this one third of 
patients with depression with more than 10 points in ESS scores experience the same 
type of sleepiness as patients with narcolepsy. The ESS is a validated scale in sleep 
disorders research but probably is not sensitive to the type of sleepiness experienced by 
patients with depression (Kaplan, 2009).  
SLEEPINESS ASSOCIATED WITH DEPRESSIVE SYMPTOMS 
There is disagreement in the literature as to whether the somatic symptoms of depression 
should be included in the diagnosis of depression of patients with chronic illness or not. 
Some but not all authors suggest the solution of excluding items related with fatigue, 
weight loss, or disturbed sleep from depression questionnaires such as BDI (Clark et al., 
1983, Aikens et al., 1999). In this sample, depressive symptoms (mean total scores) were 
not correlated with sleepiness scores (ESS). In addition, ESS scores did not correlate with 
the items of BDI directly related to sleepiness in any of the groups. These findings support 
that it is not necessary to omit items of BDI when evaluating narcoleptic patients. This is 
also suggested in a study evaluating patients with multiple sclerosis who also have 
symptoms related with somatic items such as sleepiness and fatigue (Aikens, 1999). 
OBESITY, GENDER AND MEDICATION STATUS 
The finding that BMI is higher in narcoleptics than in the normal population is in agreement 
with data found in the literature. One study performed with 129 Swiss and German 
narcoleptic patients found that at least a third of them were obese, which is similar to the 
results here presented (Dahmen et al., 2001). This finding is supported by the result that 
narcoleptic patients have fewer difficulties with appetite than patients with depression.  
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Women have higher scores in the “Tension- Anxiety” scale of POMS which is in line with 
the first study showing that women with narcolepsy are more depressed than men and 
with another study reporting that the female group of patients with narcolepsy perceived 
more social limitations than men (Ervik et al., 2006). In the other questionnaires, no 
differences were found between men and women, which must be interpreted with caution 
because of the small sample size. 
Regarding medication status, 21 patients with narcolepsy of the sample were on 
antidepressants. Although this was prescribed to reduce cataplexy, patients were still 
reporting depressive symptoms. The most reasonable explanation is that the dosage of 
antidepressants was probably not enough to reduce depressive symptoms in these 
patients. Another reason can be the type of antidepressant. Stewart et al. (2009) proposed 
that the response to tricyclic antidepressants is reduced in patients with atypical 
depression. 
ITEM BY ITEM ANALYSIS ON BDI AND SDS: ANHEDONIA 
This study shows that narcoleptic patients with depressive symptoms are more hedonistic 
than patients with depression. This result should be interpreted with caution. It is not 
sufficient evidence that narcolepsy patients with depressive symptoms maintain a normal 
hedonic level. Rather, a significant difference is reported compared to depressed patients 
in spite of the same level of depression. An explanation for this finding in patients with 
narcolepsy may be double-sided. On the one hand, anhedonia is one of the core 
symptoms of depression and a normal hedonic tone is characteristically maintained in 
subjects with atypical depression. In consequence, one might hypothesize that the patients 
with narcolepsy and depression as comorbidity are more prone to an atypical depression 
than to melancholic depression. 
Rye et al (1998) describes a single patient with narcolepsy diagnosed with atypical 
depression. Characteristically, the patient reacted when presented with positive events. In 
this case, the patient was treated with 100 mg Bupropion (NDRI) and recovered not only in 
terms of depressive symptoms, but also in terms of narcoleptic symptoms such as 
decreased daytime sleepiness (ESS points), SOREMP and increased REM sleep latency 
(Rye, Dihenia & Bliwise, 1998). The hypothesis that narcoleptic patients with depressive 
symptoms are possibly more prone to an atypical depression is in agreement with the 
emotive reactivity typically present in a cataplexy episode, which would be impossible for a 
narcoleptic patient with a melancholic depression. This premise is concordant with a 
recent study showing that phobias and anxiety are often present in narcoleptic patients 
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(Fortuyn et al., 2010). These characteristic are related to an atypical depression (American 
Psychiatric Association, 2000). On the other hand, this finding can suggest a link with the 
pathophysiology of narcolepsy. Hcrt neurons are important in regulating motivation and 
stress states (Siegel, 2004). Although we do not have data on the Hcrt status of this group 
of patients, this peptide could play a role in modulating the recompense system in the 
brain and may therefore be relevant in depression (Ganjavi et al., 2007). 
This study shows that narcoleptics are less worried about health problems than depressive 
patients. This can imply that even with depressive symptoms, narcoleptics are more 
concerned with “daily problems” such as falling asleep or having cataplectic attacks during 
inappropriate situations than with physical problems. Narcoleptic patients reported fewer 
diurnal variations of mood; this can be explained because narcoleptics are more wakeful 
during the morning due to the recent night’s sleep. Diurnal mood variation can also be 
related with disrupted social rhythms in depressed patients (Germain, 2008). For this 
reason, the results suggest that the refreshed feeling in the early morning for narcoleptic 
patients can be a protecting factor because it helps maintain social rhythms at least during 
the first hours of the day. According to Bech (2008), diurnal variations of mood are more 
an indicator for depression and not for sadness related to stress or when under adversity, 
which is in line with a chronic illness such as narcolepsy. Diurnal variation is also a feature 
of depression more related to melancholic features of depression in DSM-IV. 
6.2.2. Subjective and unspecified question: Do you feel depressed? 
When patients with narcolepsy were asked if they felt currently depressed, avoiding any 
question associated with symptoms, they answered positively and on the same level as 
patients with depression. Considering that depressive symptoms were, in this study, based 
on the patient’s self report, it is not possible to argue that patients were only taking into 
account his/her somatic symptoms that are included in DSM-IV or in ICD-10 in the criteria 
of depression. Furthermore, this is concordant with the finding that in these patients the 
somatic dimension of BDI was not more dominant than the cognitive dimension.  
These data provide only a partial answer to the question on the features of depressive 
symptoms in patients with narcolepsy, leaving the question open on whether the kind of 
depression described by narcoleptic patients is prone to an atypical depression or not. 
According to DSM-IV, the diagnosis of atypical depression is characterized by mood 
reactivity (also called paradoxical anhedonia) and should include two or more symptoms, 
which include hypersomnia, increased weight or appetite, sensation of heaviness in limbs, 
and a long-term pattern of hypersensitivity to perceived personal rejection. If it were 
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possible to demonstrate that mood reactivity is present in narcolepsy despite other 
depressive symptoms, it would be very difficult to fulfill the criteria because three of the 
symptoms are similar features of narcolepsy. The exception is the criterion of subjective 
personal rejection, which should be further investigated in narcoleptic patients with a 
coexisting depression. Previous reports of psychosocial consequences and 
psychopathology in narcoleptic patients with cataplexy show that in the symptom checklist-
90 (SCL-90), one of the three dimensions with the highest scale elevations is interpersonal 
sensitivity while the other one is depression and obsessive-compulsiveness. These 
interpersonal difficulties can be seen as a consequence of negative reactions from others 
toward his or her illness (Kales et al., 1982). 
It will be an issue of future studies to evaluate the presence of atypical depression in 
narcoleptic patients with depressive symptoms using structured or semi-structured 
interviews. 
Discussion empirical part III 
 
6.3. Discussion empirical part III: “Factor analysis of Beck Depression Inventory 
in patients with narcolepsy”. 
Because symptoms of narcolepsy and depression can be similar, there is a risk of 
misdiagnosing narcoleptic patients as depressives. The rate of depressive symptoms in a 
one-dimensional model would show that around 45% of patients of this sample are at least 
moderately depressed according to the total BDI scores. In this study, the factor structure 
of the BDI was derived from a relatively large sample of patients with narcolepsy 
considering the low prevalence of narcolepsy in the population. This data indicates that 
there is a moderately robust structure to the BDI responses of patients with narcolepsy, 
which can shed light on the phenomena of depressed mood and major depressive 
disorder in patients with narcolepsy, having important clinical repercussions. 
6.3.1. Negative attitude toward self  
The exploratory factor analysis revealed a five components solution. In a meta-analysis of 
the factor structure of BDI, others found that the average of components reported in 33 
studies (also using the varimax rotation) was a four components solution (Shafer, 2006). 
This average of components found in a meta-analysis corresponds to studies with healthy 
participants and with patients. 
Negative attitude toward self is the most relevant component in BDI which explains 36% of 
the variance of the factor analysis, much more than all other factors. This is a central 
finding, because only cognitive items of BDI load in this factor. Based on this result, it is 
not possible to support the theory that somatic items were responsible for the severity of 
depressive symptoms in narcolepsy. The second factor is clearly the negative mood. The 
highest loading items included sadness, hopelessness, anhedonia and suicidal ideation. 
The association between hopelessness and suicide is well documented in Beck’s theory.  
As reported, factors emerged related to somatic items, including those related with eating 
and sleep, although they were not the most important in explaining the depressive 
symptoms. This means that the symptoms can be not understood as inflating the scores in 
BDI. The low degree of somatic items endorsed versus the high degree of cognitive 
symptoms of depression refutes the idea that depressive symptoms in narcoleptics are just 
an expression of typical symptoms of the sleep disorder.  
In a sample of 477 depressive patients, Hautzinger (1994) reported a first factor or 
component called performance impairment (19.2% of the variance), which consists of a 
push to work, fatigability, social anhedonia, sadness, indecisiveness, crying, anhedonia 
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and health worries. A second component in the depressive sample, the so called negative 
attitude toward self, explained 18.6% of the variance and shows guilt, self blame, sense of 
failure, self hate, hopelessness and suicide ideation. A third component, somatic 
disturbance, explained 7.6% of the variance and included weight loss, loss of appetite and 
insomnia. Compared to the results of Hautzinger (1994) in patients with depression, the 
components obtained in this sample of narcoleptics have only few similarities. Negative 
attitude toward self explained also the most of the variance in patients with depression 
(18%) but in narcoleptics this component explains twice as much of the variance obtained 
(36%). This is the most similar component. The others are not comparable because they 
include different items. Women with narcolepsy showed a higher severity of depressive 
symptoms related to the cognitive dimension. In consequence, they should be largely 
screened during an interview with a physician. It is not clear why women with narcolepsy 
are more depressed than men. This is also seen in the non-narcoleptic population and is 
explained by different theories. 
6.3.2. Cognitive dimension 
The results of this sample suggest that the cognitive symptoms play an important role in 
women. The item related with body image could not be identified in any factor, indicating 
that this is not a central theme in the context of depressive symptoms neither in men nor in 
women. This suggests that the treatment could be oriented, for instance, to a cognitive 
therapy focussing on the negative attitude toward self. This factor structure means that the 
content of these scores shows a relatively large amount of symptoms which are not 
necessarily only related with a chronic illness but which also characterize a depression. 
Interestingly, among the items with weak loadings were irritability, indecisiveness, change 
of body image, push to work and health worries. The lower importance of push to work and 
health worries suggests that patients discriminate between the impact of the illness and 
the motivation to work. Furthermore, patients are aware of the characteristics and 
consequences of the illness.  
Further work needs to be done to establish the utility of the current factor solution. This 
study requires replication using confirmatory factor analytic methods, preferably. 
Furthermore, it would be important to compare this factor solution with another population 
of hypersomnia patients.  
General discussion 
6.4. Overall findings of all three studies 
One of the central findings is that 40% of narcoleptic patients are at least mildly depressed 
according to self-report questionnaires. This is four times as much as in controls. This 
result is in line with a review of current literature on narcolepsy and depression, which 
leads to the conclusion that patients with narcolepsy show an increased prevalence of 
depressive symptoms when compared to controls (Dauvilliers et al., 2009; Daniels et al., 
2001; Pawluk, Hurwitz, Schluter, Ullevig & Mahowald, 1995; Stepanski et al., 1990; Beutler 
et al., 1981). Although depressive symptoms are often reported, a diagnosis of major 
depressive disorder is infrequent (Fortuyn et al., 2010; Adda et al., 1997; Roy, 1976). 
Previous reports demonstrate that although patients have depressive symptoms and have 
a low quality of life (which includes some items regarding depression) most of the studies 
fail to probe whether they have a major depressive disorder (MDD). In the cases where 
MDD was diagnosed, literature suggests that it was not more prevalent than in the general 
population.  
6.4.1. Similar severity of depression in NC+ and NC- 
One issue was to distinguish if the two newly differentiated forms of narcolepsy (with and 
without cataplexy) have a role on depressive symptoms. This question is primarily founded 
in the neurotransmitter Hcrt (See 1.2.4 Etiology). The Hcrt deficiency, which is observed in 
most cases of NC+ but rarely in cases of NC-, generates an interesting hypothesis 
because of the possible role of Hcrt in depression. 
Salomon and colleagues already described that there is no outstanding decrease of CSF 
Hcrt values in depressed subjects (Salomon et al, 2003). This suggests that Hcrt 
deficiency is an improbable cause of primary depression. The results reported here found 
no evidence to state that patients with cataplexy are more depressed than those without 
cataplexy. Further research could be performed looking for a correlation between the level 
of Hcrt in CSF and the severity of depressive symptoms in patients with narcolepsy. 
Another topic on this point was to find out the determinants of depression in patients with 
narcolepsy. The key result in this part was that the presence of cataplexy alone is not 
enough to predict depressive symptoms. This is in line with Dodel and colleagues, who 
reported that sleep episodes have a major impact on the quality of life of patients with 
narcolepsy (Dodel et al., 2007).  
Nevertheless, this result should be treated with fine consideration because it is not 
possible to conclude that the severity of cataplexy is not associated with depression. This 
result reveals only that the presence of the symptom does not explain “by itself” the 
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presence of depressive symptoms. The severity and frequency of cataplexy should be 
analyzed in further studies because this factor could have an influence on the depressive 
symptoms. There may also be some patients under anticataplectic medication in almost 
the same condition as patients without cataplexy.  
Furthermore, narcolepsy patients with cataplexy can have mild cataplectic episodes, for 
instance, only affecting the face. This does not necessarily affect social relationships or 
quality of life compared to patients who have cataplectic episodes with a total loss of 
muscular tone, thereby making them more dependent on their peers. The current data are 
contrary to a previous study carried out in France that reported that narcolepsy patients 
with cataplexy are more depressed than those without cataplexy (Dauvilliers et al., 2009). 
One possible explanation is the fact that this French study grouped NC- patients together 
with IH.  
6.4.2. Daytime sleepiness scores and mood state 
Daytime sleepiness seems to be the major symptom affecting mood states. The fact that 
daytime sleepiness was not significantly different between narcoleptics (with and without 
cataplexy) and IH patients, has been previously reported (Martinez-Rodriguez et al., 
2007). IH patients showed higher scores in total mood disturbances in POMS. In 
particular, they reported more impairment in the sub-scales fatigue and confusion than 
patients with narcolepsy without cataplexy. This difference in fatigue and confusion could 
be explained by the typical unrefreshing naps for IH patients. Not-refreshing naps are 
more characteristic in IH than in narcolepsy. Unlike in patients with narcolepsy, daytime 
sleepiness in IH is not imperative but it is permanent (American Academy of Sleep 
Medicine, 2005). The consequences of this permanent daytime sleepiness are frequent 
naps that are not refreshing. Another interpretation may be that IH patients are very 
heterogeneous and IH may have multifactorial pathogenesis (Bassetti et al., 1997). 
According to the results, there are no differences in the depressive symptoms reported by 
narcoleptics and IH patients.  
6.4.3. Excluding items related to sleepiness from depression 
questionnaires 
In the literature of depression and narcolepsy, it was unclear if the symptoms of 
depression were masked by the symptoms of the sleep disorder, or if they were 
independent. Indeed, questionnaires measuring depression always include questions 
regarding sleep disturbances. However, the items of the depression questionnaires (BDI 
and SDS) that enquire specifically about sleep do not have as relevant an influence on the 
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total scores of these questionnaires as expected. This suggests that these items should be 
not excluded when the tests are used as a routine in patients with narcolepsy. This is 
consistent with studies performed in other clinically ill populations (e.g. patients with 
diabetes, chronic pain), which conclude that removing items did not improve their 
accuracy. As a consequence, full BDI is also considered valid in those populations 
(Geisser, Roth & Robinson, 1997; Lustman, Griffith & Clouse, 1997).  
6.4.4. Determinants of depression in narcolepsy 
SEX 
Data reporting differences between men and women with narcolepsy regarding depression 
in the literature are rare and conflicting. The results of this dissertation show that women 
with narcolepsy are more depressed than men. In IH most of the patients are men, hence 
it is not possible to examine a possible difference. Male narcoleptics are more impaired in 
some studies while female narcoleptics are more impaired in others. Bruck reported that 
men were more affected than women, specifically regarding sexual problems and Ervick 
and colleagues further suggested that women have more social limitations than men (Ervik 
et al., 2006; Bruck, 2001). Therefore, this is an unsettled matter. The fact that women 
report more depressive symptoms is an interesting finding because this was not 
emphasized until now except for some contradictory results from previous studies. Such a 
difference is widely reported in epidemiologic studies in the normal population. It is not 
possible to establish whether this significant difference between men and women is 
explained by the same reasons as in the normal population or if it can be attributed to 
narcolepsy per se. 
IMPACT OF MEDICATION 
The results show that medication, specifically the combination of stimulants and 
antidepressants are associated with depressive symptoms in patients with narcolepsy. 
Some authors consent that the combination of antidepressants and stimulants can play a 
negative role in depressive symptoms (Bruck, 2001, Daniels et al., 2001, Dauvilliers et al., 
2009 ). More than a few of the studies reviewed suggest that medication may have an 
influence on depressive symptoms and on the quality of life of patients with narcolepsy. 
However, in the span of the last 10 years, the pharmacological treatment for narcolepsy 
has been substantially improved. This implies a factor difficult to be compared and 
controlled.  
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For instance, old stimulants such as amphetamines had side effects associated with 
anxiety such as hypomania, tremble, fast heart beat or wet hands. Modafinil changed the 
scenario in a positive way. As treatment for daytime sleepiness has been promoted to 
improve patients’ quality of life, so has the treatment of cataplexy. The use of sodium 
oxybate, a newly approved medicament for cataplexy, has a definite important benefit for 
the symptoms of narcolepsy that can also explain positive changes in the depressive 
symptoms of patients. This does not mean that sodium oxybate acts as an antidepressant, 
but can be a consequence of the improvement of the symptoms. Moreover, and no less 
important, the use of sodium oxybate is responsible for weight loss in some obese patients 
and, consequently, diminishes the probability of developing sleep apnea. The 
improvement of the medication is a big change. This is not yet well investigated but could 
be an implicit explanation of the differences found in the current literature. It is worth 
mentioning that in the sample of narcoleptics only three patients were taking sodium 
oxybate. 
6.4.5. Distinctive depressive symptoms between narcolepsy and 
depression  
The second study was performed in the subgroup of narcoleptics reporting depressive 
symptoms. The goal was to find out whether depressive symptoms of narcoleptic patients 
are different than in depressed non-narcoleptics. Indeed, there were differences in the 
depressive symptoms of both groups. This was observed even when the intensity of 
depressive symptoms was similar. The differences were associated to hedonic tone, 
health worries and diurnal variation of depressive symptoms. 
HEDONIC TONE 
The central finding on this part of the dissertation is that narcoleptics are less impaired in 
their capacity to feel rewarded, called anhedonia. This is important because anhedonia is 
one of the core symptoms of depression. The maintenance of interest and enjoyment in 
the activities reported by depressed narcoleptic patients was significantly higher than in 
patients with depression. As a consequence of this finding, it has been discussed whether 
patients with narcolepsy and depression as a comorbidity are more prone to atypical 
depression than to melancholic depression. The reason is that depression with atypical 
symptoms is differentiated from the melancholic type by the maintenance of the reactivity 
under positive experiences. Depressive patients frequently report that they have lost their 
sense of humor, for instance they do not get happiness from a joke or a cartoon. Beck 
called this loss of mirth response (Beck, 1967). In narcolepsy, this symptom of depression 
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is rare because patients react with positive experiences but nonetheless can be 
depressed. This is concordant with a report showing that phobias and anxiety are often 
present in narcoleptic patients (Fortuyn et al., 2010) because phobias and anxiety are 
associated with atypical depression (American Psychiatric Association, 2000). 
Anhedonia should be further studied and can hint to a link with the pathophysiology of 
narcolepsy, considering that Hcrt neurons are central in regulating arousal, motivation and 
stress (Siegel, 2004). 
HEALTH WORRIES 
Another distinction between both groups was that depressed narcoleptics were less 
worried about health problems than depressive patients. This can imply that even with 
depressive symptoms, narcoleptics are more concerned with “daily problems” such as 
falling asleep during inappropriate situations than with physical problems.  
The sample of depressed narcoleptics studied was under medical treatment because of 
the diagnosis of narcolepsy. Therefore, this might be an explanation as to why depressed 
narcoleptic patients do not need to worry about a physical disease. In contrast, depressed 
patients may attribute their negative mood state to somatic symptoms (Beck, 1967). 
DIURNAL VARIATIONS 
An additional difference was that narcoleptic patients reported less diurnal variations of 
mood in the depression questionnaires. A possible interpretation for this result is that 
narcoleptics are more wakeful during the morning due to the recent night’s sleep. Diurnal 
mood variation can also be related to disrupted social rhythms in depressed patients 
(Germain, 2008). Moreover, diurnal variation is a feature of depression more related to 
melancholic features of depression in DSM-IV (American Psychiatric Association, 2000) 
which is concordant with the results.  
6.4.6. Relevant items contributing to depression in narcolepsy patients 
NEGATIVE ATTITUDE TOWARD SELF  
The factor analysis of Beck Depression Inventory represents an important contribution 
because it recognizes the kind of symptoms that build the components of the depressive 
symptoms in a large sample of patients with narcolepsy. This was an exploratory factor 
analysis that offered a more precise definition of the relationship between items in one of 
the most used tests in the assessment of depressive symptoms on narcoleptics.  
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The negative attitude towards self was the component that explained most of the 
symptoms of depression. Even though this is a component also found in patients with 
depression without narcolepsy, it is interesting because in patients with narcolepsy it is 
more manifest than in depressives without this sleep disorder. Yet, why do patients with 
narcolepsy report having a sense of failure, guilt, an expectation of punishment, self-hate 
and blame as the most important components of their depressive symptoms? It can be 
hypothesized that the attribution of the cause of the symptoms has been re-directed to 
themselves. Additionally, patients without cataplexy are informed at the time of diagnosis 
that cataplexy may turn up soon or later or maybe never. This can also be a source of 
anxiety and a false self-attribution of the causes of the beginning of cataplexy. 
EARLY IDENTIFICATION OF DEPRESSIVE SYMPTOMS 
Patients already diagnosed with narcolepsy, who report depressive symptoms should be 
screened for a major depressive disorder independent of the physical condition and not 
only focusing on the somatic dimension of depression but also on the cognitive one.  
Sleep specialists should be provided of basic training on identification of patients suffering 
from depressive disorders. Early identification of depressive symptoms means more 
effective treatment not only for depression but also for narcolepsy. Furthermore, sleep 
specialists should be more aware of the importance of engaging family and peers of 
patients (also adults) during treatment. The emphasis is on patients with an onset in 
adulthood probably because when the onset is during childhood, familial support is 
greater. The family of patients with depressive symptoms could help to develop coping 
strategies more easily, which could increase the chance of a chronically ill patient’s 
integration in society. Furthermore, failure in school or in the workplace together with 
obesity and the fear of not being understood are situations that every patient with daytime 
sleepiness struggles with throughout life.  
6.4.7. Limitations of the dissertation 
SAMPLE AND METHODS 
The presence of depressive symptoms or suspicion of a psychiatric condition in the clinical 
interview carried out in the sleep center was an exclusion criterion for the IH patients. 
There is a dilemma on this topic because patients who have depressive symptoms 
because of the IH symptoms will have fewer possibilities of being diagnosed due to these 
ICSD-2 criteria (Billiard & Dauvilliers, 2001b). Therefore, possibly two things occur: the first 
is that some real patients were excluded following this criterion and the second is that as a 
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consequence, a bias on this group has been unintentionally generated. During this study, it 
was possible to have contact with the patients, some of whom were very engaged in the 
organization of the meetings, even when they reported high scores in depression 
questionnaires. This seemed very contradictory but was in line with the finding of the 
second study that shows that narcoleptics with depressive symptoms are more interested 
in participating in activities, which produce satisfaction than non narcoleptic patients with a 
similar level of depression but are non narcoleptic. The type of depression in narcoleptic 
patients is, in summary, best described as an atypical depression.  
While one advantage of the present study was the matching of patients in order to have a 
similar level of depression, some limitations were encountered such as not having exact 
data on the dosage of antidepressants. This dosage was possibly higher in patients with 
depression. 
6.4.8. Future research directions  
One of the results of this dissertation shows that narcoleptic patients with depressive 
symptoms are more hedonistic than patients with depression. This does not state that 
narcolepsy patients with depressive symptoms maintain a normal hedonic level. Rather, 
the results are evidence of a significant difference in comparison with depressed patients 
in spite of the same level of depression. This outcome is interesting because anhedonia is 
a cardinal symptom of major depression and the experience of enjoyment is the typical 
trigger of a cataplexy episode. Therefore, it is possible to hypothesize that narcolepsy 
patients with cataplexy are in some way protected from the symptom of anhedonia. 
Looking at this point from a different perspective, it appears that patients who maintain a 
good level hedonic experience are more prone to experience cataplexy, because they 
expose themselves to more emotional stimuli.   Meehl suggested that there is a normal-
range of individual differences in the hedonic capacity in the general population and a 
reduced capacity to feel pleasure in non-clinical individuals may be associated with brain 
abnormalities that constitute neural markers of vulnerability for some psychiatric disorders 
(Meehl, 2001). A possible future research question would be to identify the brain regions 
whose activity during the processing of hedonic information varies in function of anhedonia 
severity in control subjects and narcolepsy patients. So far, functional neuroimaging 
studies of anhedonia have focused exclusively on two clinical populations, either 
schizophrenia or MDD (Harvey, Armony, Malla & Lepage, 2010). It is not yet known if 
narcolepsy patients differ from controls in the range of hedonic levels. 
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The possibility that narcoleptic patients with a depression are prone to an atypical 
depression is an interesting likelihood which needs further confirmation. An exploration of 
this topic should re-test this result and corroborate the presence of other symptoms of 
atypical depression such as subjective personal rejection by others.   
Conclusion 
7. CONCLUSION 
a) Depressive symptoms are present in a significantly higher proportion in patients 
with narcolepsy and IH than in healthy controls. This is four times more than the 
controls and shows that depression in these patients is not overestimated as 
suspected. However, patients experiencing clinically significant depression made 
up no more than 15% of the sample.  
 
b) Patients with cataplexy are not more depressed than those without cataplexy. The 
presence of cataplexy alone is not enough to predict depressive symptoms. 
Daytime sleepiness seems to be the major symptom affecting mood states but is a 
symptom less impressive than cataplexy, and therefore, it is often misinterpreted by 
peers as laziness. Further research should be performed to test if the severity and 
frequency of cataplexy are associated with depression. 
 
c) In spite of the differences in fatigue and confusion, there are no differences in 
depression scores between patients with narcolepsy and IH. 
 
d) Regarding the determinants of depressive symptoms, combination of 
antidepressants and stimulants, and sex contributed to depressive symptoms. 
Although it is possible that the use of stimulants and antidepressants in the 
treatment of narcolepsy may increase the occurrence of depression, this result 
needs to be studied in more detail. Women with narcolepsy are more depressed 
than men and have a higher risk of developing depression. This difference is 
reported in the general population, and it is not possible to establish if this 
difference is explained by the same reasons or can be attributed to narcolepsy per 
se. 
 
e) This dissertation attempted to answer the question of whether depression in 
narcolepsy is an epiphenomenon or if it is inherent to the disease itself. The results 
provide an argument for depression as an epiphenomenon.  
 
f) The items of the depression questionnaires used which enquire about sleep do not 
show a relevant influence in the total scores of these questionnaires as expected. 
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Hence, removing items did not improve their accuracy. In addition, somatic items 
ere not responsible for the severity of depressive symptoms in narcolepsy. w
 
g) The key difference between patients with narcolepsy and depression under similar 
intensity of depression is associated with the level of anhedonia, i.e. the capacity to 
feel rewarded. This distinction should be further studied and can hint to a link with 
the pathophysiology of narcolepsy. This is particularly the case considering that 
Hcrt neurons are central in regulating arousal, motivation and stress. 
Summary 
8. SUMMARY 
8.1. English summary 
Depression and depressive symptoms are consistently reported as a problem for patients 
with daytime sleepiness in various studies. The present dissertation attempts to compare 
depression severity and daytime sleepiness in patients with narcolepsy and Idiopathic 
Hypersomnia. The main objective of this dissertation is to determine whether the 
depressive symptoms of narcoleptic patients are different from the depressive symptoms 
of depressed non-narcoleptics. Given the large discrepancy in previous results on this 
topic, this hypothesis was to be tested in steps, therefore this dissertation is divided into 
three studies. 
The first study assesses depressive symptoms in 86 narcoleptic patients with (NC+) and 
without (NC-) cataplexy (46 women, 40 men), idiopathic hypersomnia (IH) patients (three 
women, 12 men) and age- and sex- matched healthy controls. Seventy patients were 
under treatment with stimulants and/or anticataplectics.  
The second study compares depressive symptoms between 36 narcoleptics (26 women, 
10 men) and 34 outpatients with mild to moderate depression (22 women, 12 men). The 
group of narcoleptics was selected from the sample of patients of the first study (n = 86) 
who had ≥10 points in the Beck Depression Inventory (BDI). All subjects completed the 
Beck Depression Inventory (BDI), the Zung Self-Rating Depression Scale (SDS), the 
Global Impression of Severity of Depression (GSD), the Profile of Mood States (POMS) 
and Epworth Sleepiness Scale (ESS). 
The third study identifies the components of depressive symptoms of narcoleptic patients 
using BDI. The total number of patients had to be increased to meet the basic 
requirements of a factor analysis. The sample was made up of 114 Caucasian narcoleptic 
patients (62 women, 52 men). The results show that patients with narcolepsy were more 
depressed than controls (higher scores in BDI, GSD, SDS, and POMS [in the total score 
and in all sub scale scores]); however, between the NC+ and NC- patient groups, no 
differences were found. Women and the patients using antidepressants and stimulants 
(combination) have a higher probability for depressive symptoms independent of the 
presence of cataplexy. The daytime sleepiness measured by the ESS (mean score) for the 
narcoleptic group was higher than the mean scores for the depressive group (p<.001). In 
the item analysis, differences between the narcoleptic group and depressive disorder 
group in BDI were found regarding anhedonia. Narcoleptic patients were more likely to 
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continue to feel pleasure compared to patients with depression. Further differences were 
found in the items loss of appetite and health worries.  In SDS, narcoleptics were less 
impaired in diurnal variation, loss of libido, appetite and weight than patients with 
depression. Narcoleptics and depressives were more impaired in POMS (total and all sub 
scales) compared to controls. The factor analysis of BDI revealed that the negative attitude 
towards self was the component that explained most of the symptoms of depression. Even 
though this is a component also found in patients with depression without narcolepsy, it is 
interesting because in patients with narcolepsy it is more manifest than in depressives 
without this sleep disorder.  
Taken together, the findings support the assumption that the major psychosocial burden in 
narcolepsy is associated with sleepiness and not with cataplexy. Female sex and the 
intake of antidepressants and stimulants together are two determinants connected with 
depressive symptoms in patients with narcolepsy. The prevention of depressive symptoms 
should have special focus in women with narcolepsy independent of the presence of 
cataplexy. Furthermore, with regards to prevention, the focal point should be the negative 
attitude toward self as the most relevant component. Future studies should concentrate on 
the impact of medication on depression in patients with narcolepsy.  
Summary 
 
8.2. German summary 
Wie verschiedene Studien konsistent zeigen konnten, stellen Depressionen und 
depressive Symptome ein Problem für Patienten mit Tagesschläfrigkeit dar. Die 
vorliegende Arbeit zielt darauf ab, Depressionsschweregrad und Tagesschläfrigkeit bei 
Patienten mit Narkolepsie und Idiopathischer Hypersomnie (IH) zu vergleichen. Das 
Hauptziel dieser Dissertation ist es, festzustellen, ob die depressiven Symptome von 
Narkolepsie-Patienten sich von den depressiven Symptomen von nicht-depressiven 
Narkolepsie-Patienten unterscheiden. Angesichts der großen Diskrepanz der 
bisherigen Studienergebnisse zu diesem Thema, musste die Ausgangshypothese in 
einzelnen Schritten getestet werden. Aus diesem Grund ist die vorliegende Dissertation 
in drei Studien unterteilt. 
Die erste Studie erfasst depressive Symptome bei 86 Narkolepsie-Patienten (46 
Frauen, 40 Männer) mit (NC+) und ohne (NC-) Kataplexie, bei IH-Patienten (drei 
Frauen, 12 Männer) sowie einer nach Alter und Geschlecht angepassten gesunden 
Kontrollgruppe. Siebzig Patienten waren unter Behandlung mit Stimulanzien und/oder 
Antidepressiva (Anticataplectics). 
Die zweite Studie vergleicht depressive Symptome zwischen 36 Narkolepsie-Patienten 
(26 Frauen, 10 Männer) und 34 ambulanten Patienten mit leichter bis mittelschwerer 
Depression (22 Frauen, 12 Männer). Die Gruppe der Narkolepsie-Patienten wurde aus 
der Stichprobe von Patienten der ersten Studie (n = 86) ausgewählt, die ≥ 10 Punkte in 
der Beck Depressions-Inventar (BDI) aufwiesen.  Alle Versuchspersonen füllten neben 
dem Beck Depressions-Inventar (BDI),  die Zung Selbstbeurteilung Depressionsskala 
(SDS), ein Globalmaß für die Schwere der Depression (Global Impression of Severity 
of Depression, GSD), sowie das Stimmungsbarometer „Profile of Mood States“ 
(POMS) und die Epworth Schläfrigkeitsskala (ESS) aus. 
In der dritten Studie werden auf der Grundlage des BDI die Komponenten der 
depressiven Symptome von Narkolepsie-Patienten identifiziert. Die Gesamtzahl der 
Patienten musste erhöht werden, um den grundlegenden Anforderungen einer 
Faktorenanalyse gerecht zu werden. Die Stichprobe bestand aus 114 kaukasischen 
Narkolepsie-Patienten (62 Frauen, 52 Männer). Die Ergebnisse zeigen, dass 
Narkolepsie-Patienten depressiver als Kontrollpersonen waren (höhere Werte im BDI, 
GSD, SDS und POMS [sowohl in der Gesamtwertung als auch in den Subskalen]), 
aber zwischen den beiden Patientengruppen NC+ und NC- keine Unterschiede 
gefunden wurden. Frauen und Patienten, die Antidepressiva und Stimulanzien (auch in 
Kombination) einnahmen, haben eine höhere Wahrscheinlichkeit für depressive 
Symptome unabhängig vom Vorliegen der Kataplexie. Die Tagesschläfrigkeit 
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gemessen an Hand der ESS (mittlere Punktzahl) war für die Narkolepsie-Gruppe höher 
als die Mittelwerte für die depressive Gruppe (p<.001). In der Item-Analyse des BDI 
wurden Unterschiede zwischen der Narkolepsie-Gruppe und der Gruppe mit 
depressiver Störung in Bezug auf Anhedonie gefunden. Narkolepsie-Patienten waren 
nach wie vor besser in der Lage, Freude und positive Gefühle zu empfinden als 
depressive Patienten. Weitere Unterschiede wurden bei den Items Appetitlosigkeit und 
Gesundheitsbesorgnis gefunden. 
In der SDS wiesen Narkolepsie-Patienten weniger Beeinträchtigungen in Bezug auf 
zirkadianen Rhythmus, Libidoverlust, Appetitverlust und Körpergewicht als depressive 
Patienten auf. Gemessen am POMS (Gesamtwert und Subskalen) waren Narkolepsie-
Patienten und depressive Personen stärker beeinträchtigt als die Kontrollpersonen.  
Die Faktor-Analyse des BDI zeigte, dass die negative Lebenseinstellung die 
Komponente ist, welche die meisten depressiven Symptome aufklärte. Obgleich diese 
Komponente auch bei Patienten mit Depression ohne Narkolepsie gefunden werden 
kann, ist dies interessant weil bei Patienten mit Narkolepsie es sich mehr äußert als bei 
depressiven Personen ohne diese Schlafstörung. 
Zusammengefasst unterstützen diese Ergebnisse die Annahme, dass die größte 
psycho-soziale Belastung bei Narkolepsie mit Schläfrigkeit und nicht mit Kataplexien 
verbunden ist. Weibliches Geschlecht und die Einnahme von Antidepressiva in 
Kombination mit Stimulanzien sind zwei Determinanten, welche depressiven 
Symptomen von Patienten mit Narkolepsie beeinflussen. 
Bei der Prävention von depressiven Symptomen sollte ein besonderer Fokus auf 
Frauen mit Narkolepsie gelegt werden, unabhängig davon, ob sie Kataplexie haben.  
In Bezug auf präventive Maßnahmen sollte weiterhin der Schwerpunkt auf die negative 
Lebenseinstellung gelegt werden, da diese die wichtigste Komponente darstellt. 
Zukünftige Studien sollten sich auf die Auswirkung von medikamentöser Behandlung 
von Narkolepsie-Patienten konzentrieren. 
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8.3. Spanish summary  
La presencia de depresión o de síntomas depresivos son frecuentemente reportados 
por pacientes que experiencian somnolencia diurna en diversos estudios. La presente 
disertación está dividida en tres estudios que se concentran en la temática de la 
asociación entre la somnolencia diurna (presente en la narcolepsia y la hipersomnia 
idiopática) y la depresión. 
El primer estudio evalúa los síntomas depresivos en 86 pacientes narcolépticos con  
(NC+) y sin (NC-) cataplejía  (46 mujeres, 40 hombres), pacientes con hipersomnia 
idiopática (IH) (3 mujeres, 12 hombres) y un grupo control sano pareado por edad y 
sexo. De estos pacientes, 70 estuvieron bajo tratamiento ya sea con estimulantes y/o 
con anticatapléjicos.  
El segundo estudio compara síntomas depresivos entre 36 narcolépticos (26 mujeres, 
10 hombres) y 34 pacientes ambulatorios con depresión leve a moderada (22 mujeres, 
12 hombres).  El grupo de pacientes narcolépticos fue seleccionado desde la muestra 
del primer estudio, participaron aquellos que tuvieran al menos 10 puntos o más en el 
inventario de depresión de Beck. Todos los sujetos que participaron tanto en el primer 
como en el segundo estudio completaron el Inventario de depresión de Beck (BDI), la 
escala de autoevaluación de la depresión de Zung (SDS), impresión global de la 
severidad de depresión (GSD), el perfil de estados de ánimo (POMS) y la escala de 
somnolencia de Epworth (ESS). 
El tercer estudio que conforma esta disertación tiene como objetivo identificar los 
componentes de los síntomas depresivos en pacientes narcolépticos usando el BDI. 
Para esta parte, fue necesario aumentar el número de sujetos de manera tal que se 
cumplan los requisitos básicos para realizar un análisis factorial. La muestra total fue 
de 114 pacientes narcolépticos de origen caucásico (62 mujeres, 52 hombres). Todos 
ellos completaron BDI y ESS. Los resultados muestran que los pacientes con 
narcolepsia están más deprimidos que los sujetos de control (puntajes más altos en 
BDI, GSD, SDS y POMS [tanto en el puntaje total como en el puntaje de todas las 
subescalas]); sin embargo, entre los grupos de pacientes NC+ y NC-, no se hallaron 
diferencias. Mujeres y pacientes usando antidepresivos y estimulantes (combinación) 
tienen mayor probabilidad de presentar síntomas depresivos independientemente de la 
presencia de cataplejia. La somnolencia diurna medida a través del ESS (puntaje 
promedio) para el grupo narcoléptico fue más alta que los puntajes promedio en el 
grupo de pacientes con depresión (p<.001). En el análisis de los ítemes, se 
encontraron diferencias entre el grupo de pacientes narcolépticos y de aquellos con 
depresión asociados con la Anhedonia. Específicamente los pacientes con narcolepsia 
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y síntomas depresivos tuvieron más probabilidades de continuar sintiendo la misma 
satisfacción de antes que los pacientes con depresión. Otras diferencias fueron 
halladas en los ítemes sobre pérdida del apetito y preocupaciones por la salud. En el 
SDS, los pacientes con narcolepsia tuvieron menos problemas de variabilidad durante 
el día, pérdida de líbido, apetito y peso que los pacientes con depresión. Ahora bien, 
tanto narcolépticos como depresivos tuvieron puntajes más altos en el POMS (puntaje 
total y todas las subescalas) en comparación con los controles. El análisis factorial del 
BDI reveló que el componente que mayormente explica los síntomas depresivos en los 
pacientes con narcolepsia es la actitud negativa hacia sí mismos. A pesar de que este 
componente es reconocido en personas con depresión al usar este test, en pacientes 
narcolépticos se sitúa como el componente que explica la varianza más alta a 
diferencia de otros pacientes deprimido sin este trastorno de sueño  
Tomado en conjunto, los resultado apoyan el supuesto de que la carga psicosocial 
más pesada en la narcolepsia está asociada a la somnolencia y no a la cataplejia. El 
sexo femenino y la ingesta de antidepresivos en combinación con estimulantes serían 
dos determinantes que estarían relacionados con los síntomas depresivos en 
pacientes con narcolepsia. La prevención de síntomas depresivos debiera entonces 
estar enfocada a las pacientes con narcolepsia de sexo femenino independientemente 
de la presencia de cataplejía. Dentro de la prevención la temática parece centrarse en 
la actitud negativa hacia sí mismo como el componente más relevante. En el futuro, los 
estudios debieran concentrarse en el impacto de la medicación sobre la depresión en 
estos pacientes.  
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A
u
t
h
o
r
s
 Study design &
considerations 
Sample Aim Sex 
(M:F) 
Age 
range 
(mean) 
Tests Results 
A
d
d
a
 
e
t
 
a
l
.
,
 
1
9
9
7
 
Retrospective. No statistical
analysis. Questions regarding
sleep in both instruments
were excluded but not
specified how many and
which questions were
excluded. 
12 N Evaluate 
depressive disorder 
in patients with 
narcolepsy. 
5:7  20-65 
(53)  
BDI, HAM-D  Three patients showed depressive 
symptoms in BDI and 5 patients in 
HAM-D. Only one patient (8.3%) 
reported severe depressive symptoms 
according to both questionnaires.  
B
e
c
k
e
r
 
e
t
 
a
l
.
,
 
2
0
0
4
 
Open label multicenter study,
no placebo control group.
Prospective. During 6 weeks
narcoleptic patients received
modafinil. Patients with
psychiatric disorders and/or
prior experience with
modafinil were excluded.  
123 N  Determine if 
treatment with 
modafinil for EDS 
improves fatigue, 
mood and HRQOL 
70:81  18-68 
(39)  
SF-36, POMS  Modafinil improved HRQOL based on 
SF-36. Modafinil reduced fatigue, and 
improved vigor and confusion (POMS 
subscales).  
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B
e
u
t
l
e
r
,
 
1
9
8
1
 
Prospective  50  
OSA (20)  
N (20)  
C (10)  
Investigate 
personality and 
mood 
characteristics 
50:0  OSA 
(45.6)  N 
(42.3) C 
(41.7) 
POMS, MMPI  OSA and N patients are different in 
POMS and MMPI than controls. OSA 
patients had hypochondrical and 
hysterical personality characteristics 
and N were characterized by anxiety 
and social introversion. N were relatively 
more depressed and show higher 
scores in fatigue than OSA do.  
B
r
o
u
g
h
t
o
n
 
e
t
 
a
l
.
 
,
1
9
8
4
 
Prospective  120  
Epilepsy (60)
NC+ (60)  
Compare the life 
effects attributed to 
epilepsy an those 
attributed to 
narcolepsy 
54: 66  32, 
Epilepsy 
group  
and 41, 
N group.  
Questionnaire 
published in 
previous study. 
Narcolepsy has a greater overall 
negative impact than epilepsy on quality 
of life.  
 
 Appendix-167 
B
r
u
c
k
,
 
2
0
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Prospective  129 N  Assess 
psychological 
adjustment, 
disruption due to 
symptoms and 
medication 
problems in 
N.Compared to 
normative values 
for other illness 
groups. 
57:72  18-81 
(53)  
PAIS-SR  High psychological distress in N 
patients. Males report more 
psychosocial adjustment problems than 
females. ESS was not correlated with 
any variable assessed in this study. 
Patients on tricyclic medication were 
more disturbed during the daily activities 
and during night than other groups  
D
a
n
i
e
l
s
 
e
t
 
a
l
.
,
 
2
0
0
1
 
No control group. Presence
of cataplexy not addressed. 
Prospective.  
305 N  Describe the health 
related quality of 
life of people with 
narcolepsy residing 
in UK 
120:185 18-89 
(median 
56)  
BDI and SF-36  56.9% had more or equal to 10 points 
(on the border of depression) in BDI and 
15.1% more or equal to 20 points 
(moderate to severe depression). In SF-
36, N showed lower scores in all scales 
than normative data. N taking stimulants 
and anticataplectics had poorer health 
status than the rest of the sample  
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i
l
l
i
e
r
s
 
e
t
 
a
l
.
,
 
2
0
0
9
 
PSG, MSLT and HLA of 
patients included were
retrospectively examined.
The sample of NC- and IH 
was regrouped as one group
for statistical reasons. No
control group.  
517 EDS 
(NC+=424, 
NC-=68, 
IH=25)  
Clarify the 
relationships 
between severity of 
the condition, 
psychological 
health and 
treatment 
response. 
246:271 15 or 
more 
(41.2)  
Face to face 
standardized 
clinical interviews 
and ESS, S-BDI, 
PSQI and SF36.  
55.1% had depressive symptoms in S-
BDI (26.3% had mild , 23.2%moderate 
and 5.6% severe).NC+ had higher 
scores in S-BDI and PSQI, lower in SF-
36 than NC- and IH together. NC+ using 
anticataplectic had higher S-BDI and 
lower SF-36 than NC+ using stimulants 
alone.  
F
o
r
t
u
y
n
 
e
t
 
a
l
.
,
 
2
0
1
0 Case-control study  
Age and sex matched
controls. Prospective.  
60 NC+  
120 C  
Assess symptoms 
and diagnostic 
classifications of 
mood and anxiety 
disorders 
28:32  (43) SCAN semi-
structured 
interview.  
A third of patients reported depressed 
mood and the highest odds ratio in the 
depressive symptoms was anhedonia. 
Prevalence of mood disorders was less 
preponderant than anxiety or panic 
attacks. No influence of age, sex, 
duration of illness or medication 
treatment in the prevalence of mood or 
anxiety disorders or in symptoms.  
E
r
v
i
k
 
e
t
 
a
l
.
,
 
2
0
0
6
 Cross-sectional study. No 
control group.  
Just 40% of the sample had a
PSG and MSLT. Prospective  
77 NC+  Describe HRQOL 
in Norwegian 
patients with 
narcolepsy. 
23:54  10-82 
(53)  
SF-36  Impairment in social function, bodily 
pain and general health; women were 
socially more affected than men. No 
treatment related differences in SF-36.  
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1
9
8
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Prospective. A Psychiatrist
blinded for the sleep problem
of the patient interviewed
each patient.  
50 NC+  Assess personality 
of patients with 
sleep attacks and
cataplexy. Evaluate 
the psychosocial 
consequences of 
the illness. 
22 :28  (43)  MMPI.  
A sub-group of 40 
NC+ completed 
also SCL-90, 
Rorschach and 
TAT  
In MMPI, high scores in Schizophrenia, 
depression and hysteria. In SCL-90 
elevated scores for obsessive-
compulsiveness,interpersonal sensitivity 
and depression. Projective tests showed 
a lack of emotional expressiveness.  
L
u
n
d
t
 
e
t
 
a
l
.
,
 
2
0
0
5
 
Retrospective chart review  161 MDD  Evaluate incidence 
of excessive 
daytime sleepiness 
in MDD. 
- 18-65  ESS,  
BDI  
Correlation between ESS scores and 
BDI scores. 50% of patients with MDD 
experience Excessive Daytime 
sleepiness.  
M
o
r
r
i
s
h
 
e
t
 
a
l
.
,
 
2
0
0
1
 
Post survey  
No control group. Only
abstract.  
285 N (260 
NC+, 25 NC-
)  
Assess if there are 
differences in 
HQOL and mood 
between NC+ and 
NC- 
- - BDI and SF-36  No difference between NC+ and NC-.  
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M
o
s
k
o
 
e
t
 
a
l
.
,
 
1
9
8
9
 
Retrospective.  151(patients 
in sleep 
laboratory) 
plus 82 with 
PSG and 
diagnosis of 
OSA (22), 
PLM(11), N 
(22), 
sleeping pill 
group (11)  
Prevalence of self 
reported symptoms 
of major affective 
disorders in 
patients of a sleep 
lab. Relationship 
between sleep 
disorders and 
mood associated 
with treatments 
160:73 12-51 
(46)  
POMS, 
questionnaire 
based in DSM-3 
criteria.  
67% of patients who presented in a 
sleep center reported an episode of 
depression within the previous 5 years 
and 26% described themselves as 
depressed at presentation. No 
differences in POMS with or without 
stimulant medication.  
N
e
v
s
i
m
a
l
o
v
a
 
e
t
 
a
l
.
,
 
 
2
0
0
9
 
Longitudinal study  105 N 
(NC+87, NC-
18)  
Compare the 
course and severity 
of narcolepsy in 
relation to age at 
onset and find out if 
childhood onset 
narcolepsy does 
have a more 
severe course. 
44:61  (45.4)  SSS, ESS and 
MSLT  
The severity of narcolepsy does not 
depend on the age at onset. Smoking is 
associated with the risk of hypnagogic 
hallucinations. BMI increases in linear 
proportion to age and decreased the 
MSLT values.  
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O
z
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e
t
 
a
l
.
,
 
2
0
0
8
 
Prospective. No control
group.  
137 EDS 
(NC+28, NC-
27, IH=82)  
Evaluate HRQOL 
of drug naïve NC+, 
NC- and IH without 
long sleep time. 
Explore the factors 
influencing 
HRQOL. 
66:71   20-61 
(31.2)  
SF-36, ESS, socio-
demographics and 
driving habits.  
Low HRQOL in all disease categories 
unrelated with severity.  
NC+ showed higher ESS scores in 
comparison with the other 2 groups.  
P
a
w
l
u
k
 
e
t
 
a
l
.
,
 
1
9
9
5
 
Prospective. Small sample.
No control group.  
11 NC+  Assess whether 
narcoleptic patients 
on chronic high 
dose 
methylphenidate 
develop psychosis 
and if they would 
be less prone to 
depression. 
6:5  (54.5)  MMPI, SCL-90, 
BDI, BAI. Two 
weeks later: BPRS, 
HAM-D and SSS.  
45.4% met DSM-III criteria for 
dysthymia, 9.1% for major depression. 
Two patients had symptoms of 
psychosis induced by stimulant.  
R
o
t
h
 
&
 
N
e
v
s
i
m
a
l
o
v
á
,
 
1
9
7
5
 
 
Retrospective study. No
control group.  
130  
(N 100,  
IH 30)  
Analyze the 
association 
between 
narcolepsy and 
depression. 
- -  Psychiatrist who 
treated the patients 
for depression.  
Mentioned 
questionnaires but 
no specified.  
In NC- depression occurred in 29% of 
the cases, in NC+ depression in 17% of 
the cases. In IH, depression in 26.1%.  
R
o
v
e
r
e
 
e
t
 
a
l
.
,
 
2
0
0
8
 
Prospective. Not addressed if
cataplexy.  
40 N 40 C  Evaluate the 
perception of QL in 
Brazilian patients 
with narcolepsy 
12:28  20-72 
(41.5)  
WHOQOL-BREF  N show lower scores than controls in all 
domains of questionnaire.  
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R
o
y
,
 
 
1
9
7
6
 
Prospective.  Not addressed
if cataplexy No control group.
Unclear instruments in
method.  
20 N  Explore psychiatric 
aspects of patients 
with narcolepsy 
10:10  (40)  Psychiatric 
interview, 
intelligence test and 
personality 
questionnaire 
(Eysenck)  
Intelligence was normal, no 
characteristic personality or 
psychopathology. 40% current 
psychiatric disorder (only one diagnosis 
of depression)  
S
o
u
r
s
,
 
 
1
9
6
3
 
Retrospective. Diagnosis
under Yoss and Daly’s
criteria. Historical paper.  
75 N  
(54 NC+, 21 
NC-)  
Review the role of 
psychological 
disturbances in   
and the association 
of schizophrenia 
with narcolepsy. 
45:30  (18.2)  No instruments. 
Revision of clinical 
records regarding 
psychiatric and 
neurological 
evaluation.  
Principal findings without statistical 
corroboration: Anxiety, depression, 
headaches, obesity, vivid dreams and 
irritability.  
S
t
e
p
a
n
s
k
i
 
e
t
 
a
l
 
,
 
1
9
9
0
 
Prospective.  Not addressed
if cataplexy. Age and sex
matched with controls. N and
EDS patients matched by
level of sleepiness.  
56 N, 56 
EDS controls 
and 48 C  
Relation between 
psychopathology 
and narcolepsy. 
36:20 N 
36:20 
EDS 
32:16 C 
(51.8)  MMPI and CMI.  Both EDS groups higher scores in 
MMPI scales of hypochondriasis, 
depression, hysteria, psychasthenia and 
schizophrenia and in CMI than controls. 
N had higher depression scores than 
EDS. Psychopathology related to 
narcolepsy is not specific and may be 
generalized to other disorders with 
excessive sleepiness.  
 
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory (with S, Short form); BPRS, Brief Psychiatric Rating Scale; C, controls; CMI, Cornell Medical 
Index; EDS, excessive daytime sleepiness; ESS, Epworth sleepiness scale; HAM-D, Hamilton Rating Scale for Depression; HRQOL, Health-Related Quality 
Of Life; IH, idiopathic hypersomnia; OSA, obstructive sleep apnea; MDD, major depressive disorder; MMPI, Minnesota Multiphasic Personality Inventory; 
MSLT, Multiple Sleep Latency Test; N, narcolepsy patients (no division with and without cataplexy); NC-, narcolepsy without cataplexy; NC+, narcolepsy with 
cataplexy; PAIS-SR, Psychosocial Adjustment to Illness Scale-Self Report; PLM, periodic leg movements; POMS, Profile of Mood States; PSQI, Pittsburgh 
Sleep Quality Index; SCAN interview, Schedules for Clinical Assessment in Neuropsychiatry interview; SCL-90, Symptom Check List 90; SF-36, Medical 
Outcomes Study 36-Item Short Form Health-Survey; SSS, Stanford Sleepiness Scale; TAT, Thematic Apperception Test; WHOQOL-BREF, World Health 
Organization Quality of Life instrument Brief Version. 
Appendix 
C. Information for patients and control subjects 
 
PATIENTENINFORMATION ZUM PROJEKT 
“Depression und mit Schlaf verbundene depressive Symptome bei Narkolepsie und 
anderen Störungen mit Tagesschläfrigkeit“ 
Sehr geehrte Dame, sehr geehrter Herr,  
vielen Dank für Ihre Bereitschaft, an unserer Untersuchung teilzunehmen. 
Schlafstörungen sind für die Betroffenen oft eine große Belastung im Alltagsleben. Das 
kann auch zu einer nachhaltigen Beeinträchtigung der Stimmung führen, bis hin zu den 
Anzeichen einer Depression. Auf der anderen Seite gibt es Symptome der Schlafstörung 
selbst, die dem Erscheinungsbild einer Depression sehr ähneln. Das Ziel unserer 
Untersuchung ist es, hier die Unterschiede und Gemeinsamkeiten genauer zu betrachten. 
Dazu bitten wir Sie, eine Reihe von Fragebögen auszufüllen. 
In den Fragebögen werden zum Teil sehr persönliche Dinge abgefragt. Wir versichern 
Ihnen, dass Ihre Angaben streng vertraulich behandelt und nur für die Zwecke dieser 
Untersuchung verwendet werden. Die Weiterverarbeitung erfolgt pseudonymisiert, das 
heißt ohne Bezug zu Ihrem Namen. 
Für weitere Fragen stehen wir Ihnen jederzeit gerne zur Verfügung. Die Projektleiterin ist 
Frau Cecilia Jara. Sie ist über das Schlaflabor des Bezirksklinikums Regensburg zu 
erreichen (Tel. 0941-941-2843) 
Vielen Dank für Ihre Mitarbeit 
 
Dr. Peter Geisler Cecilia Jara Unterschrift Teilnehmer 
 
Oberarzt Licenciada en Psicología 
Universidad de Santiago de 
Chile 
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Ihnen, dass Ihre Angaben streng vertraulich behandelt und nur für die Zwecke dieser 
Untersuchung verwendet werden. Die Weiterverarbeitung erfolgt pseudonymisiert, das 
heißt ohne Bezug zu Ihrem Namen. 
Für weitere Fragen stehen wir Ihnen jederzeit gerne zur Verfügung. Die Projektleiterin ist 
Frau Cecilia Jara. Sie ist über das Schlaflabor des Bezirksklinikums Regensburg zu 
erreichen (Tel. 0941-941-2843) 
Vielen Dank für Ihre Mitarbeit 
 
 
Dr. Peter Geisler Cecilia Jara Unterschrift Teilnehmer 
 
Oberarzt Licenciada en Psicología 
Universidad de Santiago de 
Chile 
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D. Informed consent  
 
EINVERSTÄNDNISERKLÄRUNG ZUM PROJEKT: 
 
“Depression und mit Schlaf verbundene depressive Symptome bei Narkolepsie und 
anderen Störungen mit Tagesschläfrigkeit“ 
 
Ich habe die Aufklärung für Studienteilnehmer über die genannte wissenschaftliche 
Untersuchung gelesen und verstanden. Mir wurden alle Fragen, die ich zu dieser 
Untersuchung habe, beantwortet und ich bin mit der Durchführung der Untersuchung 
einverstanden. 
 
Die gesetzlichen Datenschutzbedingungen werden eingehalten. 
 
Ich erkläre, dass ich mit der im Rahmen der klinischen Prüfung erfolgenden 
pseudonymisierten Aufzeichnung von Krankheitsdaten/ Studiendaten einverstanden bin. 
 
__________________, den_______________________ 
 
_____________________________________________ 
Unterschrift des Patienten 
 
_____________________________________________ 
Unterschrift der aufklärenden Psychologin 
 
_____________________________________________ 
Unterschrift Aufklärender Arzt 
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